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Alzheimer’s disease (AD) is a progressive, irreversible 
neurodegenerative disorder characterized by progressive dementia 
that culminates in death.  Its etiology and pathogenesis are complex, 
and encompass multiple genetic and environmental risk factors.   
Yet, with the exception of Aß-inducing mutations, none of these 
molecular and genetic factors appears to have absolute penetrance 
in causing the disorder.  Moreover, many individuals may possess 
the most salient risk factors for AD, as well as express profuse Aß 
and tau pathology, without ever exhibiting the clinical symptoms of 
dementia1.  In the face of such complexity and so many potential 
pathogenic mechanisms, the broad ability of epigenetics to 
coordinately alter gene expression and the many biological 
pathways that gene expression sub-serves could provide a critical, 
missing link. 
Although a unitary definition of epigenetics has yet to be 
reached, the many definitions that have been suggested all invoke 
heritability, lack of dependence on DNA sequence, and effects on 
transcription to produce diverse phenotypes.  In particular, 
epigenetic modifications are capable of altering transcriptional 
activity in a consistent manner across thousands of genes and 
dozens of biological pathways, yet can do so differentially in 
monozygotic twins or adjacent cells in the same organ, all of which 
share the same genetic code.  Epigenetics also provides a means by 
which environmental factors such as diet, hazardous exposures, and 
life events can influence gene expression. 
Gene expression in the AD brain has been shown to be altered in 
numerous reports 2-8, including a recent large-scale expression array 
study of single cell laser-captured entorhinal cortex layer II neurons 
2. Multiple pathways have been reported to be affected, from energy 
metabolism5  to inflammation 6, 8.  The extent and breadth of these 
gene expression changes suggest a complex web of interacting 
effects on large numbers of transcription factors, and also raise the 
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possibility of more unitary mechanisms that are capable of 
modulating coordinate expression of large numbers of genes.   In 
particular, there are a variety of epigenetic mechanisms that 
modulate the accessibility of genes to the transcription machinery, 
including histone modification, binding of non-histone proteins, and 
DNA methylation. 9, 10 
DNA  methylation  is  a  highly  conserved  process  that  has  
been  implicated  in  many different modalities of gene expression.  
The factors responsible for the methylation process are a family of 
DNA methyltransferases that have been shown to catalyze the 
transfer of a methyl group to single-stranded DNA using S-adenosyl 
methionine (SAM) as the methyl donor.  The recognition sequence 
for the mammalian DNA methyltransferase is relatively invariant, 
with nearly all cytosine methylations occurring on 5‘-C-p-G-3‘ CpG 
11, 12.  There are four known active DNA methyltransferases in 
mammals, DNMT1, DNMT2, DNMT3A and DNMT3B.   Of these, 
DNMT1 is the most abundant in mammalian cells.   DNMT1 has been 
reported to be a key player in maintaining methylation in somatic 
cells, and loss of this enzyme has been shown to lead to nuclear 
disorganization, increased histone acetylation, and apoptosis 13-17. 
Once methylation has occurred, methylation stability is maintained 
by the binding of specific complexes, MeCP1, to methylated regions 
of DNA.   MeCP1 is not bound directly to methylated DNA, but rather 
to a single methyl-CpG-binding domain protein, MBD2.     The 
resulting MeCP1/MBD2 complex is composed of 10 known proteins 
that include the complete nucleosome remodeling and histone 
deacetylase (NuRD) core, as well as MBD2.  This group of proteins, in 
conjunction with CDK2AP1 (Doc1), make up a complex capable of 
nucleosome remodeling and histone deacetylation 18, 19.  
Methylation and methylation stabilizing factors can orchestrate 
changes in expression of a wide range of genes 9, 10, 18, 20-23.  
Accordingly, one of the central hypotheses tested in this thesis is 
9 | P a g e  
 
that alterations in methylation and methylation stability might 
provide an over-arching mechanism that could explain expression 
differences in the thousands of genes that are reportedly altered in 
AD. 
Current research has shown that 
folate/methionine/homocysteine metabolism is critically linked to 
DNA methylation mechanisms. Folate deficiency in humans and in 
animal models, for example, typically results in global 
hypomethylation that is at least partially reversible with folate 
supplementation (reviewed in 24-26).     Deficits     in     folate     and     
alterations     in     the methionine/homocysteine cycle have been 
reported in aging and AD (reviewed in27), and may therefore provide 
a basis for the tendency to genome-wide hypomethylation in aging 
and AD. Although one prospective study failed to find an association 
between dietary folate, vitamin B12, or vitamin B6 with incident 
AD28, CSF folate has nonetheless been reported to be significantly 
decreased  in  AD  29,  as  has  CSF  and  brain  SAM  and  one  of  its  
synthesizing  enzymes, methionine S-adenosyltransferase 29-31.  
Dietary effects of folate and homocysteine manipulation have been 
implicated in cognitive impairment generally, and in a wide range of 
neurologic conditions, including AD, Parkinson’s disease, depression, 
corticobasal degeneration, multiple sclerosis, and frontotemporal 
dementia 32 . 
Epigenetic mechanisms typically involve changes in the 
micro- and macrostructure of chromatin, a complex of DNA, 
chromosome proteins, and histone proteins in which the histone 
proteins are tethered together in structures around which double-
stranded DNA is wound. Conformational changes in histone proteins 
or modifications of the way in which DNA wraps around the histones 
may then differentially alter access of the transcriptional machinery 
to some genes while leaving access to other genes intact 33.  
Although there are multiple mechanisms by which histones are 
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modified, including methylation, phosphorylation, ubiquitination, 
sumoylation, citrullination,  adenosine  diphosphate  (ADP)-
ribosylation,  and  other  posttranslational modifications of the 
amino acids that make up histone proteins, histone acetylation is 
one of the most ubiquitous and well studied. Here, histone 
acetyltransferases (HATs) catalyze the transfer of an acetyl group 
from acetyl-coenzyme A to lysine residues on the N-termini of 
histone proteins.  As a result of acetylation, the positive charge of 
the histone proteins is neutralized, decreasing interactions of the 
histone protein tails with negatively charged phosphate groups of 
associated DNA. This conformational relaxation of the chromatin 
permits access to and transcription of genes within the complex. 
Conversely, the histone deacetylases (HDACs) transfer acetyl groups 
from acetylated histone proteins back to coenzyme A, producing a 
more condensed chromatin state and decreased or silenced gene 
transcription. 
Several   reports   have   demonstrated   alterations   in   
histone   proteins   in   AD. Phosphorylation of histone 3, a key step 
in the activation of the mitotic machinery, is increased to a 
hyperphosphorylated state in AD hippocampal neurons34.   A non-
nuclear form of histone 1 has been shown to be upregulated in 
astrocytes and neurons in brain regions that are rich in AD 
pathology35.   Linker histone H1, a vital component of chromatin, has 
been reported to preferentially bind Aß42, as well as other Aß-like 
structures of numerous proteins36.  In addition, the H1 molecule has 
been shown to be a major target for poly adenosine diphosphate 
(ADP)- ribosylation in areas of AD brain with ischemic brain injury37.     
Viewed more broadly, the present thesis research has demonstrated 
globally decreased nuclear IR for both HDAC1 and HDAC2 in AD 
entorhinal cortex38. 
In summary, the broad ability of epigenetic mechanisms to 
regulate gene expression suggests that the manifold and diverse 
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gene expression changes that have been reported in aging and AD 
could be caused by alterations in the epigenetic machinery, and 
many such alterations have been found in these conditions.   The 
question then arises, however, what causes the epigenetic 
alterations?   Normal cell function requires constant exchange of 
molecules between the nucleus and the cytoplasm.  Virtually all 
nuclear proteins, for example, begin their existence in the 
cytoplasm, and their failure to be translocated back to the nucleus 
would be as catastrophic as their never having been synthesized at 
all.   Dysregulation of nucleocytoplasmic transport might also 
account for the changes in epigenetic proteins that have been  
reported  in  aging  and  AD,  particularly  decreases  in  their  nuclear  
levels  and  IR. 
  Collectively, future studies in nucleocytoplasmic transport 
dysfunction in AD may account for the diversity so often observed in 
the pathophysiology of the disease.   Whether the many other 
nuclear proteins that rely on RAN-mediated nucleocytoplasmic 
transport follow this pattern remains to be determined.  If they do, 
however, deficits in RAN followed by ectopic intracellular 
localization of epigenetic and other transcription-related molecules 
could well be a central event in the pathophysiology of AD, and 
could provide an overarching, integrative mechanism for the myriad 
pathogenic processes that occur in the disorder. 
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Abstract 
 
Epigenetic modifications help orchestrate sweeping developmental, 
aging, and disease-causing changes in phenotype by altering 
transcriptional activity in multiple genes spanning multiple biologic 
pathways.  Although previous epigenetic research has focused 
primarily on dividing cells, particularly in cancer, recent studies have 
shown rapid, dynamic, and persistent epigenetic modifications in 
neurons that have significant neuroendocrine, neurophysiologic, and 
neurodegenerative consequences.  Here, we provide a review of the 
major mechanisms for epigenetic modification and how they are 
reportedly altered in aging and Alzheimer's disease (AD).  Because of 
their reach across the genome, epigenetic mechanisms may provide 
a unique integrative framework for the pathologic diversity and 
complexity of AD. 
 
 
Key Words: Epigenetics, DNA methylation, histone acetylation, 
rDNA, miRNA, genetics, gene expression, amyloid β peptide, 
inflammation, oxidative stress, cell cycle 
 
 
Introduction 
 
Alzheimer’s disease (AD) is a progressive, irreversible 
neurodegenerative disorder culminating in dementia.  Its etiology 
and pathogenesis are complex, and encompass many  genetic and 
environmental risk factors, changes in the expression of thousands 
of genes, and upregulation of multiple pathogenic pathways such as 
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amyloid β peptide (Aβ) deposition, tau hyperphosphorylation, 
inflammation, oxidative stress, energy metabolism, and aberrant re-
entry into the cell cycle/apoptosis.  Moreover, with the exception of 
Aβ-inducing mutations, none of these molecular and genetic factors 
appears to have absolute penetrance in causing the disorder: many 
individuals may possess the most salient risk factors for AD, as well 
as express profuse Aβ and tau pathology, yet never develop the 
disorder (Lue et al. 1996).  Indeed, even monozygotic twins can have 
dichotomous AD outcomes (Raiha et al. 1997)  
 The emerging field of epigenetics has its roots in studies of 
the structure of chromatin and modifications to the structure of 
DNA, which extend back half a century or more (Felsenfeld, 2007).  
Although a unitary definition of epigenetics has yet to be reached, 
the many definitions that have been suggested all invoke heritability 
lack of dependence on DNA sequence, and effects on transcription 
to produce diverse phenotypes.  In particular, epigenetic 
modifications are capable of altering transcriptional activity in a 
coherent manner across thousands of genes and dozens of biological 
pathways, yet can do so differentially in monozygotic twins, the 
same individual at different developmental stages, or adjacent cells 
in the same organ, all of which share the same genetic code.  
Epigenetics also provides a means by which environmental factors 
such as diet, hazardous exposures, and life events can influence 
gene expression.  As such, epigenetic mechanisms may provide a 
point of intersection for the diverse risk factors and 
pathophysiologic processes of AD. 
 The purpose of this review is to briefly describe the major 
epigenetic mechanisms, histone acetylation, DNA methylation, 
ribosomal DNA (rDNA), and microRNA (miRNA), and how they are 
reportedly altered in aging and AD. 
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2.0 Epigenetic regulation of gene expression 
Epigenetic mechanisms modify heritable and non-heritable traits 
without necessarily altering the underlying DNA sequence.  Thus, 
through epigenetic modification the diverse cellular phenotypes and 
functions needed by the body can be achieved using a single genetic 
code for all cells.  These effects are typically accomplished by 
inhibition of transcriptional access to various genes, leading to their 
repression or silencing.  Conversely, release from normal epigenetic 
repression can enhance gene expression (Wilson and Jones 1983; 
Bandyopadhyay and Medrano 2003; Liu et al. 2003; Fraga and 
Esteller 2007; Poulsen et al. 2007).  These modifications can occur at 
specific gene loci in specific cells to yield specific cellular 
phenotypes, or can encompass many genes in many cells, an 
orchestrating mechanism that is widely assumed to help drive such 
broad biological processes as development and aging (Wilson and 
Jones 1983; Bandyopadhyay and Medrano 2003; Liu et al. 2003; 
Fraga and Esteller 2007; Poulsen et al. 2007). 
 Because phenotype and function are affected and effected 
by what genes are expressed and what genes are repressed, 
epigenetically regulated and dysregulated transcription states can 
give rise not only to different cell types and developmental stages, 
but also to favorable and unfavorable outcomes for specific cells 
within the same organ system.  Thus, changes in epigenetic 
regulation can cause some cells to develop structural, physiologic, 
and metabolic abnormalities, while other cells of the same type 
remain normal.  This is thought to occur, for example, in several 
hematologic malignancies after aberrant epigenetic silencing of 
genes that control proliferation (Siegmund et al. 2006). 
 In addition to direct regulation of gene expression, 
epigenetic modifications can mimic, exacerbate, or even cause 
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genetic mutations.  For example, epigenetic repression of tumor 
suppressor genes can mimic loss-of-function mutations of tumor 
suppressor genes, and both are highly associated with cancer 
development (Siegmund et al. 2006).  Epigenetic silencing of the 
alpha subunit of the stimulatory G protein, a signaling peptide 
essential for the actions of parathyroid hormone, can cause 
pseudohypoparathyroidism, just as mutations to the alpha subunit 
do (Bastepe 2008).  Epigenetic modifications can exacerbate the 
effects of gene mutations, as occurs with Apc gene mutations in 
colorectal cancers (Colnot et al. 2004), E-cadherin mutations in 
gastric cancers (Strathdee 2002), and mitochondrial DNA mutations 
in Leber's disease (Johns and Neufeld 1993).    Beyond these 
interactions, epigenetic repression of DNA repair genes may also 
induce gene mutations (Jacinto et al. 2007). 
 Finally, epigenetic mechanisms provide a means by which 
environmental events can be translated to the cellular and 
molecular level.  For example, ultraviolet ray exposure may induce 
epigenetic modifications in skin cells that culminate in cutaneous 
malignancies (Millington 2008).  Likewise, epigenetic changes 
induced by different environments, or simply by stochastic events, 
are thought to underlie the subtle phenotypic differences that 
emerge with time in monozygotic twins (Fraga et al. 2005; Flanagan 
et al. 2006). 
 
2.1 Histone modifications.   
Epigenetic mechanisms typically involve changes in the micro- and 
macro-structure of chromatin, a complex of DNA, chromosome 
proteins, and histone proteins in which the histone proteins are 
tethered together in structures around which double-stranded DNA 
is wound.  Conformational changes in histone proteins or 
modifications of the way in which DNA wraps around the histones 
may then differentially alter access of the transcriptional machinery 
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to some genes while leaving access to other genes intact (Allfrey 
1966). 
 Although there are multiple mechanisms by which histones 
are modified, including methylation, phosphorylation, 
ubiquitination, sumoylation, citrullination, ADP-ribosylation, and 
other post-translational modifications of the amino acids that make 
up histone proteins, histone acetylation is one of the most 
ubiquitous and well studied.  Here, histone acetyltransferases (HATs) 
catalyze the transfer of an acetyl group from acetyl-coenzyme A to 
lysine residues on the N-termini of histone proteins (Fig. 1).  As a 
result of acetylation, the positive charge of the histone proteins is 
neutralized, decreasing interactions of the histone protein tails with 
negatively-charged phosphate groups of associated DNA.  This 
conformational relaxation of the chromatin permits access to and 
transcription of genes within the complex.  Conversely, the histone 
deacetylases (HDACs) transfer acetyl groups from acetylated histone 
proteins back to coenzyme A, producing a more condensed 
chromatin state and decreased or silenced gene transcription. 
 
2.2 DNA Methylation.   
DNA methylation provides a further means for histone modification, 
and is highly interactive with histone acetylation and the other 
histone-modifying mechanisms.  For this reason, DNA methylation 
can, to some extent, be taken as a surrogate for histone 
modification profiles. 
 Beginning with seminal research in the late 1970s (Bird 
1978), it is now well established that adjacent cytosine-guanine 
(CpGs) dinucleotides within DNA can be methylated by the actions 
of the DNA methyltransferases, DNMT1, DNMT2, DNMT3a/b, and 
DNMT4.  In mammals, DNMT1 appears to be primarily involved in 
maintenance methylation of hemimethylated DNA after DNA 
replication, whereas DNMT3a and DNMT3b are particularly 
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important for de novo DNA methylation.  DNMT2 is typically 
considered to be an RNA methyltransferase, although it also has 5-
cytosine DNA methyltransferase activity (Tang et al., 2003) and 
forms denaturant-resistant complexes with DNA (Dong et al., 2001).  
The methyl group that is transferred to cytosine by the DNMTs 
ultimately derives from methyltetrahydrofolate through its 
interactions with S-adenosylmethionine (SAM) in the  homocysteine-
methionine cycle (Fig. 1). 
 Through these processes, approximately 70% of CpG 
dinucleotides within the human genome are methylated.  Although 
DNA methylation can take place at any CpG site, whether in coding 
or non-coding regions, previous studies have often focused on CpG-
rich stretches (CpG islands) within the promoter region.  Some 
50,267 CpG islands exist in the human genome, with 28,890 in 
simple repeat and low complexity sequences that are masked 
(Bandyopadhyay and Medrano 2003; Liu et al. 2003).  Because CpG 
islands contain a high proportion of CpGs (and opportunities for CpG 
methylation), they are, perforce, among the most highly methylated 
regions of the genome.  However, it has recently been shown that 
the percentage (rather than the absolute number) of methylated 
CpGs is relatively low in conventional CpG islands, and is actually 
higher in promoters with intermediate CpG densities (Eckhardt et 
al., 2006; Weber et al., 2007).  Moreover, tissue-specific methylation 
patterns appear to be most pronounced not at CpG islands but at 
“CpG shores”, regions within approximately 2 kb of CpG-enriched 
sequences.  It has been suggested, in fact, that methylation patterns 
of CpG shores are “sufficiently conserved to completely discriminate 
tissue types regardless of species of origin” (Irizarry et al., 2009).  
Differential methylation of CpG shores in brain compared to liver has 
also been found to be highly correlated with differences in gene 
expression for these two organs (Irizarry et al., 2009). 
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 Methylation of CpG sequences may alter gene expression by 
inducing histone modifications that inhibit access of the 
transcriptional machinery (Bird and Wolffe 1999; Zhang et al. 2002) 
(Fig. 1).  One would expect, then, that highly methylated genes 
would be repressed, and that hypomethylation of a gene would lead 
to enhanced expression or overexpression compared to the 
normally repressed, methylated state.  Some notable exceptions to 
these expected states have been found, however.  For example, the 
p16INK4a promoter is progressively hypermethylated with age (So 
et al. 2006), but expression of the p16INK4a gene appears to 
increase with age (Figueiredo et al. 2006).  More generally, Gius and 
colleagues (2004) found that chemical hypomethylation of nearly 
half the genes they surveyed resulted in silencing rather than 
upregulation.  Indeed, altering the methylation status of some CpG 
sites within a gene can be inconsequential compared to alterations 
at other sites (c.f., Murgatroyd et al., 2009; Yakovlev et al., 2009).  
Such findings indicate that it will be important to follow up genome-
wide DNA methylation profiling, which can only survey a limited 
number of CpGs per gene, with more detailed DNA methylation 
maps that include shores and flanking regions.  In addition, even 
highly-detailed DNA methylation profiles will require validation of 
functional effects at the gene expression and protein levels. 
 A second, linked mechanism by which DNA methylation may 
modify gene expression is through methyl-CpG-binding proteins 
(MeCPs) such as MeCP2.  When bound to methylated DNA, MeCP2 
has been shown to recruit HDACs, which, as noted earlier, may then 
induce a more condensed chromatin state and decreased or silenced 
gene transcription (Robertson and Jones 1998; Wade et al. 1998).  
Although previous studies assumed that MeCP2 required a 
methylated chromatin substrate for direct binding (Lewis et al. 
1992), more recent research has demonstrated that MeCP2 can 
directly condense chromatin even in the absence of DNA 
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methylation, histone deacetylase activity, or the cooperation of 
other transcriptional co-repressors such as mSin3A (Wade 2001).  
Mutations of the MeCP2 gene cause Rett’s Syndrome, with 
dysregulation of neural development, mental retardation, and 
motor dysfunction (Amir et al. 1999). 
 MeCP1, a macromolecule made up of some 10 different 
peptides, may also act as a mediator between DNA methylation and 
histone acetylation, recognizing and binding to CpG dinucleotides, 
recruiting HDACs, and inducing transcriptional repression (Feng and 
Zhang 2001).  Unlike MeCP2, however, MeCP1 does not bind directly 
to methylated DNA, but to a single methyl-CpG-binding domain 
protein, MBD2.  In addition to inducing histone modifications, 
MBD2-bound MeCP1 helps maintain the DNA methylation status of 
CpGs by recruiting DNMT1.  DNMT1 is then able to recognize and 
repair CpGs that have lost methyl groups on one DNA strand but not 
the other. 
 Recent studies have also revealed a further modification to 
methylated CpGs that may make them even more inaccessible to 
transcription.  Here, the 5-methylcytosines are hydroxylated 
(oxidized) to form 5-hydroxymethylcytosine (Valinluck and Sowers 
2007; Kriaucionis and Heintz 2009; Tahiliani et al. 2009).  
Hydroxymethylated DNA has been observed in neurons (Kriaucionis 
and Heintz 2009), and may occur as a result of oxidative damage 
and/or the actions of specific oxidative enzymes, particularly TET1 
(Tahiliani et al. 2009).  Normally, 5-hydroxymethylcytosines are 
stripped from genomic DNA by glycosylases of the base excision 
repair (BER) system (Steen et al., 2008), permitting replacement with 
unmodified cytosines for subsequent de novo DNA methylation by 
the DNMTs.  When left intact, however, 5-hydroxymethylcytosines 
reportedly reduce the interaction of DNA with DNA-binding proteins 
to an even greater extent than do 5-methylcytosines (Valinluck et al. 
2004; Valinluck and Sowers 2007).  Because hydroxymethylated 
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CpGs might go undetected by 5-methylcytosine antibodies or 
conventional bisulfite sequencing, it is also possible that 
hydroxymethylation could lead to under-reporting of DNA 
methylation, a possibility that the present authors are now 
investigating.  
  
2.3 RNA-related mechanisms.   
Epigenetic regulation also extends to mechanisms involving RNA 
such as micro-RNAs (miRNAs) and hereditable and cell cycle-
maintained silencing of a portion of the ribosomal RNA genes.  rRNA 
transcripts from repeated rRNA genes (rDNA) provide a structure 
and primary catalytic site for the eukaryotic ribosome, wherein gene 
expression culminates in protein synthesis.  Different cell types 
exhibit different proportions of active rRNA genes, suggesting that 
the fraction of rRNA gene copies may be altered in development and 
differentiation.  Epigenetic mechanisms are now known to play 
important roles in this process by silencing rRNAs, thereby providing 
a dynamic balance between active and inactive rRNAs.  DNA 
methylation appears to be one of these epigenetic mechanisms, and 
may be of particular importance given the unusually high frequency 
of CpG dinucleotides within the rRNA genes and their unusually high 
states of DNA methylation.  For example, two studies have shown a 
correlation between DNA methylation status and activity of rRNA 
genes (Bird et al., 1981; Santoro & Grummt, 2001), and treatment 
with 5-aza-2-deoxycytidine (azacytidine), a hypomethylating agent, 
enhances expression by rDNA genes (Santoro & Grummt, 2001).  For 
an excellent and comprehensive summary of rDNA methylation, as 
well as histone modifications and chromatin remodeling, which also 
play key roles in epigenetic regulation of rDNA, the reader is 
referred to the recent review of McStay and Grummt (2008). 
 The study of miRNAs represents an additional, critical area 
for epigenetics research.  Often deriving from their own genes with 
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their own promoter and regulatory elements, approximately 700-
800 miRNAs have been identified in the human genome.  These 
small (~22 nucleotide) RNAs regulate gene expression in a post-
transcriptional manner by binding to their target mRNAs, inhibiting 
translation or, less often, inducing cleavage of the mRNAs (reviewed 
in Yang, 2007). 
 
 
3.0 Dynamic epigenetic regulation in adult neurons 
 
3.1  Histone modifications.  
 Histone modifications have been implicated in broad 
neurobiological processes such as development of the CNS 
(reviewed in MacDonald and Roskams, 2009), post-traumatic stress 
disorders (Sokolova et al., 2006), childhood abuse/suicide (Meaney 
et al., 2007; McGowan et al., 2009), memory formation (Gupta et al., 
2010), and addiction (Impey, 2007); specific physiologic processes 
such as neuronal differentiation (Kular et al., 2009), regulation of 
choline acetyltransferase activity (Aizawa and Yamamuro, 2010), 
astrocyte GDNF and BDNF transcription (Wu et al., 2008), microglial 
apoptosis (Chen et al., 2007), and axon pathfinding (Zinovyeva et al., 
2006); and various neurologic disorders, including Parkinson’s 
disease (Chen et al., 2007; Wu et al., 2008), motor neuron disease 
(reviewed in Echaniz-Laguna et al., 2008), multiple sclerosis 
(reviewed in Gray and Dangond, 2006), X-linked mental retardation 
(Tahiliani et al., 2007), and stroke/cerebral palsy (Meisel et al., 
2006).  All of these histone-related processes occur in the context of 
the CNS, and many have been reported to function as dynamic 
regulatory mechanisms in postmitotic neurons. 
 
3.2  miRNA.  
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 Like histone modifications, miRNA has been implicated in both 
broad and specific CNS processes and disorders.  For example, 
miRNA-206 appears to promote neuromuscular synapse 
regeneration (Williams et al., 2009), and miR-329, miRNA-134 and 
miRNA-381, which are induced by neuronal activity, have been 
suggested to be essential for activity-dependent dendritic outgrowth 
of hippocampal neurons (Khudayberdiev, Fiore, and Schratt, 2009).  
In turn, these and other miRNA-mediated mechanisms have been 
investigated in various CNS disorders, including HIV-dementia 
(Witwer et al., 2010), amyotrophic lateral sclerosis (Williams et al., 
2009), Tourette’s syndrome (Abelson et al., 2005), AD (see section 
5.2, below), and other neurologic conditions (reviewed in Maes et 
al., 2009).  Once again, these epigenetic processes have been 
demonstrated to occur in the context of postmitotic neurons.  
Indeed, it has been reported that the switch from a replicative state 
to the postmitotic state of neurons may itself be controlled by 
miRNA mechanisms (Yoo et al., 2009). 
 
3.3  DNA methylation.  
 Previously, DNA methylation reactions were considered primarily in 
the context of maintenance of the DNA methylation pattern across 
cell divisions.  Why neurons and other postmitotic cells should 
express DNA methylation markers such as DNMT1 was therefore 
unclear.  Likewise, how long-term DNA methylation alterations 
might be accomplished and sustained in postmitotic cells was 
unknown.  Recently, however, new studies have shown that hypo- 
and hypermethylation are dynamic events that can occur within cells 
(Kangaspeska et al., 2008; Metivier et al., 2008), including 
postmitotic neurons (Levenson et al., 2006; Murgatroyd et al., 2009),  
on the scale of tens of minutes.  These findings open the door for 
long-suspected, dynamic epigenetic mechanisms that may help 
mediate neuronal and synaptic plasticity (e.g., (Arendt 2005).  For 
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example, gene-specific hypomethylation of hippocampal neurons 
after DNMT inhibition blocks long-term potentiation (Levenson et al. 
2006) and fear conditioning (Miller and Sweatt 2007).  Weaver and 
co-workers (Weaver et al. 2005) have suggested that early life 
events—specifically, maternal care—alter adult stress responses 
through sustained DNA methylation changes in rat hippocampal 
neurons. 
 The role of DNA methylation in dynamic regulation of 
neuronal activity and function began to emerge with studies by 
Bredy and colleagues (2003), and has been vividly confirmed by 
recent work linking early-life stress to enduring molecular, 
physiologic, memory, and behavioral changes in mice via epigenetic 
modifications to hypothalamic neurons (Murgatroyd et al. 2009).  In 
particular, early exposure of mice to stress during the first 10 days of 
life has been found, as much as a year later, to be associated with 
impaired step-down avoidance learning, sustained hyperactivity of 
the hypothalamic-pituitary-adrenal axis, and corticosterone and 
pituitary adrenocorticotropin pro-hormone hypersecretion.  These 
effects, in turn, were elegantly traced to persistent arginine 
vasopressin (AVP) overexpression by parvocellular neurons of the 
hypothalamic paraventricular nucleus, and to hypomethylation of 
specific CpG sites within the AVP gene.  Notably, age-dependent 
increases in AVP gene hypomethylation at multiple CpG sites were 
observed in control mice in these studies, but hypomethylation of 
CpGs within a CpG island (CGI3) in the AVP enhancer region 
approximately 0.5 kb downstream from the AVP gene itself 
appeared to be the primary determinant of AVP overexpression in 
early-life stress mice.  Further experiments went on to show that 
CGI3 hypomethylation was specific to the paraventricular nucleus 
compared to the supraoptic nucleus, and to provide a key 
mechanism for the epigenetic modifications that were observed:  
CGI3 CpG sequences serve as preferential and selective DNA-binding 
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sites for MeCP2.  Phosphorylation of MeCP2 by calmodulin-
dependent protein kinase II as a result of neuronal membrane 
depolarization decreases MeCP2 occupancy of CGI3 CpGs, thereby 
enhancing transcription (Murgatroyd et al. 2009).  This landmark 
study therefore shows that dynamic and long-lasting DNA 
methylation changes can and do occur in postmitotic neurons. 
 Similarly, Yakovlev et al. (2010) have traced age-dependent 
downregulation of caspase-3 production in rat brain to significantly 
lower levels of histone 3 acetylated Lys14 and histone 4 acetylated 
Lys5, 8, 12, and 16, as well as to differential methylation of specific 
CpG sites within the caspase-3 promoter.  These sites are in a region 
that is essential for caspase-3 promoter activity, and  correspond to 
predicted binding sites for several transcription factors such as Ets-1 
and Ets-2 that are known to help control caspase-3 synthesis and to 
play critical roles in neuronal differentiation, development, and 
death.  Notably, Ets-1 and Ets-2 themselves did not show age-related 
decline in the study, highlighting the potential importance of 
interactions between DNA methylation modifications and 
transcription factor activity.  That is, transcriptional control of a gene 
by its transcription factors may be significantly altered by differential 
methylation of the binding sites for those transcription factors. 
 New research has also shown that, in addition to their roles 
in DNA methylation, MBD2 and DNMT3a/b may participate in 
dynamic demethylation processes.  It has been reported, for 
example, that transient co-expression of MBD2 and methylated 
promoters results in demethylation and activation of gene 
expression, whereas knockdown of MBD2 inhibits replication-
independent, active demethylation by valproate (reviewed in Szyf, 
2009).  Cyclical methylation/demethylation processes that mediate 
bouts of active and inactive transcription over periods of tens of 
minutes have also been demonstrated, and appear to help regulate 
the expression of multiple genes (Metivier et al., 2008; Kangaspeska 
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et al., 2008).  Here, DNMT3a/b, in concert with p68, bind and 
deaminate selective CpG sites, creating mismatches that are 
recognized by TDG and repaired by the BER.  Because the repaired 
CpGs are no longer methylated, the local chromatin environment 
becomes poised for transcription.  Following transcription, MBDs, 
MeCP2, and DNMTs are recruited and remethylate the CpG sites.  
Transcription is therefore turned off or retarded.  The cycle may 
then begin again with DNMT3-mediated CpG deamination (Metivier 
et al., 2008).  Although these dynamic MBD and DNMT 
demethylating mechanisms have, as yet, been examined only in non-
CNS cells, there is no obvious reason why they should not occur in 
neurons.  Similarly, a recent study has suggested that histone 
acetylation and deacetylation, like DNA methylation and 
demethylation, are dynamic, rapid-turnover processes that can 
poise genes for transcription in peripheral cells (Clayton et al. 2006).  
As such, all these mechanisms may warrant significant attention in 
future neuroepigenetics research. 
 
4.0 Epigenetic regulation of aging 
Aging is universally considered to be one of the most salient risk 
factors for AD, with increasing risk for the disorder cumulating until 
at least the ninth decade of life (Gao et al. 1998; Kukull et al. 2002).  
Why aging should be a risk factor for AD (and other age-related 
disorders), however, is not well understood, particularly at a 
mechanistic level.  Potentially deleterious changes in 
mitochondria/oxidative stress (Crouch et al. 2007), gonadotropins 
(Fuller et al. 2007), calcium (Thibault et al. 2007), glucocorticoids 
(Blalock et al. 2004), inflammation (Duenas-Gonzalez et al. 2008), 
trace metals (Brewer 2007), insulin (Craft 2005), cerebrovascular 
supply (Bailey et al. 2004),  the cell cycle (Macaluso et al. 2006), Aβ 
(Selkoe 2003), tau (Maeda et al. 2006), and hundreds to thousands 
of genes (Parachikova et al. 2007; Berchtold et al. 2008) occur both 
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in aging and AD, but a coherent explanation for why they occur and 
if their co-occurrence in aging and AD is coincidence or meaningful 
remains elusive.   
 DNA methylation and histone modifications have been 
widely implicated in the phenotypic alterations that occur during 
cellular senescence and the aging of various organisms (reviewed in 
(Wilson and Jones 1983; Bandyopadhyay and Medrano 2003; Liu et 
al. 2003; Fraga and Esteller 2007; Poulsen et al. 2007), and may 
provide a link between aging and AD.  Histone acetylation 
mechanisms, particularly those involving the Sir2 family of histone 
deacetylases, have been linked to aging and senescence in yeast and 
invertebrates (reviewed in (Bandyopadhyay and Medrano 2003), but 
have yet to be investigated in mammals.  By contrast, many studies 
have reported a genome-wide tendency to DNA hypomethylation 
with age in multiple vertebrate organs, including brain, liver, small 
intestine mucosa, heart, and spleen; multiple cell types, including 
fibroblasts and T lymphocytes; and multiple vertebrate species, 
including aging salmon, mice, rats, cows, and humans (Romanov and 
Vaniushin 1980; Romanov and Vanyushin 1981; Wilson et al. 1987; 
Golbus et al. 1990; Lu et al. 2006).  Yu and colleagues (Guo et al. 
2006) assayed human peripheral blood mononuclear cell DNA for 
the percentage of methylated to total cytosines and observed a 3% 
per decade decrease from the first to the tenth decade of life.  In 
vitro, hypomethylation of human and mouse fibroblasts cultured to 
senescence has also been observed (Wilson and Jones 1983).  
Likewise, progressive age-related decline in total genomic 
methylcytosine has been reported in various organisms (Mays-
Hoopes 1989).  Because DNMT1, which is responsible for 
maintaining DNA methylation of CpG sites, is also progressively lost 
with age (Lopatina et al. 2002), it has been speculated that 
progressive, age-related, genome-wide hypomethylation may be 
due to parallel DNMT1 deficits (Liu et al. 2003), and that the process 
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overall may serve as a counting mechanism that triggers cellular 
senescence (Neumeister et al. 2002).  Age-dependent increases in S-
adenosyl-homocysteine (SAH) relative to SAM (Varela-Moreiras et 
al. 1994) might also play a role, since SAH inhibits methylation 
reactions, including DNA methylation.  In turn, overall decline in 
genomic  methylation with age has been linked to specific age-
related pathogenic processes such as aberrant cell cycle events (e.g., 
p-53-dependent apoptosis) (Jackson-Grusby et al. 2001) and the 
increased inflammatory tone that occurs with advancing age (Wilson 
2008). 
 Hypomethylation of non-coding regions and other sites also 
occurs with age and has been suggested to be relevant to the aging 
process.  For example, repetitive sequences (Romanov and 
Vanyushin 1981; Mays-Hoopes et al. 1986; Rath and Kanungo 1989), 
retrotransposons (Barbot et al. 2002), and endogenous retroviruses 
(Ono et al. 1989) that are normally repressed by DNA methylation 
can become hypomethylated with age, potentially promoting 
chromosome translocations, retrotransposon activation, and 
retrovirus emergence, respectively (reviewed in (Lu et al. 2006).  
 Age-dependent hypomethylation of a number of specific 
genes related to AD has been reported.  For example, methylation of 
cytosines in the APP promoter, particularly GC-rich elements from 
approximately -270 to -182, is significantly lower in autopsy cases 
≥70 years old compared to cases <70 years old (Tohgi et al. 1999).  
DNA methylation within the tau promoter reportedly declines 
overall with age, but with interesting variations at different 
transcription factor binding sites:  binding sites for GCF, which 
represses GC-rich promoters, become hypomethylated with age, 
whereas binding sites for Sp1, a transcriptional activator, become 
hypermethylated.  These changes might therefore represent a 
double hit on tau gene transcriptional activity, causing decreased 
activity overall with age (Tohgi et al. 1999).  Promoter methylation 
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of the receptor for advanced glycation end products (RAGE) gene 
exhibits similar complexity.  Overall methylation of the promoter 
declines with age, but the change is manifest at cytosine residues 
other than CpG dinucleotides:  CpC, CpA, and CTG sequences within 
AP2 and SP1 binding sites show significant hypomethylation  with 
age (Tohgi et al. 1999).  Expression of the immune/inflammatory 
antigen CD11a increases with age (Pallis et al. 1993), an effect that 
appears to be linked to an age-related hypomethylation of flanking 
repeats some 1 kb 5’  to the CD11a promoter start site (Zhang et al. 
2002).  
 Despite the trend to genome-wide and gene-specific DNA 
methylation with age, it should be emphasized that the trend is no 
more than that, as many genes exhibit age-related decreases in 
expression rather than the upregulation that is predicted by 
hypomethylation or histone acetylation.  CpG islands on several 
specific genes undergo age-dependent hypermethylation (e.g., 
estrogen receptors, insulin-like growth factor 2) (Issa et al. 1994; Issa 
et al. 1996).  Tumor suppressor genes appear particularly apt to 
show increasing methylation with age, providing a potential link to 
age-related cancers (Romanov and Vaniushin 1980; Mays-Hoopes 
1989; Issa et al. 1994; Issa and Baylin 1996; Neumeister et al. 2002; 
Liu et al. 2003; Figueiredo et al. 2006; Lu et al. 2006; So et al. 2006; 
Fraga and Esteller 2007; Jacinto et al. 2007).  Many of these 
hypermethylation events could be due to age-related increases in 
DNMT3a/b expression (Lopatina et al. 2002; Liu et al. 2003), as these 
methyltransferases are responsible for de novo methylation of DNA.  
Alternatively, they have also been linked to demethylation processes 
(Metivier et al., 2008; Kangaspeska et al., 2008). 
 Further adding to the complexity of aging changes in DNA 
methylation, tissue-specific patterns should also be noted.  For 
example, the tumor suppressor gene c-fos exhibits increasing CpG 
methylation with age in liver, but not brain or spleen (Ono et al. 
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1989).  In brain, methylation profiles may differ substantially from 
one region to another (Ladd-Acosta et al. 2007) and even from one 
subregion to another (e.g., hippocampal dentate gyrus and CA fields) 
(Brown et al. 2008), underscoring the value of brain regional 
comparisons in  epigenetic studies of aging and AD. 
 In addition to aging, epigenetics plays a major role in 
development (reviewed in (Reik et al. 2001).  These mechanisms 
could be relevant to AD since overt clinical symptoms of the disorder 
virtually never appear until after the developmental stages of 
infancy, childhood, and early adolescence have been completed, and 
this is true not simply in late-onset patients but in patients carrying 
APP, PS1, or PS2 mutations.  Thus, epigenetic changes earlier in life 
might be a necessary but not sufficient step toward AD in 
susceptible individuals, a key concept in the “LEARn” (latent early-
life associated regulation) model of age-related neurologic disorders 
(Lahiri et al. 2007; Wu et al. 2008a).  Support for this hypothesis 
comes from APP transgenic mouse research wherein earlier 
epigenetic manipulations appear to accelerate or delay the 
expression of Aβ pathology (Fuso et al. 2008).  Likewise, early 
exposure of monkeys to Pb reportedly decreases DNMT activity, 
increases APP, BACE, and SP1 expression, and alters levels and 
distribution of Aβ in the animals in late life (Wu et al. 2008b).  
 
5.0 Epigenetic alterations in AD 
 
5.1 Histone modifications.   
Several reports have demonstrated alterations in histone proteins in 
AD.  Phosphorylation of histone 3, a key step in the activation of the 
mitotic machinery, is increased to a hyperphosphorylated state in 
AD hippocampal neurons (Ogawa et al. 2003).  A non-nuclear form 
of histone 1 appears to be upregulated in astrocytes and neurons in 
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brain regions that are rich in AD pathology (Bolton et al. 1999).  
Linker Histone H1, a vital component of chromatin, has been 
reported to preferentially bind Aβ-42, as well as Aβ–like structures 
of numerous proteins (Duce et al. 2006).   In addition, the H1 
molecule has been shown to be a major target for poly (ADP-
ribosyl)ation in areas of AD brain with ischemic brain injury (Love et 
al. 1999).  
Manipulation of histone tail acetylation with HDAC inhibitors has 
been investigated in several animal models of AD.  For example, it 
has been reported that after fear conditioning training in APP/PS1 
mice, levels of hippocampal acetylated histone 4 (H4) were about 
50% lower than in wild-type littermates. Treatment with the HDAC 
inhibitor Trichostatin A increased the levels of acetylated H4 and 
contextual freezing performance to wild-type values (Chessell et al. 
1994).  Treatment with HDAC inhibitors has also been shown to 
induce sprouting of dendrites, increase the number of synapses, and 
reinstate learning behavior and access to long-term memories in CK-
p25 transgenics (Fischer et al. 2007).  In addition, valproic acid, 
which has HDAC1 inhibitor activity, has been shown to decrease Aβ 
production and reduce plaque burden in the brains of 
PDAPP(APP(V717F)) transgenic mice (Su et al. 2004).  Similarly, in 
the Tg2576 mouse model of AD, a daily dose of phenylbutyrate, 
another HDAC inhibitor, reversed spatial memory loss and 
normalized levels of phosphorylated tau in the hippocampus, but 
failed to alter Aβ levels (Ricobaraza et al. 2009).  Conversely, in a 
cortical neuron culture model, overexpression of APP resulted in a 
decrease in histone 3 and histone 4 acetylation, as well as a 
decrease in CREB-binding protein levels (Lonze and Ginty 2002; 
Rouaux et al. 2003). 
In summary, although it appears that histone modifications occur in 
AD, AD animal models, and AD culture models, the pattern of 
changes is complex and could entail both histone acetylation 
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increases and decreases at specific loci that function disjointedly or 
in concert.  
 
5.2 miRNAs. 
Global analyses of AD versus normal elderly control brains have 
revealed changes in the levels of several specific miRNAs that were 
concordant across two separate studies (Hebert et al., 2008; Nunez-
Iglesias et al., 2010).  Notably, however, both positive and negative 
relationships between levels of the miRNAs and levels of their 
targets were observed, suggesting the operation of upstream factors 
(Tsang, Zhu, and van Oudenaarden, 2007).  A third study has 
provided the additional caveat that significant AD changes in many 
miRNAs may be common to both pathologically-vulnerable and 
pathologically-spared brain regions.  Other miRNAs, however, were 
specific both to AD and to areas of extensive AD pathology, and their 
targets had resonance with mainstream AD pathologic pathways 
(Cogswell et al., 2008).  In vitro experiments with HeLa, COS1, and 
HEK293 cells have shown that luciferase expression controlled by 
the APP 3’UTR can be regulated by miR-20a, miR-17-5p, and miR-
106b miRNAs.  Transient transfection of these miRNAs 
downregulated APP expression—in the case of miR-20a by inhibiting 
translation rather than by degradation of APP mRNA.  Conversely, 
blocking expression of miR-20a increased endogenous APP levels by 
some 50%.  Subsequent developmental studies of mouse brain 
revealed dramatic reductions in all three miRNAs that were 
significantly correlated with increased APP protein expression.  The 
fact that APP mRNA levels remained stable under these conditions 
again suggested that the miRNAs have their effects on APP by 
inhibiting translation rather than promoting cleavage of APP mRNA.  
Finally, human pathology studies have shown that miR-106b is 
significantly decreased in AD cortex.  Although all these findings 
indicate that APP may be targeted by miRNA mechanisms, levels of 
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miR-20a, miR-17-5p, and miR-106b in AD cortex do not appear to 
correlate with levels of APP protein (Hebert et al., 2009). 
Two studies have used computational analysis methods to reveal 
miRNA target sites in BACE mRNA that may be functionally relevant 
to AD pathogenesis.  Wang and colleagues (2008) found multiple 
target sites for miR-107 in the 3’-untranslated region of BACE, and 
went on to show significant decreases in miR-107 that were 
apparent even in early AD cases, particularly in the large pyramidal 
cell cortical layers that may be especially vulnerable to AD pathology 
(Rogers and Morrison, 1985).  Moreover, when assayed in the same 
cases BACE mRNA expression appeared to be negatively associated 
with miRNA-107 levels (Wang et al., 2008).  An additional miRNA, 
miR-29a/b-1, also appears to target BACE mRNA and, like miR-107, is 
decreased in AD and inversely correlated with BACE—in this case, 
BACE protein levels (Hebert et al., 2008). 
 
5.3 DNA methylation. 
 
5.3.1 Genome-wide and multi-gene studies.   
Although an early analysis reported no significant difference in 
percent CCGG methylation of DNA in AD cortex, a number of caveats 
were given (Schwob et al. 1990), particularly the fact that CCGG 
methylation only covers approximately 20-30% of CpG sites in the 
genome.  Methylation status of 12 specific genes that have been 
implicated in AD pathology has also been reported to exhibit 
significant "epigenetic drift", although the manner in which the data 
were analyzed makes it difficult to determine whether methylation 
was increased or decreased in AD.  The study did note, however, 
that  an age-specific epigenetic drift was observed in some of the 
CpG sites within the DNMT1 promoter (Wang et al. 2008). 
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 From a genome-wide perspective, our laboratory has 
reported decreased immunoreactivity for some seven different 
markers of DNA methylation in AD compared to matched, non-
demented elderly control (ND) cortical neurons and glia (Figs. 2, 3), 
whereas no such changes were observed in cerebellum, a brain 
region that is relatively spared in AD (Mastroeni et al. 2008).  Highly 
similar results were subsequently obtained in a set of monozygotic 
twins discordant for AD (Mastroeni et al. 2009) (Fig. 4A), as well as in 
APP-overexpressing transgenic mice (Fig. 4B).  
 As previously noted, folate/methionine/homocysteine 
metabolism is critically linked to DNA methylation mechanisms.  
Folate deficiency in humans and in animal models, for example, 
typically results in global hypomethylation that is at least partially 
reversible with folate supplementation (reviewed in (Choi and 
Mason 2002; Choi et al. 2005).  Deficits in folate and alterations in 
the methionine/homocysteine cycle have been reported in aging 
and AD (reviewed in Smith, 2008), and may therefore provide a basis 
for the tendency to genome-wide hypomethylation summarized 
earlier in this review.  Although one prospective study failed to find 
an association between dietary folate, vitamin B12, or vitamin B6 
with incident AD (Morris et al. 2006), CSF folate has nonetheless 
been reported to be significantly decreased in AD (Serot et al. 2001), 
as has CSF and brain SAM and one of its synthesizing enzymes, 
methionine S-adenosyltransferase (Bottiglieri et al. 1990; Morrison 
et al. 1996).  Increases in brain SAH (Kennedy et al., 2004) and 
plasma homocysteine (Clarke et al. 1998), which inhibit DNA 
methylation, have also been observed.  Elevated plasma 
homocysteine has been reported to be a significant risk factor for AD 
in dementia-free cohorts of both the Framingham Study of Aging 
(Seshadri et al. 2002) and the Conselice Study of Brain Aging 
(Ravaglia et al. 2005).  In fact, dietary effects of folate and 
homocysteine manipulation have been implicated in cognitive 
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impairment generally, and in a wide range of neurologic conditions, 
including AD, Parkinson's disease, depression, cortico-basal 
degeneration, multiple sclerosis, and fronto-temporal dementia 
(Obeid et al. 2007).  
 
5.3.2  Aβ-related genes.  
 Epigenetic influences on Aβ-producing mutations have long been 
suspected based on the heterogeneity of clinical presentation by 
patients who share mutations in the same APP, BACE, or PS1 
genes—sometimes in identical promoter sites (Larner and Doran 
2006).  Consistent with this notion, recent reports have established 
that the genes encoding APP (West et al. 1995; Miller et al. 2004; 
Mani and Thakur 2006), BACE, and PS1 are methylated at CpG sites 
under normal conditions, whereas TACE and ADAM10 are not (Fuso 
et al. 2005).  A case study has reported complete demethylation of 
the APP gene in an AD postmortem cortical sample, but not in 
similar samples from a normal control or Pick's disease patient 
(West et al. 1995). 
 In vitro  exposure of cultured neurons to folate/B12-deficient 
medium results in hypomethylation of PS1 and BACE, increased PS1 
and BACE expression, and enhanced Aβ production (Fuso et al. 
2005).  Similarly, exposure of APP-overexpressing transgenic mice to 
a folate/B12/B6-deficient diet is associated with enhanced SAH 
relative to SAM, PS1 and BACE upregulation, enhanced Aβ 
deposition, and an accelerated appearance of intraneuronal Aβ and 
cognitive deficits (although the latter was quite modest) (Fuso et al. 
2008).  By contrast, exposure to exogenous SAM inhibits the 
hypomethylation of PS1 and decreases Aβ secretion in 
neuroblastoma cell lines (Fuso et al. 2005).   
 Finally, it has been demonstrated that Aβ itself may induce 
genome-wide hypomethylation in murine cerebral endothelial cell 
cultures while, at the same time, causing specific hypermethylation 
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and repression of the gene for neprilysin, an Aβ degrading enzyme 
(Chen et al. 2009).  Our laboratory has replicated the global 
hypomethylating effects of Aβ in human SK-N-BE2 neuroblastoma 
cells, and extended the results to show hypomethylation (as well as 
several instances of hypermethylation) of specific CpG islands in the 
BACE (Fig. 5) and caspase-3 genes (Grover et al., unpublished).  
Together with hypermethylation of neprilysin, these effects suggest 
the potential for a vicious cycle in which Aβ-induced methylation 
changes feed back to enhance Aβ production, further methylation 
changes, and further Aβ production.  Moreover, if the overall trend 
to hypomethylation after Aβ exposure were to functionally impact 
other key AD genes, additional synergisms might occur.  For 
example, TNF-α (Wilson, 2008) and caspase-3 are upregulated when 
hypomethylated (Muerkoster et al. 2008), and increased levels of 
TNF-α (Janelsins et al. 2008; McAlpine et al. 2009; Sommer et al. 
2009) and caspases (Xie et al. 2008; Xiong et al. 2008) enhance Aβ 
expression, potentially generating new vicious cycles.  
 
5.3.3 Tau.  
 Methylation mechanisms with respect to tau and neurofibrillary 
tangle formation have also been explored.  As previously noted, in 
normal adults the AP2 binding site of the tau promoter is not 
methylated, but the SP1 and GCF binding sites are.  SP1, a 
transcriptional activator site, is increasingly methylated and GCF, a 
promoter repressor site, is increasingly demethylated with age, 
suggesting an overall downregulation of tau gene expression (Tohgi 
et al. 1999).  Although a corresponding age-related decrease in 
normal tau protein, particularly in frontal cortex and hippocampus, 
has been reported, there was no correlation with the modest 
neurofibrillary tangle pathology in the same subjects (Mukaetova-
Ladinska et al., 1996). 
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 Tau phosphorylation mechanisms are, however, subject to 
cytoplasmic methylation reactions, and have been the subject of 
several recent reports.  Our studies, for example, revealed co-
localized immunoreactivity for the methyl binding complex 
component p66α (as well as HDAC1) with PHF1-positive 
neurofibrillary tangles (Mastroeni et al. 2008).  PP2A is an enzyme 
that can dephosphorylate phosphorylated tau, an action that may be 
potently activated by methylation of the PP2A catalytic subunit at its 
L309 site.  In N2a cultures carrying the APP Swedish mutation 
(APPswe) and in APPswe/PS1 transgenic mice, levels of 
demethylated PP2A at L309 were significantly increased, 
corresponding with increases in tau phosphorylation at the Tau-1 
and PHF-1 sites.  Treatment with Aβ25-35 led to demethylation and 
enhanced tau phosphorylation  (Zhou et al. 2008).  Like treatment 
with Aβ25-35, exposure of rodent primary neuron cultures to 
methotrexate, a folate antagonist, also has been reported to result 
in demethylation of PP2A, with attendant enhancement of tau 
phosphorylation (as well as upregulation of APP and BACE) (Yoon et 
al. 2007).  Consistent with all these findings, injections of 
homocysteine into rats for two weeks yielded decreased PP2A L309 
methylation and PP2A activity, effects that were reversed by 
simultaneous administration of folate and vitamin B12.  
Hippocampal samples from the rats and from AD patients exhibited 
immunohistochemical co-localization of demethylated, but not 
methylated PP2A with hyperphosphorylated tau (Poleshko et al. 
2008). 
 
5.3.4  Aberrant cell cycle/apoptosis.  
 A wide range of evidence suggests that attempted or aberrant re-
entry into the cell cycle and/or apoptosis of neurons may be a 
common neurodegenerative mechanism in AD (reviewed in 
(Corneveaux et al. 2010).  Many of the critical components of the 
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cell cycle and apoptosis pathways are upregulated in degenerating 
AD neurons, and are subject to regulation by DNA methylation, 
including the P16, P21, P27, P53, RB1 (Honda et al. 2005), cyclin B2 
(Tschop and Engeland 2007), ARF (Robertson and Jones 1998), 
caspase 1 (Jee et al. 2005), caspase 3, caspase 7, caspase 8, and 
caspase 9 (Muerkoster et al. 2008) genes.  Hypomethylation of these 
genes would be expected to promote aberrant cell cycle events, and 
global hypomethylation has been reported to occur in cells as they 
move from the G(0) stage characteristic of postmitotic neurons to 
the G(1) stage characteristic of cell cycle re-entry (Brown et al. 
2007).  Indirect support for the role of hypomethylation in aberrant 
cell cycle events is provided by studies demonstrating apoptosis of 
cultured neurons when exposed to high homocysteine levels (Ho et 
al. 2002).  Although many other biologic effects are possible, such 
treatment is known to hypomethylate DNA (Reynolds, 2006), and 
concurrent treatment with SAM antagonized the apoptotic effect 
(Ho et al. 2002).  Interactions of the histone acetyltransferase Tip60 
with the γ-secretase-generated APP C-terminal fragment APP-CT58, 
which translocates to the nucleus, also lead to apoptosis of human 
H4 neuroglioma cells (Kinoshita et al. 2002).     
 
5.3.5  Inflammation.   
Key genes at almost every level of the inflammatory response 
appear to be subject to DNA methylation influences.  A highly 
abbreviated list of examples includes complement C3, factor B, IL-
1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, TNF-α, TNFRI, INF-γ, SOCS, 
S100A2, the chemokine receptors CXCR4 and CCR7, clusterin (apoJ), 
and iNOS (Mejia et al. 1995; Li et al. 2005; Buslei et al. 2006; 
Suuronen et al. 2007; Mi and Zeng 2008; Nile et al. 2008; Parker et 
al. 2008; Pieper et al. 2008; van Panhuys et al. 2008; van Rietschoten 
et al. 2008).  The TNF-α promoter, for example, contains 12 CpG-rich 
sites.  Two of those sites (-304 and -205) are hypomethylated on 
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exposure of macrophages to the classic inflammatory stimulus 
lipopolysaccharide, and their extent of hypomethylation is 
correlated with increasing expression of TNF-α (Wilson 2008).  
Likewise, a single CpG site in the IL-6 promoter (-1,181) is 
significantly hypomethylated in rheumatoid arthritis and this 
hypomethylation is correlated with IL-6 mRNA levels (Nile et al. 
2008).     Although virtually none of the many factors in 
inflammation has been investigated with respect to its DNA 
methylation status in AD, this could be a fertile area for investigation 
given the heightened expression of these molecules in the disorder.  
A recent Parkinson’s disease study, for example, has demonstrated 
that the TNF-α promoter is hypomethylated in the substantia nigra 
relative to several other brain regions.  Since DNA methylation of 
CpG sites in the TNF-α promoter inhibits SP1 and AP-2 transcription 
factor binding and decreases TNF-α expression, it has been 
speculated that nigral TNF-α hypomethylation might explain the 
heightened vulnerability of nigral dopamine neurons to TNF-α-
mediated inflammatory reactions  (Pieper et al. 2008). 
 
5.3.6.  Apolipoproteins.   
Again, no specific studies have been done on the methylation status 
of apolipoprotein E (ApoE) in AD.  Notably, however, Wang and 
colleagues (2008) have reported that although the ApoE promoter is 
poorly methylated, the ApoE ε4 allele contains methylated CpG 
sequences that are not extant in the ε2 or ε3 alleles.  Because not all 
ε4 carriers develop AD, it would be of great interest to know if 
methylation status at ε4 CpG sites is altered in ε4 carriers who 
develop (or do not develop) AD.  Similarly, it might be useful to 
determine whether the significant but relatively low penetrance of 
ApoJ (clusterin) SNPs to AD risk (Harold et al. 2009; Lambert et al. 
2009) might be explained by methylation changes, since the ApoJ 
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promoter is rich in CpG sites and expression is increased on 
hypomethylation (Suuronen et al. 2007).  
 
Conclusions 
Global epigenetic changes, acting on a wide range of genes and 
biological pathways, appear to help orchestrate the cellular 
alterations that drive development, aging, and, in some cases, 
disease.  Likewise, global epigenetic changes have been observed in 
pathologically-vulnerable regions of the AD brain, and key genes in 
virtually every mainstream pathologic pathway in AD are known to 
be labile to such changes.  The ability of epigenetic mechanisms to 
initiate an extremely wide range of pathogenic responses—an 
orchestrating capacity perhaps equaled only by transcription factors 
(which themselves often work together with epigenetic mechanisms 
to direct expression in specific sets of genes) (e.g., (Agrawal et al. 
2007; Ivascu et al. 2007)—provides a relatively unique integrative 
framework for the diverse genetic factors and multifactorial 
pathology of AD, including Aβ, tau, inflammation, mitochondrial 
metabolism, oxidative stress, and aberrant cell cycle/apoptosis 
events.  Moreover, the epigenetic modifications that have been 
reported in AD, particularly with respect to DNA methylation, 
typically resonate with similar trends in aging, and may therefore 
help explain not only the pathologic complexity of AD, but also the 
particular salience of aging as an AD risk factor. 
 Finally, whereas the field of epigenetics has previously 
emphasized mechanisms for preserving epigenetic profiles across 
generations of dividing cells, there is now ample precedent for 
active, dynamic epigenetic alterations in postmitotic cells, including 
neurons, that play important roles in neuroendocrine, learning and 
memory, and apoptotic processes.  These latter, landmark studies 
provide the tools for subsequent explorations of how the epigenetic 
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modifications that have already been reported in AD occur, as well 
as a mechanistic underpinning for the AD genome-wide methylation 
profiling that is now in progress. 
 
Future Directions 
At the level of basic research, DNA methylation profiling of aging and 
AD subjects is eagerly awaited in order to develop a better portrait 
of the normal methylation status of all genes across the AD genome, 
how that status may change in AD, and whether or not such changes 
implicate AD-related proteins and pathogenetic processes.  These 
studies would be especially significant if they were conducted in 
tandem with genome-wide gene expression arrays because the 
experiments would then provide validation of the functional effects 
of DNA methylation changes on gene expression.  In addition, 
knowing the methylation states of genes containing putative AD 
SNPs could be useful.  Many such SNPs, for example, remain 
controversial because their odds ratios for disease risk consistently 
hover at the statistical edges of significance or they fail to replicate 
in some studies but not others.  Epigenetic regulation of the SNP 
genes could account for this variability.  For example, a gain or 
decrease of function SNP could be compensated for by epigenetic 
downregulation or upregulation, respectively, of the gene’s 
expression, so that some carriers might in effect possess the SNP 
with relative impunity.   Finally, as valuable as large-scale epigenetic 
profiling of the AD genome will be, it will still not tell us why or how 
the profiles were altered, nor will it give us a detailed profile of each 
gene.  Genome-wide methylation profiling is presently only able to 
sample a few of the CpG-rich sites within each gene.  Because both 
hyper- and hypomethylation can occur at different CpG sites in the 
same gene, with one but not the other causing functional changes in 
gene expression (e.g., Murgatroyd et al., 2009), follow-up studies 
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giving detailed methylation maps of AD-relevant genes and 
concomitant changes in their expression will be essential.  These 
same considerations may also apply to other neurologic conditions 
such as schizophrenia and bipolar disorders, where epigenetic 
mechanisms are being pursued (reviewed in Pidsley and Mill, 2010). 
 Of course, to hypothesize that epigenetic changes play a role 
in brain aging, AD, and other neurologic disorders still begs the 
question of what causes the epigenetic changes?  The environment 
that cells and organisms are exposed to can have a profound 
influence on epigenetic mechanisms (Waterland and Michels., 2007; 
Smith and Kim, 2008), but simple stochastic processes may do so as 
well (Jaenisch and Bird, 2003).  Whether as environmentally-driven 
or randomly-occurring events, however, the probability of 
epigenetic modifications must logically increase with time, and 
increased time is precisely what the advanced ages reached by many 
human beings may afford.  Some of these modifications may be 
inconsequential, depending on the CpG site, the gene, or the organ.  
For example, inadvertent upregulation of an Aβ-synthesizing gene 
might have little to no impact on a muscle cell, whereas it could be 
highly significant in a pyramidal neuron.  Similarly, the brain lacks 
several major defenses against inflammatory attack (Gasque et al. 
2002; Zanjani et al. 2005), so that the inadvertent upregulation of a 
pro-inflammatory gene might be uniquely problematic there.  Thus, 
the origin and organ-specific consequences of epigenetic 
modifications are important considerations for AD epigenetic 
studies, and will continue to be critical targets for AD basic research 
into epigenetic mechanisms. 
 At the clinical level, the initiation of AD trials with folate/B 
vitamins/SAM may constitute one means of testing an epigenetic 
orchestration hypothesis of AD, although it is becoming increasingly 
evident that reversing the course of human AD with any treatment 
may be an over-ambitious goal.  For example, in a recent trial B 
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vitamin treatment  significantly slowed cognitive decline in mild AD, 
but was without effect in more advanced cases (Aisen et al., 2008).  
A trial in mild cognitive impairment patients might therefore be of 
great interest.  A second impediment to succesful treatment of 
epigenetic defects may be achieving sufficiently high levels of 
epigenetic therapeutics not only within cells, but within neuronal 
nuclei.  Moreover, the many different biochemical pathways 
impacted by epigenetic mechanisms may make targeting specific 
disease processes difficult.  Beyond folate and other such 
approaches, cancer chemotherapeutics that are directed at 
epigenetic mechanisms are available, but would need to be 
considered carefully.  DNA demethylating agents such as 5-
azacytidine and decitabine, for example, might actually prove 
harmful in AD given the profound global hypomethylation of AD 
neurons (Mastroeni et al., 2008, 2009).  HDAC inhibitors such as 
valproate, by contrast, might counter many of the epigenetic 
changes that have been reported in AD, and have, in fact, been used 
successfully to improve cognitive outcome measures in AD 
transgenic mouse models (Su et al., 2004; Fischer et al., 2007; 
Francis et al., 2009; Ricobaraza et al., 2009; Guan et al., 2009).  
Treatment trials in human AD patients, however, have not been 
particularly encouraging, perhaps due to somnolence, agitation, and 
other side effects of the drug (Profenno et al., 2005; Herrman et al., 
2007) or to lack of specificity of the drug to epigenetic mechanisms 
alone. 
 With respect to the development of new treatments for AD, 
a direct role for epigenetics would be the design and application of 
epigenetic therapeutics that have appropriate effects on specific 
epigenetic mechanisms in specific genes or sets of genes.   As we 
have emphasized throughout, however, one of the defining 
hallmarks of epigenetic mechanisms is their ability to exert effects 
over many genes, and, accordingly, virtually all present epigenetic 
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therapeutics also exert their effects over many genes.  Unless a 
broad modifier such as an HDAC inhibitor can be found that just 
happens to impact the right genes, while sparing significant effects 
in others, the specificity requirements of an AD epigenetic 
therapeutic will be challenging.  Nonetheless, elucidating specific 
genes that undergo significant epigenetic alterations in AD—as is 
now in progress in our laboratory and elsewhere—could, at the very 
least, help direct our attention to the most salient pathogenic 
elements of the disorder and to more conventional (e.g., 
agonist/antagonist) approaches to the protein products of the 
epigenetically-modified genes. 
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Figures 
 
 
 
 
 
 
Fig. 1.  Simplified schematic of histone acetylation and DNA 
methylation.  (Upper Left) In transcriptionally active genes the 
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chromatin, made up of histones (blue cylinders) around which DNA 
is wrapped, is in a relaxed state, permitting transcriptional access to 
unwound DNA.  This relaxed, euchromatin state is, in part, mediated 
by acetylation of histone tails (red rods) in which acetyl groups  
(green blocks) are transferred from acetyl-coenzyme A (acetyl-CoA) 
to the histone tails by histone acetyltransferases (HATs).  (Bottom 
Left) Within the DNA, the cytosines of adjacent C-G/G-C 
dinucleotides (CpGs) may be methylated.  The methyl group 
ultimately derives from methyltetrahydrofolate  in conjunction with 
the methionine/homocysteine cycle, and is transferred from S-
adenosylmethionine (SAM) to the cytosine  and incorporated into 
the genome by DNA methyltransferases (DNMTs).  CpG-methyl-
binding-domain proteins (MBDs) and methylation complex proteins 
(MeCPs) (which may contain MBDs) become associated with 
methylated CpGs, further inhibiting transcriptional access and 
repression of the gene.  (Upper Right).  DNA methylation and 
histone modifications are integrally linked, because MBDs and 
MeCPs attract histone deacetylases (HDACs) that transfer acetyl 
groups on the histone tail back to CoA.  Histone deacetylation, in 
turn, promotes the condensed, heterochromatin state characteristic 
of silenced or repressed genes. 
 
Fig. 2.  DNA methylation markers in AD and ND cortex.  A) Typical 
immunoreactivity for 5-methylcytosine, a global marker of DNA 
methylation, in AD and ND entorhinal cortex (from Mastroeni et al., 
2008, with permission).  Cases were well matched for age, gender, 
and postmortem intervals, which were all less than 3 hours 15 
minutes
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.  
Shaded bars represent means for different cases.  Although glia and 
virtually all types of neurons exhibit 5-methylcytosine 
immunoreactivity, layer II “island” neurons, among the most 
vulnerable to AD pathology, exhibit particularly intense staining in 
ND cases, as shown in the upper left micrograph at low power.  Such 
staining is weak to absent in AD cases (upper right micrograph).  
High power micrographs show the expected nuclear localization of 
immunoreactivity.  Far right panel shows counts of immunoreactive 
neurons per total neurons per field.  Normalizing to total neurons is 
important, as it helps to demonstrate loss of methylation within cell 
nuclei rather than loss of the methylated cell population itself.  The 
significant decrement in AD (P < 0.001) is typical of dozens of AD and 
ND cases examined, with little to no overlap in any case. B) 
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Representative immunoreactivity and cell counts for various MeCP1 
components in AD and ND neocortex.   Significant AD decrements (P 
< 0.05) were observed with all the markers—again with little to no 
overlap.  C) Western blots (normalized to β-actin) for these and 
other methylation markers exhibit immunoreactivity at appropriate 
molecular weights, with AD/ND differences similar to those 
observed by immunohistochemistry, suggesting that the latter are 
not due to cross-reactivity with other antigens.   
 
 
 
Fig. 3.  Immunoreactivity 
for DNMT1, the most 
prevalent 
methyltransferase in adult 
mammals.  A)  Typical 
DNMT1 immunoreactivity 
and cell counts (P < 0.001) 
in AD and ND neocortex.  
Shaded bars represent 
means for different cases.  
B) Western blots 
(normalized to β-actin 
standards) show 
immunoreactive bands at 
appropriate molecular 
weights for DNMT1 and a 
significant (P < 0.01) 
decrement in AD cases. 
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Fig. 4. Decreased overall 
DNA methylation in 
monozygotic twins 
discordant for AD.  A) 
Global hypomethylation 
(5-methylcytosine 
immunoreactivity) in an 
AD monozygotic twin 
compared to his normal 
sibling at low (upper 
micrographs) and high (bottom micrographs) power (Mastroeni et 
al. 2009) (courtesy of PLoS1).  B) Similar findings have recently been 
observed by our group in APP transgenic mice compared to their 
wildtype littermates. 
 
Fig. 5.  MethylMiner methylation profile of selected flanking and 
initial BACE promoter sites after exposure of differentiated SK-N-
BE(2) neuron-like cultures to 10 µM Aβ42. MethylMiner™ 
Methylated DNA Enrichment Kits (Invitrogen, Carlsbad, CA) were 
employed to enrich and fractionate double-stranded DNA based on 
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CpG methylation density. The highly methylated region showed 
significant hypomethylation while poorly methylated regions 
exhibited hypermethylation (Grover et al., unpublished).  
Correlations with Aβ production can help establish the functional 
relevance of methylation modifications at these and other CpG sites 
within the BACE gene integrally linked, because MBDs and MeCPs 
attract histone deacetylases (HDACs) that transfer acetyl groups on 
the histone tail back to CoA.  Histone deacetylation, in turn, 
promotes the condensed, heterochromatin state characteristic of 
silenced or repressed genes. 
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Abstract 
 
DNA methylation is a vital component of the epigenetic machinery 
that orchestrates changes in multiple genes and helps regulate gene 
expression in all known vertebrates. We evaluated immunoreactivity 
for two markers of DNA methylation and eight methylation 
maintenance factors in entorhinal cortex layer II, a region exhibiting 
substantial Alzheimer’s disease (AD) pathology in which expression 
changes have been reported for a wide variety of genes. We show, 
for the first time, neuronal immunoreactivity for all 10 of the 
epigenetic markers and factors, with highly significant decrements in 
AD cases. These decrements were particularly marked in 
PHF1/PS396 immunoreactive, neurofibrillary tangle-bearing 
neurons. In addition, two of the DNA methylation maintenance 
factors, DNMT1 and MBD2, have been reported also to interact with 
ribosomal RNAs and ribosome synthesis. Consistent with these 
findings, DNMT1 and MBD2, as well as p66  , exhibited punctate 
cytoplasmic immunoreactivity that co-localized with the ribosome 
markers RPL26 and 5.8 s rRNA in ND neurons. By contrast, AD 
neurons generally lacked such staining, and there was a qualitative 
decrease in RPL26 and 5.8 s rRNA immunoreactivity. Collectively, 
these findings suggest epigenetic dysfunction in AD-vulnerable 
neurons. 
 
Keywords: Epigenetics; DNA methylation; Alzheimer’s disease; 
Neuron; Ribosome 
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Introduction 
 
Gene expression in the Alzheimer’s disease (AD) brain has been 
shown to be altered in a wide variety of reports (Robinson et al., 
1994; Loring et al., 2001; Dunckley et al., 2006; Weeraratna et al., 
2007; Liang et al., 2008a,b,c), including a recent large-scale 
expression array study of sin- gle cell laser-captured entorhinal 
cortex layer II  neurons (Dunckley et al., 2006). Multiple physiologic 
and molecular pathways are affected, including energy metabolism 
(Liang et al., 2008c) inflammation (Loring et al., 2001; Weeraratna et 
al., 2007) and aberrant cell cycle events (Arendt, 2000; Bowser and 
Smith, 2002), among others. Although individual pathogenic factors 
such as amyloid peptide (A) and tau phosphorylation are clearly 
critical links, no over-arching principle to explain the consistency, 
extent, and breadth of the gene expression, physiologic, and  
molecular changes reported in AD has received consensus 
acceptance. Epige- netic mechanisms such as histone modification 
(Mclachlan et al., 1984), binding of non-histone proteins, and DNA 
methylation (Adcock et al., 2007; Suzuki and Bird, 2008) are capable 
of modulating coordinate expression of large numbers of genes 
across many different pathways, and may therefore warrant 
investigation for their potential role in AD pathogenesis. 
DNA methylation is a highly conserved process that has been 
implicated in many different modalities of gene expression. The 
factors responsible for the methylation process are a family of DNA 
methyltransferases that have been shown to catalyze the transfer of 
a methyl group to single-stranded DNA using S-adenosyl methionine 
as the  methyl donor. The recognition sequence for the mammalian 
DNA methyl- transferase is relatively invariant, with nearly all 
cytosine methylations occurring on 5∗-C-p-G-3∗  (CpG) (Bird, 
1986,1992). There are four known active DNA methyltransferases  
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in mammals, DNMT1, DNMT2, DNMT3A and DNMT3B. Of these, 
DNMT1 is the most abundant in mammalian cells. DNMT1 has been 
reported to be a key player in maintaining methylation in somatic 
cells, and loss of this enzyme has been shown to lead to nuclear 
disorganization, increased histone acetylation, and apoptosis (Chan 
et al., 2001; Fan et al., 2001; Jackson et al., 2004; Milutinovic et al., 
2004; Espada et al.,2007). 
Once methylation has occurred, methylation stability is 
maintained by the binding of specific complexes, MeCP1, to 
methylated regions of DNA. MeCP1 is not bound directly to 
methylated DNA, but rather to a single methyl-CpG-binding domain 
protein, MBD2. The resulting MeCP1/MBD2 com- plex is composed 
of 10 known proteins that include the complete nucleosome 
remodeling and histone deacetylase (NuRD) core, as well as MBD2. 
This group of proteins, in conjunction with CDK2AP1 (Doc1), make 
up a complex capable of nucleosome remodeling and histone 
deacetylation (Feng and Zhang, 2001, 2003). 
Because methylation and methylation maintenance fac- tors 
can orchestrate changes in expression of a wide range of genes 
(Ashraf and Ip, 1998; Nan et al., 1998; Fujita et al., 1999; Ng et al., 
1999; Feng and Zhang, 2001; Adcock et al., 2007; Suzuki and Bird, 
2008), we hypothesized that alterations in methylation and 
methylation stability might provide an over-arching mechanism that 
could help explain expression differences in the thousands of genes 
that are reportedly altered in AD (Robinson et al., 1994; Loring et al., 
2001; Dunckley et al., 2006; Liang et al., 2007, 2008a,b,c; 
Weeraratna et al., 2007). Here, we report highly significant 
decrements in immunoreactivity for two markers of DNA 
methylation and eight DNA methylation maintenance fac- tors in AD 
neurons of entorhinal cortex layer II, one of the most consistently 
vulnerable brain regions to AD pathology (Braak et al., 1993; 
Kordower et al., 2001). 
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2. Methods 
 
2.1. Subjects and brain samples 
Brain tissue was obtained through the Sun Health Research Institute 
Brain and Body Donation Program (Sun City, AZ). Specimens were 
collected under IRB-approved protocols and informed consents that 
permitted use of the samples for research by the investigators. 
Cases included in the study had received antemortem evaluation by 
board- certified neurologists and  neuropsychologists, as  well  as 
postmortem evaluation by a board-certified neuropatholo- gist. 
Evaluations and diagnostic criteria followed consensus guidelines for 
National Institute on Aging Alzheimer’s Dis- ease Centers. Diagnoses 
of patient condition included AD (N = 20) and cognitively and 
neurologically normal for age (ND) (N = 20). AD patients taking 
conventional AD therapeu- tics were not excluded from the study. At 
expiration, subject ages ranged from 60 to 97 years, with a mean of 
79.9 ± 1.3 years. Postmortem intervals for the subjects averaged 2 h 
40 min ± 12 min. Subject age, gender, and postmortem inter- val 
were well matched between the experimental groups, and there 
were no significant between-groups differences on any of these 
variables. Because neurons of entorhinal cortex layer II, which form 
clusters or “islands”, are among the earliest and most consistently 
impacted neurons in AD brain (26), this brain region was the focus 
for all experiments. 
 
2.2. Immunohistochemistry 
Temporal cortex was sliced axially into 1-cm thick slabs, immersion 
fixed for 48 h in buffered 4% paraformaldehyde at 4 ◦C, washed 
extensively in phosphate buffer (PB), and cry- oprotected in ethylene 
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glycol and glycerol. The slabs were then sectioned at 40   m a 
freezing cryostat. Free-floating sections at the level of the entorhinal 
cortex were stored in freezing solution (glycol/glycerol/PB) at −20 ◦C 
until required for experiments. Tissue sections used for bright field 
microscopy were  immunoreacted using  the  avidin–biotin 
complex/diaminobenzidine (DAB) method. Briefly, tissues were 
washed 2×, blocked in 1% hydrogen peroxide for 45 min, washed 3×, 
blocked in 3% bovine serum albumin  (BSA)  for  1 h,  washed  2×,  
and  incubated at  4 ◦Covernight in primary antibody solutions 
containing 0.25% BSA. Unless otherwise stated, all washes were with 
1× PBS Triton (PBST). Available information about the anti-bodies is 
given in Table 1. After incubation with primary antibody, sections 
were washed 3×, incubated in biotiny- lated, species-specific 
secondary antibodies (Vector) for 2 h, washed 3×, and incubated in 
avidin–biotin complex (Pierce) for 1 h. Following incubation with 
secondary antibody, the sections were washed 3×, once in PBST and 
twice in 0.05 M Tris buffer, then exposed to DAB solution containing 
125   l of 5 mg/ml DAB (Sigma), 11.125 ml 50 mM Tris buffer pH 7.6, 
and 500   l saturated nickel ammonium sulfate. Incuba- tions during 
chromagen development were no longer than 10 min, and were 
followed by two quick rinses in 50 mM Tris to stop the reaction. 
Finally, the sections were dried, taken through graded alcohols, de-
fatted in Neoclear (EMD), and  mounted with Permount (Pierce). AD 
and  ND  sec- tions were immunoreacted simultaneously using 
netwells in well-less plates. For fluorescence microscopy, the sec- 
tions were washed 3×, blocked with either 3% normal goat serum or 
3% BSA, and incubated for 2 h. The sections were then washed 2×, 
incubated in primary antibody in 0.25% BSA at 4 ◦C overnight, 
washed again, and incubated in species-specific, fluorophore-
conjugated secondary antibod- ies (Molecular Probes) at room 
temperature for 2 h. After a final wash, the sections were mounted, 
taken through Sudan Black to reduce autofluorescence, and 
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coverslipped with Vectashield mounting media (Vector). Deletion of 
primary antibody or incubation with pre-immune serum resulted in 
abolition of specific immunoreactivity in all cases (data not shown). 
Adjacent serial sections were stained with cresyl vio- let for cell layer 
identification and verification that the island neurons of layer II were 
intact. For some sections, nuclei were counterstained with 4∗,6∗-
diamidino-2-phenylindole (DAPI) (Invitrogen) before mounting. 
Double-label immunohistochemistry was also employed to 
evaluate possible associations of epigenetic factors with ribosomes    
and neurofibrillary tangles. Briefly, sections were washed, blocked 
with either 3% normal goat serum or 3% BSA, and incubated for 1–2 
h. Sections were then washed 2×, incubated in primary antibodies 
raised in different species in 0.25% BSA/PBST at 4 ◦C overnight. After 
primary incubation sections were washed 3× in PBST, and incubated 
in species–specific, fluorophore-conjugated secondary antibodies 
(Molecular Probes) at room temperature for 2 h. After a final wash, 
the sections were mounted, taken through Sudan Black to reduce 
autofluorescence, and  coverslipped with Vectashield mounting 
media (Vector). Immunostained tis- sue sections were examined on 
Olympus IX51 and Olympus IX70 microscopes equipped with 
epifluorescence illumina- tion or with confocal laser scanning using 
argon and krypton lasers (Olympus IX70). The findings were 
documented pho- tographically with an Olympus DP-71 color digital 
camera or, for confocal microscopy, by Fluoview software 
(Olympus). 
 
2.3. Cell quantification and statistical analysis 
For cell quantification, number-coded sections from three AD and 
three ND subjects were randomly selected fromthe pool of 20 AD 
and 20 ND subjects for each of the methylation factors (i.e., samples 
from different or overlap- ping subjects were evaluated for each 
factor). Measurements were made by an investigator blind to the 
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subjects’ exper- imental condition. At 40× magnification, the total 
number of neurons, which were readily discriminated from glia by 
their large nuclei, within each of three randomly selected entorhinal 
cortex  layer  II  islands, and  the  total  number of  neurons  within  
each  of  those  islands  that  exhibited clear immunoreactivity for 
the antibody being tested was recorded. A conventional two-tailed 
t-test of the percentage of cells labeled per island was then 
conducted to analyze the results. 
 
3. Results 
 
3.1. Immunoreactivity for markers of DNA methylation 
Nuclear labeling with 5-methylcytosine and 5- methylcytidine   has   
been   used   to   assess   methylation status in many reports (e.g., 
Halle et al., 1995; Havlis and Trbusek, 2002). In addition, both of 
these markers have also been reported to be associated with 
ribosomal RNA (rRNA) (Dunn, 1960; Tantravahi et al., 1981; Obara et 
al., 1982; Negre et al., 1989). 
 
3.1.1. Nuclear staining 
Nuclear  immunoreactivity  for  5-methylcytosine  and 5-
methylcytidine was clearly evident in entorhinal cortex layer II 
neurons in ND cases, but was markedly decreased in AD cases (Fig. 
1). The percentage of neurons showing positive  5-methylcytosine 
nuclear  immunoreactivity was 91.3% ± 1.3% in ND and 39.9% ± 3.4% 
in AD subjects (t = 514.0,  P < 0.0001).  Positive  5-methylcytidine 
nuclear immunoreactivity was observed in  90.1% ± 1.3% of  ND 
neurons, but only 51.8% ± 6.1% of AD neurons (t = 383.1, P < 
0.0001). There was no overlap in these data for ND and AD  cases.  
By  contrast,  in  pathologically  spared regions  of  brain  such  as  
cerebellum,  immunoreactivity for 5-methylcytosine and 5-
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methylcytidine was similar in ND and AD sections (Fig. 1D and 
Supplementary Fig. 1). Staining of entorhinal cortex glia could be 
discerned at high power in ND cases, but was dramatically 
decreased or not seen in AD cases (Fig. 2). Deletion of primary 
antibody or pre-absorption with primary antigen completely 
abolished staining with 5-methylcytosine, 5-methylcytidine, and all 
other antibodies employed in this study. 
 
 3.1.2. Cytoplasmic staining 
In ND neurons,  cytoplasmic 5-methylcytidine and  5- methylcytosine 
immunoreactivity was evident at the light level (Fig. 3A1 and C1). 
With confocal microscopy, the immunoreactivity had a  punctate 
morphology (Fig. 3A2, and C2), and was highly co-localized with 
immunoreactiv ity for the ribosomal protein RPL26 (Fig. 3A3 and C3). 
By contrast, 5-methylcytosine and 5-methylcytidine stain- ing was 
faint to absent in the cytoplasm of AD neurons (Fig. 3B1 and D1), 
and where it could be discerned, there was  no  co-localization with  
RPL26 (Fig.  3B2,  B3,  D2, D3). 
 
3.2. Immunoreactivity for DNA methylation stabilizing factors 
To investigate mechanisms that might underlie the changes 
observed in neuronal DNA methylation, we next examined a wide 
range of proteins that methylate CpG sites or help maintain normal 
methylation status. 
 
3.2.1. Nuclear staining 
Nuclear immunoreactivity for DNMT1, a major methyl- transferase 
(Mortusewicz et  al.,  2005), and  six  different components of  the  
MeCP1/MBD2 methylation complex, including   MTA2,   HDAC1,   
HDAC2,   p66  ,   RbAp48, and  MBD2/3, was  significantly diminished 
in  entorhinal cortex layer II neurons of AD compared to ND subjects 
(Fig. 4) (see also Supplementary Fig. 2). Mean percent of 
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immunopositive neurons (± SEM) and comparisons by t-test were: 
DNMT1—ND (91.9% ± 1.0%), AD (7.6% ± 2.4%) (t = 33.0,    P < 
0.0001);    HDAC1—ND   (65.1% ± 4.2%), AD  (17.0% ± 4.2%)  (t = 8.1,  
P < 0.0001);  HDAC2—ND (91.7% ± 2.7%), AD (12.7% ± 3.3%) (t = 
18.6, P < 0.0001); p66  —ND      (79.8% ± 4.6%),      AD      (12.7% ± 
3.0%) (t = 12.3,    P < 0.0001);    MTA2—ND    (94.7% ± 1.5%), AD 
(11.1% ± 2.4%) (t= 29.8, P < 0.0001); RbAp48—ND (93.7% ± 0.4%), 
AD (21.4% ± 2.8%) (t = 25.1, P < 0.0001); and MBD2/3—ND (98.3% ± 
1.4%),  AD  (9.1% ± 2.0%), (t = 37.1, P < 0.0001). By contrast, when 
these factors were evaluated in cerebellum, a region that exhibits 
little to no AD pathology, immunoreactivity in ND and AD sections 
was again equivalent (Supplementary Fig. 1). 
 
3.2.2. Cytoplasmic staining 
Methylation of pre-rRNA is necessary for correct mat- uration of 
rRNA, and three of the methylation factors that were evaluated, 
DNMT1, HDAC1, and MBD2, have pre- viously been reported to 
interact with rRNA as important components of ribosome synthesis 
(Ghoshal et al., 2004; Zhou and Grummt, 2005). Consistent with 
these findings in peripheral cells, DNMT1, MBD2, as well as p66  , 
another member of the MeCP1/MBD2 complex, exhibited punctate 
cytoplasmic immunoreactivity and co-localization with the ribosome 
markers RPL26 and 5.8 s rRNA in ND neurons (Fig. 5). HDAC1, 
however, showed only diffuse cytoplasmic reactivity without a 
punctate appearance and without RPL26 or 5.8 s rRNA co-
localization (not shown). In AD neurons, by contrast, ribosome-
associated cytoplasmic immunoreactivity for DNMT1, MBD2, and 
p66    was weak or not observed (Fig. 5). Moreover, consistent with 
the important role of these methylation factors in the synthesis of 
ribosomes, there was a noticeable decrease in immunoreactivity for 
the ribosome markers themselves in AD neurons (Fig. 5). 
Compromised expression of rRNA was also suggested by the 
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absence in AD neurons of punctate nuclear immunoreactivity for 
SNF2H, a component of NoRC, which is integral to rRNA synthe- sis, 
whereas punctate nuclear SNF2H immunoreactivity was clearly 
evident in ND neurons (see Supplementary Fig. 4). 
 
3.3. Relationship of methylation markers to neurofibrillary tangles 
Even in many ND cases, entorhinal cortex layer II is char- acterized 
by high densities of neurons with neurofibrillary tangles. 
Interestingly, there appeared to be an inverse relation- ship of 
entorhinal cortex layer II nuclear immunoreactivity for DNA 
methylation markers and markers for late-stage tan- gles (Fig. 6). 
This was especially true for 5-methylcytosine methylation in AD 
cases, where it was extremely difficult to find any PHF1 or PS396 
immunopositive tangle-bearing neu- rons that also exhibited 
discernable nuclear 5-methylcytosine immunoreactivity (Fig. 6A). 
Similar but less extreme results were seen for MeCP1 complex 
components (Fig. 6C, D and supplementary Fig. 3). Even in ND cases, 
the majority of layer II PHF1 and PS396 immunopositive neurons 
showed little to no co-localized MeCP1 component immunoreactiv- 
ity, and where such co-localization was seen the MeCP1 component 
staining appeared to be cytoplasmic, not nuclear (Fig. 6D, arrow). 
 
Discussion 
 
Perhaps because epigenetics is  itself a  relatively new field and has 
been primarily investigated in the context of oncology, epigenetic 
changes in AD are just beginning to be explored (Scarpa et al., 2003; 
Siegmund et al., 2007; Silva et al., 2008; Spremo-Potparevic et al., 
2008; Wang et al., 2008; Wu et al., 2008). However, the changes in 
mani- fold individual genes in multiple cellular pathways that are 
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emerging from large-scale gene expression array studies of AD 
(Robinson et al., 1994; Loring et al., 2001; Dunckley et al., 2006; 
Liang et al., 2007, 2008a,b,c; Weeraratna et al.,2007) suggest that 
epigenetic mechanisms could play a role in the disorder because of 
the ability of such mechanisms to modulate the coordinate 
expression of large numbers of genes. Here we provide, for the first 
time in human brain, immunohistochemical evidence that a wide 
range of epi- genetic markers and regulators are  expressed in  
neurons from control entorhinal cortex layer II and are dramatically 
decreased in AD patients, consistent with the high vulnerability of 
this brain region to AD pathology. In addition, we show co-
localization of methylation stabilizing factors with rRNA (5.8 s rRNA) 
and the ribosomal protein RPL26, a decrement in AD samples, and 
an apparent decrease in AD ribosomes themselves. We also show 
loss of SNF2H, a core component of the NoRC that is directly 
involved in rRNA expression. The present findings suggest that 
global DNA and RNA methylation status in  entorhinal cortex  layer  II  
neurons is  significantly diminished  in  AD.  A  complete  loss  of 
methylation is, of course, unlikely in any cell, and, indeed, extensive 
digital enhancement of superficially blank fields in AD cases often 
revealed faint nuclear and cytoplasmic immunoreactivity for most of 
the methylation markers.  Several previous studies have examined 
methylation at specific gene loci in AD cortex. One report examined 
methy- lation status of 12 specific genes that have been implicated 
in AD pathology. Significant “drifts” in status were observed in some 
of the loci, but the manner in which the data were analyzed makes it 
difficult to determine whether methylation  was  increased or  
decreased in  AD  (Wang et  al., 2008).  A second paper found AD 
cytosine methylation changes in two genes, one of which, S100A2, 
exhibited a significant decrease in  methylation. Cytidine methyla- 
tion  was  not  examined (Siegmund et  al.,  2007). Scarpa et  al.  
(2003)  have reported  loss  of  methylation control of the BACE and 
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presenilin 1 genes and its potential to cause overexpression of APP 
in AD. A very early, more global analysis found no significant 
difference in percent CCGG  methylation of  DNA in  AD  cortex, but  
a  num- ber of caveats were given (Schwob et al., 1990). CCGG 
methylation, for example, would only cover approximately 20–30% 
of CpG sites. Because only DNA extracts were assayed, alterations in 
cytoplasmic ribosomal methylation would also have been missed. 
Data on postmortem delay for the samples, which could have a 
substantial effect on methylation integrity, were unavailable. By 
contrast, post- mortem intervals for the present study averaged 2 h 
40 min, and were well matched among AD and ND cases. Moreover, 
as the authors of the previous research themselves noted, 
“Degenerating neurons, the cells most likely to reflect the molecular 
derangements of AD, probably contributed little to the bulk-
extracted DNA from brain slices from patients with AD.” Our 
analysis, on the other hand, included all cells on the entorhinal 
cortex sections. Finally, in lympho- cyte preparations, Silva et al. 
(2008) did not observe AD methylation changes in the SIRT3, 
SMARCA5, or CDH1 genes, but did report significant 
hypermethylation of the HTERT gene. The lymphocyte HTERT gene, 
however, is unusual in that its hypermethylation is believed to result 
in increased expression rather than the more usual silencing (Silva et 
al., 2008). AD  decrements in  methylation status, as  assayed by 5-
methylcytosine and  5-methylcytidine immunoreactivity, were 
accompanied by decrements in all eight of the methy- lation 
stabilizing factors examined. These factors are critical components 
of MeCp1, NoRC, and NuRd, which, in turn, are important to 
maintenance of normal methylation state. The  loss  of  many  of  
these  factors  may  be  interlinked. For example, DNMT1 is recruited 
by HDAC1, and both are recruited by NoRC (Zhou et al., 2002; Zhou 
and Grummt, 2005). Functionally, improper maintenance of 
methylation in somatic cells leads to nuclear disorganiza- tion, de-
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differentiation, upregulation of  tumor suppressor proteins, and an 
increase in histone acetylation (Chen et al.,  1998; Santos et  al.,  
2002; Zhu  and  Otterson, 2003; Hoffmann and Schulz, 2005). That 
methylation deficits in the present study were functionally 
associated with neurodegeneration is also suggested by their co-
occurrence with PHF1 and PS396 immunoreactivity, which are 
considered markers for the late stages of neurofibrillary tangle 
forma- tion. 
Methylation is involved in many aspects of cellular 
regulation, including ribosomal control and function. In addition to 
nuclear changes, we also report, for the first time, loss of 
cytoplasmic immunoreactivity for 5-methylcytidine and 5-
methylcytosine, markers of methylation, and three methy- lation 
stabilizing factors, DNMT1, MBD2, and p66, in AD entorhinal cortex 
island neurons. Genes for rRNA are heavily methylated in both 
transcribed and non-transcribed regions of the repeat unit (Bird, 
1978), leading to the suggestion that changes in epigenetic factors 
may disrupt processing and  function of  rRNA (Espada et  al.,  2007). 
Our findings are wholly consistent with this hypothesis. (1) Loss of 
rRNA methylation alters rRNA post-transcriptional modification 
(Swaminathan et al., 2007), and AD neurons showed a near absence 
of the two key methylation markers  5-methylcytosine and  5-
methylcytidine. (2)  DNMT1 deficits, as reported here for AD 
neurons, have been previously demonstrated to disrupt DNA 
methylation and increase acetylation levels of lysine 16 histone H4 
on rRNA genes (Espada et al., 2007). (3) The normal association of 
methylation  stabilizing  factors  such  as  DNMT1,  MBD2,  and p66  
with rRNA was nearly absent in entorhinal cortex layer II AD 
neurons. (4) SNF2H, a component of NoRC that is integral to rRNA 
synthesis, appeared to be lost in AD neurons. Indeed, we observed 
qualitative decreases in immunoreactivity for two markers of 
ribosomes themselves, RPL26 and 5.8 s  rRNA, in  these neurons. It  
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will therefore be of interest in future studies to test the hypothesis 
that  loss  of  methylation markers and  methylation stabilizers in  AD  
neurons may  cause deficits in  rRNA gene expression, rRNAs, 
ribosomes, and ribosomal protein synthesis. 
A final point that may warrant further research follows from 
the ability of epigenetic shifts to orchestrate entry or re-entry into 
the cell cycle (reviewed in (Golubnitschaja, 2007), a process that 
would presumably lead to apoptosis in postmitotic neurons (Nagy et 
al., 1998; Arendt, 2000; Nagy, 2000; Copani et al., 2001; Bowser and 
Smith, 2002; Herrup and Arendt, 2002). Many reports have 
suggested a derangement of cell cycle events in AD, including the 
observation that premature centromere division of the X 
chromosome is increased in AD (Spremo-Potparevic et al., 2008). 
Treatment of terminally differentiated PC12 neurons with the 
demethylating agent 5-azacytodine, for example, causes the cells to 
retract their processes, express cell cycle pro- teins, and apoptose 
(Hossain et al., 1997). Similarly, loss of methylation and DNMT1 in 
cultured neurons has been shown to lead to increased expression of 
cell cycle-related genes in vitro (Mattson, 2003). Thus, the 
decrements in methylation and methylation stabilization observed in 
the present study could provide an explanation for the many 
previous reports that have suggested an aberrant re-entry of  AD  
neurons into  the  cell  cycle  and/or  their  apoptosis. Development 
and  aging are  processes that  have  been consistently linked  to  
epigenetic orchestration (reviewed in (Wu et al., 2008), and aging 
remains one of the most salient risk factors for AD. Epigenetic shifts 
have also been considered as major causative factors in disease 
states, par- ticularly cancer (reviewed in (Esteller, 2008; Gonzalo et 
al., 2008; Vucic et al., 2008). Thousands of genes have been reported 
to increase or decrease their expression in AD neu- rons (Liang et al., 
2008a), suggesting that there may be some over-arching, but 
presently unknown principle under- lying these massive genomic 
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changes. It will therefore be of great interest to explore, in 
prospective studies, interactions of AD pathology with the 
epigenetic mechanisms and factors that are highlighted by the 
present descriptive findings. 
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Table 1 
Antibodies. 
 
 
Antibody 
 
Host/type 
 Dilution  
   Cata# 
 
Antigen/epitope 
 
 
NSE 
 
Chicken polyclonal 
 
1:500 
 
Chemicon/AB9698 
 
Synthetic peptides from rat and 
human     neuro  specific enolase 
NeuN Mouse 1:1000 Chemicon/MAB377B Uncharacterized vertebrate neuron 
specific 
 monoclonal/biotin   nuclear protein 
     
GFAP Rabbit polyclonal 1:1000 Chemicon/ab5804 Bovine glial fibrillary acidic protein 
     
RAC1 Lectin 1:1000 Vector/B-1085 Ricinus communis agglutinin I 
pS396 Rabbit polyclonal 1:1000 Invitrogen/44-752G Phosphopeptide serine 
396 tau 
     
PHF1 Mouse monoclonal 1:1000 Gift of Dr. P. Davies Human tau, phosphorylated serine 
396 and 404 regions 
     
MBD3 Mouse monoclonal 1:400 Abcam/ab45027 Human 
MBD3/CKAFMVTDEDIRKQEE 
DOC1 Rabbit polyclonal 1:400 Abcam/ab31794 Human 
DOC1/TSSQYRQLLSDYGPPS 
DNMT1 Rabbit polyclonal 1:400 Abcam/ab19905 Human DNMT1/Within residues 
100-200 
5-Methylcytidine Mouse monoclonal 1:500 Genway/20-783-71663 5-Methylcytidine  
     
RPL26 Rabbit polyclonal 1:500 Abcam/ab59567 Human 
RPL26/MKFNPFVTSDRSKNRKR 
HDAC1 Rabbit polyclonal 1:400 Abcam/ab19845 Human HDAC1/Within residues 
450 to the C-terminus 
     
P66 alpha Rabbit polyclonal 1:400 Abcam/ab13714 Human P66  /amino acids 137-150 
MTA2 Rabbit polyclonal 1:400 Abcam/ab8106 Human MTA2/amino acids 652-668 
HDAC2 Rabbit monoclonal 1:400 Abcam/ab32117 Human HDAC2/residues within C-
terminal 
     
rRNA 5.8S Mouse monoclonal 1:500 Novus/NB100-662 5.8S protein associated with rRNA 
5-Methylcytosine Mouse Monoclonal 1:500 Genway/20-003-40005 5-Methylcytosine 
     
RbAp48 Mouse monoclonal 1:400 Abcam/ab488 RbAp48/amino acids 1-425 
MBD2 Goat polyclonal 1:400 Abcam/ab58241 MBD2/RNDPLNQNKGKPDLN 
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Fig.1. Representative micrographs of 5-methylcytosine and 5-
methylcytidine immunoreactivity in entorhinal cortex layer II and cerebellar 
neurons from AD and ND cases. (A1) High power micrograph of entorhinal 
cortex labeled with an antibody to 5-methylcytosine. (A2) Same field 
labeled with an 
antibody to neuron-
specific enolase to show 
co-localization (ND 
case). (B1) Low power 
micrograph of 5-
methylcytosine 
immunoreactivity in 
entorhinal cortex of an 
ND case to show 
general staining 
pattern. (B2) 5-
methylcytosine, AD 
case, entorhinal cortex. 
(C1) 5-methylcytidine, 
ND case, entorhinal 
cortex. (C2) 5-
methylcytidine, AD 
case, entorhinal cortex. 
(D1) 5-methylcytosine, 
ND case, cerebellum. 
(D2) 5-methylcytosine, 
AD case, cerebellum. Staining with 5-methylcytidine in AD and ND 
cerebellum was virtually indistinguishable from that with 5-methylcytosine 
(see Supplementary Fig. 1). 
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Fig. 2.  Representative high power micrographs of 5-methylcytosine 
immunoreactivity in entorhinal cortex microglia and astrocytes. (A1) 
Immunoreactivity for the microglial marker RAC1 in an ND case. (A2) 
Same field labeled with 5-methylcytosine. (A3) Merged image to 
show co-localization (arrows). (B1)  RAC1 immunoreactivity in an AD 
case, where microglia were typically more abundant than in AD 
cases. (B2) Same field labeled with 5-methylcytosine. (B3) Merged 
image. (C1) Immunoreactivity for the astrocyte marker GFAP in an 
ND case. (C2) Same field labeled with 5-methylcytosine. (C3) Merged 
image. (D1) GFAP immunoreactivity in an AD case. (D2) Same field 
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labeled with 5 methylcytosine. (D3) Merged image. (Calibration bars 
in all fields equal 20 um). 
  
 
Fig.  3. Representative micrographs of cytoplasmic immunoreactivity 
for 5-methylcytosine and 5-methylcytidine (green fluorophore in 
confocal micrographs) and their co-localization with 
immunoreactivity for the ribosomal protein RPL26 (red fluorophore 
in confocal micrographs) in AD and ND entorhinal cortex layer II 
neurons. Confocal planes were chosen that emphasized cytoplasmic 
rather than nuclear staining. (A1) 5-methylcytosine, ND case, bright 
field. (A2) 5-methylcytosine, ND case, confocal microscopy. (A3) 
Same field as A2 for RPL26. (B1) 5-methylcytosine, AD case, bright 
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field. (B2) 5-methylcytosine, AD case, confocal microscopy. (B3) 
Same field as B2 for RPL26. (C1) 5-methylcytidine, ND case, bright 
field. (C2) 5-methylcytidine, ND case, confocal microscopy. (C3) 
Same field as C2 for RPL26. (D1) 5-methylcytidine, AD case, bright 
field. (D2) 5-methylcytidine, AD case, confocal microscopy. (D3) 
Same field as D2 for RPL26. 
  
 
Fig. 4. Representative micrographs of immunoreactivity for selected 
com- ponents of the MeCP1/MBD2 complex in entorhinal cortex 
layer II neurons. (A1) MTA2, ND case. (A2) MTA2, AD case. (B1) 
HDAC2, ND case. (B2) HDAC2, AD case. (C1) RBAP, ND case. (C2) 
RBAP, AD case. Similar results were obtained for all eight of the 
factors evaluated(see Supplementary Fig. 2). 
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Fig. 5. Representative micrographs of cytoplasmic immunoreactivity 
for p66   (green fluorophore), its co-localization with 5.8 s rRNA (red 
fluorophore), and AD decrements in 5.8 s rRNA and the ribosomal 
protein RPL26 in entorhinal cortex layer II neurons. (A1) 5.8 s rRNA, 
ND case, confocal microscopy. (A2) Same field as A1 for p66  . (B1) 
5.8 s rRNA, AD case, confocal microscopy. (B2) Same field as B1 for 
p66  . Similar results were observed for MBD2 and DNMT1. (C1) 5.8 s 
rRNA, ND case, bright field. (C2) 5.8 s rRNA, AD case, bright field. 
(D1) RPL26, ND case, bright field. (D2) RPL26, AD case, bright field. 
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Fig. 6. Decreased 5-methylcytosine and p66   nuclear 
immunoreactivity in entorhinal cortex layer II island neurons that 
were immunoreactive for the late-stage tangle markers PS396 and 
PHF1. (A1) 5-methylcytosine immunoreactivity, AD case. (A2) Same 
field, PS396 immunoreactivity. (A3) Merged image. (B1) 5-
methylcytosine immunoreactivity, ND case. (B2) Same field, PS396 
immunoreactivity. B3) Merged image. (C1) p66   immunoreactivity, 
AD case. (C2) Same field, PHF1 immunoreactivity. 
 (C3) Merged image. (D1) p66   immunoreactivity, ND case. (D2) 
Same field, PHF1 immunoreactivity. (D3) Merged image. See 
Supplementary Fig. 3 for HDAC1/PHF-1 co-localization. 
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Abstract   
 
DNA methylation (Adcock et al. 2007; Suzuki and Bird 2008) is 
capable of modulating coordinate expression of large numbers of 
genes across many different pathways, and may therefore warrant 
investigation for their potential role between genes and disease 
phenotype. In a rare set of monozygotic twins discordant for 
Alzheimer's disease (AD), significantly reduced levels of DNA 
methylation were observed in temporal neocortex neuronal nuclei 
of the AD twin.  These findings are consistent with the hypothesis 
that epigenetic mechanisms may mediate at the molecular level the 
effects of life events on AD risk, and provide, for the first time, a 
potential explanation for AD discordance despite genetic similarities.       
 
 
 
Introduction 
Wide varieties of studies have examined candidate genes for 
associations with Alzheimer’s disease (AD).  Although such 
associations have been found, they are probabilistic rather than 
inevitable, with the exception of familial AD.  A potential explanation 
of the probabilistic nature of the association between specific genes 
and disease may be the apparent genetic complexity of AD.  
However, the existence of rare monozygotic twins discordant for AD 
offers the opportunity to examine other factors that may be 
contributing to the probabilistic nature of the association between 
genes and AD, specifically epigenetic mechanisms.  Since epigenetic 
modifications contribute to the phenotypic differences that emerge 
in monozygotic twins, including discordant disease states (Poulsen et 
al. 2007), we examined DNA methylation, an important epigenetic 
mechanism, in monozygotic twins discordant for Alzheimer's disease 
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(AD).  As has been described in sporadic AD cases  (Mastroeni et al. 
2008), neurons of the AD twin exhibited dramatic decrements across 
multiple DNA methylation markers compared to the non-AD twin.  
Epigenetics may therefore, constitute a basic molecular genetic 
mechanism in the pathophysiology of AD. 
      
 Methods 
 
*Ethics Statement:   
Written informed consent for autopsy was obtained for both cases 
in compliance with institutional guidelines of Boston University. The 
Boston University Institutional Review Board approved this study 
including recruitment, enrollment, and autopsy procedures. Both 
twins and their respective next-of-kin consented to brain autopsy for 
the purpose of research analysis as participants in the Boston 
University Alzheimer’s Disease Center. The human brain tissue used 
in this manuscript was from routine existing autopsies, which fully 
qualifies for 4C exemption by NIH guidelines.  In addition samples 
were analyzed anonymously (e.g. twin 1 and twin 2) throughout the 
experimental process.     
 
Subjects and brain samples.   
Using standard protocols of NIH AD Centers, both twins were 
thoroughly evaluated antemortem and postmortem by board-
certified neurologists and a neuropathologist who determined their 
respective diagnoses as AD and neurologically normal, non-
demented (ND).  The AD twin was a white male chemical engineer 
who had extensive pesticide contact in his work.  He developed AD 
symptoms at age 60, first manifest as the inability to read maps, 
followed by progressive loss of memory and intellect over 16 years 
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until his death at age 76.  His identical twin, also a chemical engineer 
with an identical education but different work environment, died at 
79 years from prostate cancer. At the time of his death, he was 
cognitively intact. The twins were autopsied at the same facility 
using the same tissue processing protocols.  Post mortem delay for 
the control twin was 3h 10 minutes and 7h 20 minutes for the AD 
twin. Both subjects were immediately snap frozen on aluminum 
plates cooled to -80ºC on dry ice and immediately transferred to -
80ºC freezer for long term storage. In the AD twin post-mortem 
examination confirmed severe AD (NIA-Reagan: high, CERAD plaque: 
frequent, Braak: VI). In the non-demented twin post-mortem 
examination revealed sparse neuritic plaques and entorhinal and 
transentorhinal NFTs (NIA-Reagan: low, CERAD: sparse, Braak: II).  
The AD twin showed dense plaques and neurofibrillary tangles (NFT) 
in the anterior temporal cortex, while these stigmata were 
remarkably rare in the non-demented twin (Figure 1). 
   
Immunohistochemistry.  
 Temporal neo-cortex was sliced axially into 1-cm thick slabs, 
immersion fixed for 48h in buffered 4% paraformaldehyde at 4°C, 
washed extensively in phosphate buffer (PB), and cryoprotected in 
ethylene glycol and glycerol.  The slabs were then sectioned at 40 
µm on a freezing cryostat.  Free-floating sections were stored in 
freezing solution (glycol/glycerol/PB) at -20°C until required for 
experiments.  Tissue sections used for bright field microscopy were 
immunoreacted using the avidin-biotin complex/diaminobenzidine 
(DAB) method.  Briefly, tissues were washed 2X, blocked in 1% 
hydrogen peroxide for 45 min, washed 3X, blocked in 3% bovine 
serum albumin (BSA) for 1 h, washed 2X, and incubated at 4ºC 
overnight in primary antibody solutions containing 0.25% BSA.  
Unless otherwise stated, all washes were with 1X PBS Triton (PBST).  
Available information about the antibodies is given in (Table 1). After 
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incubation with primary antibody, sections were washed 3X, 
incubated in biotinylated, species-specific secondary antibodies 
(Vector) for 2 h, washed 3X, and incubated in avidin-biotin complex 
(Pierce) for 1 h.  Following incubation with secondary antibody, the 
sections were washed 3X, once in PBST and twice in 0.05M Tris 
buffer, then exposed to DAB solution containing 125 μl of 5 mg/ml 
DAB (Sigma), 11.125 ml 50 mM Tris buffer pH 7.6, and 500 μl 
saturated nickel ammonium sulfate.  Incubations during chromagen 
development were no longer than 10 min, and were followed by two 
quick rinses in 50 mM Tris to stop the reaction.  Finally, the sections 
were dried, taken through graded alcohols, de-fatted in Neoclear 
(EMD), and mounted with Permount (Pierce).  AD and ND sections 
were immunoreacted simultaneously using netwells in well-less 
plates.  For fluorescence microscopy, the sections were washed 3X, 
blocked with either 3% normal goat serum or 3% BSA, and incubated 
for 2 h.  The sections were then washed 2X, incubated in primary 
antibody in 0.25% BSA at 4°C overnight, washed again, and 
incubated in species–specific, fluorophore-conjugated secondary 
antibodies (Molecular Probes) at room temperature for 2 h.  After a 
final wash, the sections were mounted, taken through Sudan Black 
to reduce autofluorescence, and coverslipped with Vectashield 
mounting media (Vector).   Deletion of primary antibody or 
incubation with pre-immune serum resulted in abolition of specific 
immunoreactivity in all cases (data not shown).  Adjacent serial 
sections were stained with cresyl violet for cell layer identification 
and verification that the island neurons of layer II were intact. For 
some sections, nuclei were counterstained with 4',6'-diamidino-2-
phenylindole (DAPI) (Invitrogen) before mounting. 
 
Double-label immunohistochemistry 
 was also employed to evaluate the associations of epigenetic 
factors with specific neuronal, and glial cell types.  Briefly, sections 
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were washed, blocked with either 3% normal goat serum or 3% BSA, 
and incubated for 1-2 h.  Sections were then washed 2X, incubated 
in primary antibodies raised in different species in 0.25% BSA/PBST 
at 4°C overnight.  After primary incubation sections were washed 3X 
in PBST, and incubated in species–specific, fluorophore-conjugated 
secondary antibodies (Molecular Probes) at room temperature for 2 
h.  After a final wash, the sections were mounted, taken through 
Sudan Black to reduce autofluorescence, and coverslipped with 
Vectashield mounting media (Vector).   Immunostained tissue 
sections were examined on Olympus IX51 and Olympus IX70 
microscopes equipped with epifluorescence illumination or with 
confocal laser scanning using argon and krypton lasers (Olympus 
IX70).  The findings were documented photographically with an 
Olympus DP-71 color digital camera or, for confocal microscopy, by 
Fluoview software (Olympus).  
 
Cell Quantification and statistical analysis.  
Using the Fluoview software, integrated fluorescence intensities for 
5-methylcytosine of layer II and layer III of the anterior temporal 
neocortex from each individual were analyzed. Briefly, sections were 
processed in parallel using identical antibody concentrations.  DAPI + 
Nuclei of NSE+ cells were randomly selected in coded slides.  The 
detection bandwidth was set at 488nm for 5-methylcytosine 
indicator, and fluorescence intensity of the nucleus was recorded 
(N=20 per layer per case). 
      
Results 
DNA methylation Immunoreactivity. Figure2a shows representative 
immunohistochemistry of anterior temporal neocortex for 5-
methylcytosine, a marker of methylated CpG sites on DNA.  In the 
AD twin, decreased immunoreactivity relative to the ND twin was 
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readily apparent in the anterior temporal neocortex, a region 
severely affected in AD.  Similar results were obtained in the 
pathologically-vulnerable superior frontal gyrus (Figure S1). To 
develop quantitative data, integrated fluorescence intensities of 
immunoreactivity for 5-methylcytosine were recorded for layer II 
and layer III nuclei of DAPI-and neuron specific enolase positive cells 
from coded slides.  By two-tailed t-test, all markers exhibited highly 
significant (P < 0.0001) decrements in immunoreactivity in the AD 
twin compared to the ND twin (Figure 2b).  These findings are 
consistent with our previous results for non-twin AD and ND 
subjects (Mastroeni et al. 2008).   
 To show that the results obtained in neocortex were not due 
to differences in tissue handling, storage time, or quality, DNA 
methylation markers were also evaluated in cerebellum, a brain 
region that is largely spared from AD pathology.  As in our previous 
assessment of AD and control cases (Mastroeni et al. 2008), the 
cerebella of both twins exhibited virtually identical staining patterns 
and intensity for 5-methylcytosine (Figure 2a), as well as for another 
methylation marker, 5-methylcytidine (Figure S1) and several 
methylation stabilizing factors (MBD2/3 and HDAC2; Figure S2) 
 
Relationship of DNA methylation marker 5-metylcytosine to 
neurons and Glial cells.  In Figure 3 we examine co-localization of 
the DNA methylation marker, 5-methylcytosine, with markers for 
neurons (neuron specific enolase), for reactive astrocytes (GFAP) 
and for microglia (RCA1).  These figures show that DNA methylation 
is present in all three cell types in non-demented brain and that the 
decrement in DNA methylation seen in AD extends to all three cell 
types. 
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Discussion 
 
Large-scale expression array studies have reported significant up- or 
downregulation of thousands of genes in AD (Liang et al. 2008a; 
Liang et al. 2008b).  These alterations in gene expression span 
multiple pathogenic pathways, including amyloid β peptide (Aβ) 
processing, tau hyperphosphorylation, and inflammation, among 
others.  Because many genes across the genome have methylation 
sites in their promoters (Suzuki and Bird 2008), extensive 
hypomethylation in AD may provide an over-arching principle that 
accounts for significant aspects of the molecular and pathogenic 
complexity of the disorder.  For example, amyloid precursor protein 
(APP), the Aβ precursor, has been shown to be  normally 
methylated, and hypomethylated with age (Tohgi et al. 1999) which 
apparently enhances Aβ production (West et al. 1995).  However, 
more recent data indicates no difference in methylation of the APP 
gene in AD (Wang et al. 2008).  Furthermore, inducible nitric oxide 
synthase, interleukin 1, and tumor necrosis factor-α are all increased 
as part of the inflammatory response in AD cortex (Akiyama et al. 
2000); all their respective genes are methylated; and all show 
enhanced secretion with hypomethylation (Kovacs et al. 1987; Chan 
et al. 2005; Sato and Mitchell 2006).  At the protein level, protein 
phosphatase 2A is methylated (probably by peptidylarginine 
methyltransferases or lysine methyltransferases), and its 
hypomethylation results in tau hyperphosphorylation (Sontag et al. 
2007).   
 The present findings indicate that epigenetic mechanisms 
may provide a molecular basis for the effect of life events, including 
exposure to hazardous substances, on AD risk.  More specifically, 
they may provide a rationale for the consistent epidemiologic and 
neuropathologic association of AD with homocysteine elevation and 
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folate deficiencies (Seshadri et al. 2002; Luchsinger et al. 2008), 
since folate ultimately provides the methyl group for DNA 
methylation.  Maintaining adequate dietary folate (and B12) or 
increasing S-adenosylmethionine levels might therefore be useful, 
inexpensive strategies to decrease risk for AD.  Since epigenetic 
patterns can be passed on to subsequent generations, epigenetics 
may also constitute a mechanism by which AD in a first degree 
relative confers increased risk of “sporadic” disease. 
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Figures / Tables 
 
 
 
 
 
 
Table 1: Antibody source/sequence and dilution  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
Antibody Host Dilution Source/Catalogue# Recognition / sequence 
NSE Chicken 
plyclonal 
1:500 Chemicon/AB9698 Neuron Specific Enolase 
GFAP Rabbit  
polyclonal 
1:1000 Chemicon/ab5804 class-III intermediate filament 
RAC1 lectin 1:1000 Vector/B-1085 Ricinus communis agglutinin I 
pS396 Rabbit 
polyclonal 
1:1000 Invitrogen/44-752G Serine 396 
PHF1 Mouse 
monoclonal 
1:1000 Gift of Dr. P. Davies Paired Helical Filament 1 
MBD3 Mouse 
monoclonal 
1:400 Abcam/ab45027 CKAFMVTDEDIRKQEE 
5-methylcytidine Mouse  
monoclonal 
1:1000 Genway/20-783-71663 Methylation 
MTA2 Rabbit  
polyclonal 
1:500 Abcam/ab8106 Amino acids 652-668 
HDAC2 Rabbit  
monoclonal 
1:500 Abcam/ab32117 Reidues within C-terminal end 
5-methylcytosine Mouse  
Monoclonal 
1:1000 Genway/20-003-40005 Methylation 
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Figure 1. Thioflavin S plaques and PHF1  neurofibrillary tangle 
pathology in middle temporal gyrus  (MTG) of non-demented and 
AD twin. AD pathology  was remarkably rare in the non-demented 
twin and abundant in the AD twin.   
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Figure 2.  a) Anterior temporal  neocortex  (left and  right  top  
panels) and  cerebellum  (left and  right  bottom panels) 
immunoreactivity  for DNA methylation  marker in a pair of 
monozygotic  twins discordant  for Alzheimer’s disease. Sections 
were processed  in parallel using identical antibody concentrations 
to 5-methylcytosine  (1:1000) with nickel intensification. Note 
similarity of immunoreactivity  in cerebellar granule  cell layer of 
both twins in this brain region that is relatively unaffected  in 
Alzheimer’s disease. b) Integrated  fluorescence  intensities of DAPI-
counterstained anterior temporal  neocortex  layer II and layer III 
neuronal nuclei in a set of monozygotic  twins discordant  for AD. 
Sections were processed  at the same time using  identical 
immunohistochemical methods [4] and  antibody  concentrations. 
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Nuclei of NSE+ cells (N = 20/brain) were randomly  selected  and 
traced  from  coded  slides  by  an  investigator  blind  to  subject  
condition.  The appropriate detection  fluorescence  bandwidth (488 
nm)  for  5- methylcytosine  indicator was then  set, and the 
integrated fluorescence intensity within the traced area was taken. 
Highly significant decrements in the pathologically-vulnerable  
entorhinal cortex was observed  in the AD twin (p,3.51E-08 for layer 
II and p,3.71E-06 for layer III), whereas readings for the cerebellum  
were nearly identical in the AD and ND twin (data not shown). 
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Figure 3. Co-localization of immunoreactivity for 5-methylcytosine 
with neuron specific enolase, GFAP, RCA1 (microglial marker) in non-
demented and Alzheimer’s disease twin. Note extensive co-
localization of 5-methylcytosine in ND twin with all three cell specific 
markers, and the lack of co-localization with 5-methylcytosine  in the 
AD twin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 | P a g e  
 
 
 
 
References 
 
1. Adcock IM, Tsaprouni L, Bhavsar P, Ito K (2007) Epigenetic regulation of 
airway inflammation. Curr Opin Immunol 19: 694-700. 
 
2. Suzuki MM, Bird A (2008) DNA methylation landscapes: provocative 
insights from epigenomics. Nat Rev Genet 9: 465-476. 
 
3. Poulsen P, Esteller M, Vaag A, Fraga MF (2007) The epigenetic basis of 
twin discordance in age-related diseases. Pediatr Res 61: 38R-42R. 
 
4. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, et al. 
(2008) Epigenetic changes in Alzheimer's disease: Decrements in DNA 
methylation. Neurobiol Aging. 
 
5. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, et al. (2008) 
Altered neuronal gene expression in brain regions differentially affected by 
Alzheimer's disease: a reference data set. Physiol Genomics 33: 240-256. 
 
6. Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, et al. (2008) 
Alzheimer's disease is associated with reduced expression of energy 
metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A 
105: 4441-4446. 
 
7. Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Genda Y, et al. (1999) 
Reduction with age in methylcytosine in the promoter region -224 
approximately -101 of the amyloid precursor protein gene in autopsy 
human cortex. Brain Res Mol Brain Res 70: 288-292. 
 
126 | P a g e  
 
8. West RL, Lee JM, Maroun LE (1995) Hypomethylation of the amyloid 
precursor protein gene in the brain of an Alzheimer's disease patient. J Mol 
Neurosci 6: 141-146. 
 
9. Wang SC, Oelze B, Schumacher A (2008) Age-specific epigenetic drift in 
late-onset Alzheimer's disease. PLoS ONE 3: e2698. 
 
10. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. (2000) 
Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421. 
 
11. Chan GC, Fish JE, Mawji IA, Leung DD, Rachlis AC, et al. (2005) 
Epigenetic basis for the transcriptional hyporesponsiveness of the human 
inducible nitric oxide synthase gene in vascular endothelial cells. J Immunol 
175: 3846-3861. 
 
12. Kovacs EJ, Oppenheim JJ, Carter DB, Young HA (1987) Enhanced 
interleukin-1 production by human monocyte cell lines following 
treatment with 5-azacytidine. J Leukoc Biol 41: 40-46. 
 
13. Sato TA, Mitchell MD (2006) Molecular inhibition of histone 
deacetylation results in major enhancement of the production of IL-1beta 
in response to LPS. Am J Physiol Endocrinol Metab 290: E490-493. 
 
14. Sontag E, Nunbhakdi-Craig V, Sontag JM, Diaz-Arrastia R, Ogris E, et al. 
(2007) Protein phosphatase 2A methyltransferase links homocysteine 
metabolism with tau and amyloid precursor protein regulation. J Neurosci 
27: 2751-2759. 
 
15. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, et al. (2002) 
Plasma homocysteine as a risk factor for dementia and Alzheimer's 
disease. N Engl J Med 346: 476-483. 
 
16. Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R (2008) Body mass 
index, dementia, and mortality in the elderly. J Nutr Health Aging 12: 127-
131. 
127 | P a g e  
 
 
17. Jungling K, Nagler K, Pfrieger FW, Gottmann K (2003) Purification of 
embryonic stem cell-derived neurons by immunoisolation. Faseb J 17: 
2100-2102. 
18. Mannoji H, Yeger H, Becker LE (1986) A specific histochemical marker 
(lectin Ricinus communis agglutinin-1) for normal human microglia, and 
application to routine histopathology. Acta Neuropathol 71: 341-343. 
 
19. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, et al. (2001) 
Interaction of tau isoforms with Alzheimer's disease abnormally 
hyperphosphorylated tau and in vitro phosphorylation into the disease-like 
protein. J Biol Chem 276: 37967-37973. 
 
20. Chapman G, Beaman BL, Loeffler DA, Camp DM, Domino EF, et al. 
(2003) In situ hybridization for detection of nocardial 16S rRNA: reactivity 
within intracellular inclusions in experimentally infected cynomolgus 
monkeys--and in Lewy body-containing human brain specimens. Exp 
Neurol 184: 715-725. 
 
21. Boyes J, Bird A (1991) DNA methylation inhibits transcription indirectly 
via a methyl-CpG binding protein. Cell 64: 1123-1134. 
 
22. Espada J, Ballestar E, Fraga MF, Villar-Garea A, Juarranz A, et al. (2004) 
Human DNA methyltransferase 1 is required for maintenance of the 
histone H3 modification pattern. J Biol Chem 279: 37175-37184. 
 
23. Caballero R, Setien F, Lopez-Serra L, Boix-Chornet M, Fraga MF, et al. 
(2007) Combinatorial effects of splice variants modulate function of Aiolos. 
J Cell Sci 120: 2619-2630. 
 
24. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, et al. 
(2008) Class I histone deacetylase expression has independent prognostic 
impact in human colorectal cancer: specific role of class I histone 
deacetylases in vitro and in vivo. Clin Cancer Res 14: 1669-1677. 
 
128 | P a g e  
 
25. Maki WC, Mishra NN, Cameron EG, Filanoski B, Rastogi SK, et al. (2008) 
Nanowire-transistor based ultra-sensitive DNA methylation detection. 
Biosens Bioelectron 23: 780-787. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
129 | P a g e  
 
 
 
Chapter 5 
 
 
 
Consistent decrease in global DNA 
methylation and hydroxymethylation in 
the hippocampus of Alzheimer’s disease 
patients. 
 
Leonidas Chouliaras 
a,1
, Diego Mastroeni 
a,b,1
, Elaine Delvaux b, 
Andrew Grover 
b
, Gunter Kenis 
a
, Patrick R. Hof 
c
, Harry W.M. 
Steinbusch 
a
, Paul D. Coleman 
b
 , Bart P.F. Rutten 
a,2
 , Daniel L.A. 
van den Hove 
a,e,2,*
 
 
a  School for Mental Health and Neuroscience (MHeNS), Department 
of Psychiatry and Neuropsychology, Faculty of Health, Medicine and 
Life Sciences, European Graduate School of Neuroscience (EURON), 
Maastricht University Medical Centre, Maastricht, The Netherlands. 
b  Banner Sun Health Research Institute, Sun City, AZ USA 
c Fishberg Department of Neuroscience and Friedman Brain 
Institute, Mount Sinai School of Medicine, New York, USA 
d Department of Psychiatry, Psychosomatics and Psychotherapy, 
University of Würzburg, Würzburg, Germany 
1,2 These authors contributed equally to this work 
* Corresponding author: Daniel van den Hove, PhD 
 
130 | P a g e  
 
Abstract 
 
Epigenetic   dysregulation   of   gene   expression   is   thought   to   
be   critically   involved   in   the pathophysiology of Alzheimer’s 
disease (AD). Recent studies indicate that DNA methylation and DNA 
hydroxymethylation are two important epigenetic mechanisms 
which regulate gene expression in the aging brain, yet, very little is 
known about the levels of markers of DNA methylation and 
hydroxymethylation in the brains of patients with AD, the cell-type-
specificity of putative AD-related alterations in these markers, as 
well as the link between epigenetic alterations and the gross 
pathology of AD. The present quantitative immunohistochemical 
study investigated the levels of the two most important markers of 
DNA methylation and hydroxymethylation, i.e. 5-methylcytidine (5-
mC) and 5- hydroxymethylcytidine (5-hmC), in the hippocampus of 
AD patients (n=10) and compared these to non- demented, age-
matched controls (n=10). In addition, the levels of 5-hmC in the 
hippocampus of the two individuals of a monozygotic twin pair 
discordant for AD were assessed. The levels of 5-mC and 5-hmC 
were furthermore analyzed in a cell-type and hippocampal 
subregion-specific manner, and were correlated  with  amyloid  
plaque  load  and  neurofibrillary  tangle  load.  The  results  showed  
robust decreases in the hippocampal levels of 5-mC and 5-hmC in AD 
patients (19.6% and 20.2%, respectively). Similar results were 
obtained for the twin with AD when compared to the non-demented 
co-twin. Moreover, levels of  5-mC as well as the levels of  5-hmC 
showed a significant negative correlation with amyloid plaque load 
in the hippocampus (rp=-0.539, p=0.021 for 5-mC and rp=-0.558, 
p=0.016 for 5-hmC). These human postmortem results thus 
strengthen the notion that AD is associated with alterations in DNA 
methylation and hydroxymethylation, and provide a basis for further 
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epigenetic studies identifying the exact genetic loci with aberrant 
epigenetic signatures. 
 
Keywords: Epigenetic, 5-methylcytidine (5-mC), 5-
hydroxymethylcytidine (5-hmC), twins 
Introduction 
 
 Introduction 
 
The biological mechanisms that underlie age-related dysfunction 
and the pathophysiology of Alzheimer’s disease (AD) are still largely 
unknown. Recent findings have suggested that aging and AD are 
associated with profound changes in the epigenetic regulation of 
gene expression, especially at the level of DNA methylation 
(Chouliaras et al. , 2010, Mastroeni et al. , 2011). DNA methylation, 
one of the fundamental epigenetic mechanisms, regulates gene 
transcription and can result in long-term changes in cellular function 
(Jaenisch and Bird, 2003). Methylation of CpG di-nucleotides is 
catalyzed by DNA methyltransferases (Dnmts), disrupts the binding 
of transcription factors and recruits proteins known as methyl-CpG-
binding domain proteins (MBDs) that are associated with chromatin 
compaction and gene silencing (Cedar and Bergman, 2009). DNA 
hydroxymethylation is a newly described epigenetic modification 
derived from the oxidation of methylated cytosines by ten-eleven 
translocation (TET) enzymes (Kriaucionis and Heintz, 2009, Tahiliani 
et al. , 2009). Recent evidence suggested that the biological role of 
DNA hydroxymethylation might be different from DNA methylation, 
while it is highly abundant in the brain compared to other tissues 
(Jin et al. , 2011, Munzel et al. , 2010, Valinluck and Sowers, 2007, 
Valinluck et al. , 2004). 
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Next to genetic mutations and the Apolipoprotein E4 
genotype, aging is the most important risk factor for developing AD 
and is associated with aberrant DNA methylation patterns. In 
particular, aging has been linked with global DNA hypomethylation 
and hypermethylation of CpG islands in various bran regions, 
including the frontal and temporal cortex (Christensen et al. , 2009, 
Hernandez et al. , 2011, Siegmund et al. , 2007). Other recent 
reports have also shown alterations in the DNA hydroxymethylation 
marker 5-hydroxymethylcytidine (5-hmC) in the aging mouse brain 
(Chouliaras et al. , 2012, Song et al. , 2011, Szulwach et al. , 2011) 
Evidence from genetic and immunohistochemical studies on 
AD cases further supports the notion that aberrant DNA methylation 
and hydroxymethylation is involved in the pathophysiology of AD. A 
genetic association study reported an increased risk of AD for 
carriers of certain genetic variants in TET1 (Morgan et al. , 2008). 
Immunohistochemical studies showed decreased levels of the DNA 
methylation marker 5-methylcytidine (5-mC) and a variety of 
enzymes and proteins involved in the process of DNA methylation, 
such as Dnmt1, and methyl-CpG binding protein 2 (MeCP2), in the 
entorhinal cortex of AD patients, (Mastroeni et al. , 2010), while 
similar findings of decreased 5-mC were observed in the frontal 
cortex of a monozygotic twin pair discordant for AD (Mastroeni et al. 
2009) — the same twin pair used in the present study. Recent 
epigenetic studies furthermore indicate gene-specific alterations in 
DNA methylation in the brain, peripheral lymphocytes and 
transgenic mouse models of AD neuropathology (Bakulski et al. , 
2012, Bihaqi et al. , 2011, Bollati et al. , 2011, Fuso et al. , 2012, 
Wang et al. , 2008); for review see (Chouliaras et al. , 2010). For 
example, Bakulski et al. (2012)  have  found  disease-associated  
methylation  differences  in  948  out  of  27,578  CpG  sites 
examined using a genome-wide DNA methylation array in DNA 
derived from the human prefrontal cortex (Bakulski et al. , 2012), 
133 | P a g e  
 
while Fuso and colleagues (2012) have reported a decrease in the 
methylation of the presenilin 1 gene (PSEN1) promoter induced by 
vitamin B deficiency in cell lines and transgenic mouse models of AD, 
carrying familial mutations of the amyloid precursor protein (APP) 
gene (Fuso et al. , 2011). 
Thus, accumulating evidence suggests a role for DNA 
methylation and hydroxymethylation in AD. However, it is currently 
unknown whether the previously reported AD-related decrements in 
DNA methylation and associated molecules in the entorhinal cortex 
are also present in the hippocampus, while alterations in DNA 
hydroxymethylation have not been investigated so far in AD. 
Furthermore, given the fact that most investigations were carried 
out on whole-tissue homogenates, it remains unclear whether the 
various hippocampal subregions and hippocampal cell types show 
selective vulnerability for alterations in epigenetic markers, and 
whether hippocampal alterations in epigenetic markers correlate 
with hippocampal amyloid plaque and/or neurofibrillary tangle load. 
 
Materials and Methods 
 
Human subjects and tissue processing 
Postmortem brain materials were collected through the Banner Sun 
Health Research Institute Brain and Body Donation Program (Sun 
City, AZ). Blocks of fixed, paraffin-embedded hippocampal tissue (at 
the level of the lateral geniculate nucleus) from 10 AD cases and 10 
age-matched controls were obtained from the donated brains. All 
tissue samples were collected under Institutional Review Board 
(IRB)-approved protocols and informed consents, according to the 
Declaration of Helsinki (BMJ 1991; 302: 1194), permitting the use of 
samples for research purposes. Antemortem evaluation by board- 
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certified neurologists and neuropsychologists and postmortem 
evaluation by a board-certified neuropathologist was performed for 
all cases as described previously (Beach et al. , 2012). The diagnostic 
criteria followed consensus guidelines for National Institute on Aging 
Alzheimer’s Disease Centers. Age, gender and postmortem interval 
were well matched between the groups (see Table 1). The 
hippocampal tissue was sliced axially into 1-cm thick blocks, 
immersed to 4% parafolmaldehyde fixative solution for 48h at 4oC 
and embedded in paraffin. Subsequently, the paraffin blocks were 
cut into 6μm thick slices on a rotary microtome (Leica, Wetzlar, 
Germany), placed on microscope slides (VWR, Batavia, IL, USA) and 
stored in a dark at room temperature until further use. 
The tissue from the monozygotic twin pair was obtained 
from the Boston University Alzheimer’s Disease Center. Written 
informed consent for autopsy was obtained for both cases in 
compliance with institutional guidelines of Boston University, 
according to the Declaration of Helsinki (BMJ 1991; 302: 1194). 
Details regarding this monozygotic twin pair discordant for AD have 
been described previously (Mastroeni et al. , 2009). In brief, 
antemortem and postmortem evaluations were performed by board 
certified neurologists and a neuropathologist who determined the 
diagnosis according to the standard NIH AD centers protocols. The 
AD twin died at 76 years of age and the non-demented control (ND) 
twin at 79 years of age. Postmortem delay was 7.3 hours for the AD 
twin and 3.1 for the ND twin. They were autopsied at the same 
facility using the same tissue processing protocols. Due to limitations 
in hippocampal tissue availability only sections containing the CA1 
region were available (see protocols below). In brief, the sections 
were sliced axially into 1-cm thick slabs, immersion fixed for 48 h in 
4% parafolmaldehyde at 4°C, washed in phosphate buffer (PB), and 
cryoprotected in ethylene glycol and glycerol. The slabs were then 
sectioned at 40 µm on a cryostat. Free-floating sections were stored 
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in freezing solution (glycol/glycerol/PB) at −20°C until further use 
(Mastroeni et al. , 2009). 
 
Immunohistochemistry and image analysis 
For each marker, the sections were immunoreacted simultaneously 
using standard immunohistochemical procedures. In case of 
paraffin-embedded sections, deparaffination in two series of  xylene,  
and  rehydration  in  series  of  100%,  96%,  and  80%  ethanol,  and  
distilled  water  were performed before the immunohistochemical 
procedure. Briefly, the sections were further rinsed in PBS- T, 
followed by antigen retrieval using 10 mM citrate buffer at 95oC for 
20 minutes, after which the sections  were  rinsed  again  with  PBS-T  
and  incubated  in  1%  H2O2   for  30  minutes  to  quench 
endogenous peroxidase. Subsequently, the sections were rinsed in 
PBS-T blocked in 3% bovine serum albumin (BSA) and incubated with 
the primary antibodies (5-mC, diluted 1:1000, Genway Biotech, San 
Diego CA, USA; 5-hmC, diluted 1:5000, Active Motif, Carlsbad, CA, 
USA) overnight at room temperature.  After primary antibody 
incubation the sections were washed again and incubated for 2 
hours with the secondary antibody (goat anti-mouse alexa 488 for 5-
mC and goat anti-rabbit alexa 488 for 5-hmC, 1:5000, Invitrogen, 
Grand Island, NY, USA). Following washing in PBS-T, the sections 
were counterstained  with  Neurotrace  red  fluorescent  stain  
(Invitrogen),  washed  again  in  PBS-T,  taken through Sudan Black B 
(Sigma Aldrich, St Louis, MO, USA) to reduce autofluorescence, air-
dried overnight and coverslipped using Vectashield mounting 
medium (Vector Labs, Burlingame, CA, USA). The  Neurotrace  
counterstain  was  performed  to  employ  neuron-specific  analyses  
based  on  the characteristic  morphology  and  size  of  neuronal  
cells  when  stained  with  this  counterstain.    The specificity of the 
5-mC and 5-hmC primary antibodies was confirmed by using 
methylated or hydroxymethylated nucleotides (10 nM 5-mC dCTP, 
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10 nM 5-hmC dCTP; Zymoresearch, Irvine, CA, USA), which 
decreased the IR signal when pre-incubated with the primary 
antibodies (data not shown). 
An  Olympus IX51  microscope  (Olympus, Tokyo,  Japan)  was  
used for  all imaging  procedures. Images were taken with the 40x 
objective using a green fluorescence filter for each staining, while 
their corresponding Neurotrace-counterstained images were taken 
using a red fluorescence filter. All images were taken using identical 
camera, microscope lens and light settings. One hippocampal 
section was used per each staining, where images were taken from 
five sites in the DG, five sites in the CA3, and five sites in the CA1 per 
subject (total of 15 images per subject for each staining concomitant 
with 15 corresponding Neutrorace-counterstained images).  
Fluorescence  intensity  analysis  was  performed  using  ImageJ  
software  (ImageJ,  U.S. National Institutes of Health, Bethesda, 
Maryland, USA,  imagej.nih.gov/ij/).  The intensity measurements 
were corrected for background differences by dividing the measured 
intensities with the average intensity of a cell-free region, such as 
the hippocampal white-matter, in each section. For each image, the 
fluorescence intensity of 15 individual neurons and 15 individual 
cells of non-neuronal origin were analyzed by delineating the 
nucleus of each cell and measuring the mean intensity value. Thus, 
the fluorescence intensity of a total of 450 cells per individual was 
analyzed per staining. The discrimination between cells of neuronal 
and non-neuronal origin was done based on their characteristic 
morphology and size of neurons when using the Neurotrace 
counterstain (Sekirnjak et al. , 2003). According to these criteria, a 
clear differentiation between neurons and glia in the DG was not 
possible and thus no cell-type specific analyses were carried on in 
this subregion. Of note the measurements of fluorescence 
intensities were calculated in arbitrary units and do not represent 
absolute levels of these markers (Figure 1). 
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Statistical analysis 
A multilevel linear mixed model was used for the statistical analyses. 
For each marker, the fluorescence intensities were used as the 
dependent variable and the AD diagnosis as the independent 
variable. Measurements of individual cells (level 1) were clustered in 
the different subjects (level 2). Statistical significance was set at α = 
0.05. Following the multilevel analyses, stratified analyses for 
neuronal cells and cells of non-neuronal origin (glial cells) were 
performed for each hippocampal subregion (CA3, CA1-2) or just for 
neuronal cells (DG) separately using the same statistical model. 
Correlation analyses were carried out by calculating the Pearson’s 
correlation coefficient (rp). All statistical calculations were 
performed using STATA 11 (StataCorp, Texas, USA) or the Statistical 
Package for Social Science (SPSS 17, SPSS Inc., Chicago, IL, USA). 
Graphs were built in GraphPad Prism (Version 4, GraphPad Software, 
San Diego, USA). 
 
Results 
 
Qualitative analysis and quantitative analyses of 5-mC and 5-hmC 
IR in the hippocampus 
5-mC and 5-hmC IR was detected in all cells, and was primarily 
observed as punctate IR in the nucleus. Microscopic inspection 
suggested a striking decrease in IR of both markers in the AD 
hippocampus when compared to controls (Figures 2, 3), and a 
similar pattern was observed for 5-hmC IR in the hippocampus of 
the AD twin when compared to the ND co-twin. Quantitative image 
analyses were further carried on to confirm these findings. 
Multilevel linear model analysis revealed a decrease of 5-mC IR in 
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the hippocampus of AD patients when compared to ND controls (-
19.6%, p = 0.006). Similarly a significant decrease of 5-hmC IR (-
20.2%, p = 0.012) was observed in the AD hippocampus when 
compared to ND controls. 
  
 
5-mC and 5-hmC in glial cells and neurons of the hippocampal 
subregions 
Analysis of 5-mC IR in neurons and glial cells in the three 
hippocampal subregions revealed that AD patients had a 
significantly decreased level of 5-mC in glial cells in the CA3 (-26.9%, 
p = 0.016), neurons in the CA1 (-21.1%, p = 0.01) and glial cells in the 
CA1 (-25.7%, p = 0.003), but no statistically significant differences for 
the DG or the CA3 neurons.  Analysis of 5-hmC IR in neurons and 
glial cells in the three hippocampal subregions revealed that AD 
patients had a significantly decreased level of 5-hmC in cells of the 
DG (-16.1%, p = 0.042) and glial cells in  the CA3 (-34.2%,  p =  0.011), 
while  tendencies  towards  statistical significance  were observed 
for neurons within the CA3 (-18.4%, p = 0.064) and the neurons in 
the CA1 (-17.8%, p =0.083). No statistically significant differences for 
glia cells in the CA1 were found. 
 
5-hmC in the monozygotic twins discordant for AD 
Analysis of 5-hmC fluorescence intensity in the twins discordant for 
AD revealed a 31.4% reduction of 5-hmC IR in the CA1 of the 
hippocampus of the AD twin. Stratified analyses showed a reduction 
of 39.6% in the neurons and 20.7% in the glial cells of the CA1 
subregion of the AD twin compared to the ND twin. 
 
Correlation analyses 
Linear correlation analyses revealed significant negative correlations 
between 5-mC IR and hippocampal amyloid plaque load (rp= -0.539, 
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p = 0.021), as well as 5-hmC IR and hippocampal amyloid plaque 
load (rp= -0.558, p = 0.016). Similarly, a trend towards statistical 
significance for a 
negative correlation was observed between hippocampal 5-mC IR 
and neurofibrillary tangle load (rp= -0.461, p = 0.054). 
 
 
Discussion 
 
Qualitative and quantitative assessment of the sections of the 
human hippocampus revealed an AD- related decrease of both the 
DNA methylation marker 5-mC and the DNA hydroxymethylation 
marker 5- hmC. Moreover, similar patterns of decreased 5-hmC IR 
where observed in the CA1 hippocampal subregion in the affected 
twin of a monozygotic twin pair discordant for AD. 
 
AD is associated with decreased hippocampal 5-mC IR 
In the present study, we report that 5-mC IR, as a marker for global 
DNA methylation, is decreased in the hippocampus of AD patients 
when compared to ND controls. Pooled data from all cell types and 
all regions also revealed a decrease of 5-hmC IR, reflecting global 
DNA hydroxymethylation. Stratification of the data according to cell 
type and subregions reveals that the observed differences are 
particularly pronounced in the CA1 neurons and glia and in the glial 
cells residing in the CA3, while no differences were observed in the 
DG.  The observed differences in 5-mC are in agreement with 
previous reports of  a global loss of methylation in the entorhinal 
cortex of AD patients (Mastroeni et al. , 2010) and can further be 
linked to aberrant methylation patterns previously associated with 
AD (Bakulski et al. , 2012, Siegmund et al. , 2007, Wang et al. , 2008). 
Although the exact reason of the observed methylation changes is 
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not yet clear, this might be related to AD-specific deficits in the 
nuclear transport of epigenetic molecules, such as Dnmt1, which is 
responsible for maintenance of DNA methylation (Mastroeni et al. 
submitted). This disturbed nucleocytoplasmic transport has been 
linked with the downregulation of the Ras-related nuclear protein 
(RAN), which plays an important role in the transport of molecules 
into and out of the cell nucleus (Mastroeni et al.,2013). 
 
AD is associated with decreased hippocampal 5-hmC IR 
Besides DNA methylation marker 5-mC, which reflects a well-known 
epigenetic modification, the present study also addressed 5-hmC, 
which represents a recently described epigenetic modification. To 
our knowledge, this is the first study to investigate changes of 5-hmC 
in human AD. Pooled analyses showed a decrease of 5-hmC IR in the 
hippocampus of AD patients compared to ND controls, while 
stratified analyses showed that the observed changes were more 
pronounced in the CA3 and the DG regions. As with 5-mC IR, an AD-
associated decrease was the main effect, in both neurons and glial 
cells. Because 5-hmC is an exclusive product of 5-mC, it could be 
speculated that the observed changes  in  5-hmC  are  closely  
associated  with  the  decrease  of  5-mC.  Interestingly,  while  age- 
associated increases of hippocampal 5-hmC have been reported 
(Chouliaras et al. , 2012, Song et al. ,2011) in normal aging our 
recent work in transgenic APPswe/PS1ΔE9 mice suggests a 
misbalance of hippocampal 5-mC and 5-hmC in APPswe/Ps1ΔE9 
when compared to wild-type mice (Chouliaras et al, submitted), In 
parallel, another study reported that a genetic variant of TET1, one 
of the enzymes that catalyze DNA hydroxymethylation, is associated 
with an increased risk of developing AD (Morgan et al., 2008). Such 
findings suggest that 5-hmC and an altered 
methylation/hydroxymethylation potential might be linked with AD 
pathology (Van den Hove et al. , 2012). The exact consequences of 
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the observed changes of 5-hmC are unknown, but as with 5-mC, 
could be associated with gene expression alterations and cell-cycle 
reprogramming of cells in AD (Blalock et al. , 2004, Busser et al. , 
1998, Nagy et al. , 1998), considering that 5-hmC is known to play an 
important role in regulating stem cell function (Haffner et al. , 2011, 
Pastor et al. , 2011, Szulwach et al. , 2011). 
 
Twins 
Similar to the comparison between AD cases and controls, 5-hmC IR 
was diminished in the hippocampus of the AD twin compared to the 
ND sibling. Unfortunately, due to limitations associated with the 
availability of brain materials from monozygotic twins discordant for 
AD, we were only able to examine 5-hmC IR in the CA1 hippocampal 
subregion. Previous reports on the same cases have already shown 
decrements of DNA methylation and associated markers in the 
temporal neocortex of this twin pair (Mastroeni et al. , 2009). We 
now report that the hippocampal 5-hmC changes are comparable to 
the general cohort, with an AD-associated decrease of hippocampal 
5-hmC IR. Notably, the occupation-related environmental exposures 
of the AD twin were different from those of the ND twin and this 
could be associated with the development of AD (Mastroeni et al. , 
2009). 
 
Negative correlations between hippocampal AD pathology and 
DNA (hydroxy) methylation markers 
There were negative correlations between hippocampal 5-mC and 5-
hmC IR and amyloid plaque pathology. Moreover, a trend towards 
significance pointed to a negative correlation between 5-mC IR and 
hippocampal neurofibrillary tangle load. Such findings suggest that 
AD pathology is associated with epigenetic changes. However, it is 
not yet clear whether the observed epigenetic changes are the 
cause or the consequence of AD pathology and future studies should 
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therefore assess whether the observed epigenetic changes precede 
AD pathology. 
  
Conclusions and future directions 
 
Future studies should identify the gene-specific epigenetic changes 
that are associated with AD. Most of the techniques developed to 
date require large amounts of input DNA, and whole-tissue 
homogenates are mainly used for that purpose. However, cell-type- 
and subregion-specific changes, and neuronal loss occur in AD, 
which might alter the neurons/glia ratio when comparing AD brains 
to controls (Morrison and Hof, 2002, Torres-Munoz et al. , 2004). 
Thus, novel epigenetic approaches utilizing cell-sorting or laser-
capture microdissected tissues and requiring less input material 
should be further developed. 
Interestingly, as epigenetic changes are responsive to environmental 
stimuli, it should be examined whether brain-related profiles 
correlate with peripheral profiles, and whether changes of 
epigenetic markers in accessible tissue types may be used as a 
biomarker for AD. Epigenetic  mechanisms are influenced by 
environmental exposures, and the data on discordant monozygotic 
twins further supports this notion. Specific environmental exposures 
that might be associated with AD, such as previous reports on metal-
lead exposure, related to the latent early-life associated regulation 
(LEARn) model hypothesis, appear promising in this aspect (Bihaqi 
and Zawia, 2012, Lahiri et al. , 2009). Furthermore, specific gene-
environment interactions should be investigated, as it is known that 
the effect of certain environmental exposures is highly dependent 
on individual genetic susceptibility (Chouliaras et al. ,2010). 
143 | P a g e  
 
Future research needs also investigate the exact genomic 
localization and downstream effects of the observed AD-associated 
epigenetic changes, such as the effects on histone modifications, 
and gene and protein expression. While it is not yet clear whether 
epigenetic dysregulation is a cause or a consequence of  the disease, 
the fact that similar effects have also been observed in transgenic 
APPswe/PS1ΔE9 mice (Chouliaras et al, submitted) suggest that the 
observed DNA methylation and hydroxymethylation changes might 
be triggered by the Aβ pathology and may be associated with 
disturbances of nuclear-cytoplasmic transport of epigenetic 
molecules (Mastroeni et al., 2013). Given the limitations of the 
current technologies and the limited availability of brain tissue, 
examination of peripheral blood in cohort studies or animal studies 
could possibly answer these certain and related questions. 
Furthermore, examination of correlations with markers associated 
with the disease, such as synaptic deficits and neuronal loss, is of 
high importance (Coleman and Yao, 2003, Rutten et al. , 2005, 
Selkoe,  2002).  Furthermore,  the  exact  consequences  of  the  
observed  epigenetic  changes  are unknown, but considering the 
role of epigenetic programming in the development and 
differentiation of cells, it could be speculated that the observed 
epigenetic changes induce gene expression changes, the  
accumulation  of  which  may  result  in  neuronal  loss.  As  such,  it  
will  be  crucial  to  clarify  the involvement of epigenetic changes in 
the pathophysiology of AD.  The present findings suggest that AD is 
associated with global changes of DNA methylation and 
hydroxymethylation and further show negative correlations 
between these epigenetic markers and hippocampal AD pathology. 
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Table / Figures 
 
 
Table 1 Descriptive statistics 
 
Figure-1. Hippocampal 5-methylcytidine (5-mC) immunoreactivity 
(IR) and Neurotrace counterstain. Representative photomicrograph 
of 5-mC IR (green) and the corresponding Neurotrace image (red) 
taken from the CA1 hippocampal subregion. Based on the 
Neurotrace morphology, a total of  15 neurons and 15 glial cells 
were delineated within each photomicrograph and their 
fluorescence intensity was analyzed using the
 
Subject Non-demented (ND) 
controls 
Alzheimer’s disease 
(AD) cases 
 
Age 
 
Mean = 77.91, s.d.= 4.1 
 
 
Mean = 75.36, s.d. =5.5 
 
Gender W = 3, M = 7 W = 3, M = 7 
Postmortem 
interval 
 
Mean = 2.77, s.d.= 0.61 
 
 
Mean = 2.98, s.d. =0.93 
 Braak 
Staging 
 
I-III 
 
V-VI 
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ImageJ software (see text for more details). A total of 15 images per 
subject for each staining concomitant with 15 corresponding 
Neutrorace-counterstained images were analyzed. Scale bar = 50 
μm. 
 
 
 
 
 
 
 
Figure-2. Representative photomicrorapgs of 5-mC IR. High 
magnification representative photomicrographs of the hippocampal 
DG, CA3, and CA1-2 regions. A-C represent non-demented control 
cases (ND), and D-F Alzheimer’s disease cases (AD). Note: A loss of 5-
mC IR is observed in AD cases when compared to ND controls in all 
three hippocampal subregions. The images were taken with a 40x 
objective. Scale bar = 50 μm. 
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Figure-3. Representative photomicrographs of 5-
hydroxymethylcytosine (5-hmC) IR. High magnification 
representative photomicrographs of the hippocampal DG, CA3, and 
CA1-2 regions. A-C represent non- demented control cases (ND), and 
D-F Alzheimer’s disease cases (AD). Note: A decrease of 5-hmC IR is 
observed in AD cases when compared to ND controls in all three 
hippocampal subregions. The images were taken with a 40x 
objective. Scale bar = 50 μm. 
 
Figure-4. 5-mC and 5-hmC 
hippocampal fluorescence 
intensities. Mean and standard error 
of the mean of fluorescence 
intensity measurements of 5-mC (A) 
amd 5-hmC (B) IR. Pooled data from 
the three hippocampal subregions of 
ND cases in white bars and AD cases 
in black bars. The percentage of 
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decrease in each analysis and the significant effects (p < 0.05 in all 
cases) are indicated with an asterisk in each graph. AU= arbitrary 
units. 
 
 
Figure-5. Stratified hippocampal 5-mC fluorescence intensities. 
Mean and standard error of the mean of fluorescence intensity 
measurements of 5-mC IR (A-C). Pooled data from the ND (white 
bars) and AD cases (black bars) are represented separately for the 
DG (A), CA3 (B) and CA1-2 (C). The percentage of decrease in each 
analysis and the significant effects (p < 0.05 in all cases) are 
indicated with an asterisk in each graph. AU= arbitrary units. 
 
 
Figure-6. Stratified hippocampal 5-hmC fluorescence intensities. 
Mean and standard error of the mean of fluorescence intensity 
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measurements of 5-hmC IR (A-C). Pooled data from the ND (white 
bars) and AD cases (black bars) are represented separately for the 
DG (A), CA3 (B), and CA1-2 (C). The percentage of decrease in each 
analysis and the significant effects (p < 0.05 in all cases) are 
indicated with an asterisk in each graph. AU= arbitrary units. 
 
Figure 7. Hippocampal 5-hmC fluorescence intensities in the 
monozygotic twin pair discordant for AD. Mean and standard error 
of the mean of fluorescence intensity measurements of 5-hmC IR (A-
B). Pooled data (A) and stratified data from neurons and glial cells 
(B) from the ND (white bars) and AD twin (black bars) are 
represented for the CA1 hippocampal subregion. The percentages of 
decrease in each analysis are indicated in each graph. AU= arbitrary 
units 
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Figure 8. Correlation analysis between hippocampal 5-mC, 5-hmC IR 
and amyloid plaque and neurofibrillary tangle loads. Spearman’s 
correlation coefficients and p values are noted in the bottom of each 
graph. 
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Abstract 
 
Brain aging has been associated with aberrant DNA methylation 
patterns, and a global loss of methylation and related markers has 
been observed in the entorhinal cortex of Alzheimer’s disease (AD) 
patients. DNA hydroxymethylation, however, has been sparsely 
investigated in aging and AD. We have recently reported that the 
levels of the DNA methylation marker 5-methylcytidine (5-mC) and 
the DNA hydroxymethylation marker 5-hydroxymethylcytidine (5-
hmC) increase in the mouse hippocampus during aging from 12 to 
24 months, while caloric restriction attenuated these changes. We 
have also reported robust decreases in 5-mC and 5-hmC in the 
hippocampus of AD patients compared to non demented controls. In 
the present study, we investigated 3- and 9-month-old 
APPswe/PS1ΔE9 transgenic and wild-type mice for possible age-
related alterations in 5-mC and 5-hmC levels in three hippocampal 
subregions (dentate gyrus, CA3, CA1-2) using quantitative 
immunohistochemistry. While age-related increases in levels of both 
5-mC and 5-hmC were found in wild-type mice, APPswe/PS1ΔE9 
mice showed decreased levels of 5-mC and no age-related changes 
in 5-hmC throughout the hippocampus. Altogether, these findings 
suggest that aberrant amyloid processing impact on the balance 
between DNA methylation and hydroxymethylation in the 
hippocampus during aging of mice.  
 
 
Keywords 
Aging; Alzheimer’s Disease (AD); APPswe/PS1ΔE9; Epigenesis; 
Epigenetics; DNA methylation; 5-methylcytidine (5-mC); DNA 
hydroxymethylation; 5-hydroxymethylcytidine (5-hmC). 
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Introduction 
 
Alzheimer’s disease (AD) is the most common form of dementia and 
its neuropathology is known to be associated with altered gene 
expression, in a hippocampal subregion-specific manner (Dunckley 
et al., 2006; Liang et al., 2010). Mutations in the genes encoding 
amyloid precursor protein (APP) and presenilin 1 (PS1) have been 
identified in autosomal dominant cases of AD and are known to 
affect brain function by altering APP processing during aging, and 
producing toxic amyloid beta (Aβ) protein species (Hardy, 1999, 
2009; Tanzi and Bertram, 2001, 2005). 
Recent evidence suggests that epigenetic regulation of gene 
expression is critically involved in the pathophysiology of AD 
(Chouliaras et al., 2010a; Mastroeni et al., 2011). Decreased levels of 
the DNA methylation marker 5-methylcytidine (5-mC) have been 
observed in the entorhinal cortex of AD patients when compared to 
age-matched controls (Mastroeni et al., 2010). This loss of DNA 
methylation is further associated with reduced levels of DNA 
methyltransferase (Dnmt) 1, methyl-binding protein (MBD) 2, and 
histone deacetylase (HDAC) 2 (Mastroeni et al., 2010). Similar 
findings were further observed in a monozygotic twin pair 
discordant for AD (Mastroeni et al., 2009). Interestingly, alterations 
of various global and gene-specific methylation profiles have been 
observed in post-mortem brain material of AD patients, in peripheral 
lymphocytes of AD patients and also in animal and cell culture 
models of AD neuropathology (Bollati et al., 2011; Chen et al., 2009; 
Fuso et al., 2009; Siegmund et al., 2007; Wang et al., 2008; West et 
al., 1995; Wu et al., 2008) (for review see (Chouliaras et al., 2010a)). 
Further implication of epigenetic dysregulation in AD is supported by 
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studies showing that treatment with HDAC inhibitors (HDACi), drugs 
that target the epigenetic machinery, reversed contextual memory 
impairment in APPswe/PS1 mice (Kilgore et al., 2010). 
Advances in the field of epigenetics have recently revealed 
that hydroxymethylation of DNA, which yields 5-
hydroxymethylcytosine (5-hmC) (Kriaucionis and Heintz, 2009; 
Tahiliani et al., 2009), represents an intermediate, previously 
unknown product in the pathway of active DNA demethylation (Guo 
et al., 2011) and that 5-hmC is particularly abundant in the brain. 
Thus, one could speculate that 5-hmC may be crucially involved the 
dynamic regulation of gene expression in the brain during aging and 
in neurodegenerative disorders such as AD. To date, little is known 
on the role of DNA hydroxymethylation in AD (Van den Hove et al., 
2012). Recent studies on the mouse hippocampus and cerebellum 
reported dynamic changes of 5-hmC during neurodevelopment and 
aging, such as an age-associated increase of hydroxymethylation of 
genes related to amyloid processing, (Song et al., 2011; Szulwach et 
al., 2011). Interestingly, a genetic association between AD and one 
of the enzymes that catalyze the 5-mC to 5-hmC conversion, TET1, 
has been reported (Morgan et al., 2008), suggesting that the 
conversion from 5-mC to 5-hmC might be particularly important in 
AD. Furthermore, we have recently reported a robust reduction of 
the DNA methylation marker 5-mC and the DNA methylation marker 
5-hmC in the hippocampus of AD patients compared to matched 
controls (Chouliaras et al,2013), as well as an AD-associated 
decrease in 5-hmC in the hippocampus of a monozygotic twin pair 
discordant for AD (Chouliaras et al, 2013). 
Aging is the most important risk factor for AD and age-
related changes in epigenetic mechanisms in AD-vulnerable brain 
regions may thus be involved in setting the stage for the 
development of AD (Chouliaras et al., 2010a; Hernandez et al., 
2011). We have previously shown in large cohorts of wild-type (WT) 
161 | P a g e  
 
mice that aging is associated with increased levels of 5-
methylcytidine (5-mC) (Chouliaras et al., 2011b), as well as increased 
levels of the DNA hydroxymethylation marker 5-hmC in the various 
hippocampal cell layers (Chouliaras et al., 2012). However, no 
experimental animal studies to date have investigated whether age-
related aberrations in APP and Aβ processing impact on the balance 
between 5mC and 5hmC in the brain.  As such, it remains unknown 
whether the recent reports of global epigenetic changes in the AD 
brain are closely associated with aberrant amyloid processing.  
Based on the postulated disbalance between DNA methylation and 
DNA hydroxymethylation in the pathophysiology of AD (Van den 
Hove et al., 2012) and our recent findings in the hippocampus of AD 
patients and controls, the aim of the current study was to 
investigate age-related changes in the hippocampal levels of the 
DNA methylation marker 5-mC, and the DNA hydroxymethylation 
marker 5-hmC, in a mouse model carrying familial mutations of AD. 
For that purpose, 5-mC and 5-hmC immunoreactivity (IR) was 
assessed in three hippocampal subregions, the dentate gyrus (DG), 
CA3, and CA1-2 of 3-month-old and 9-month-old wild-type (WT) 
mice and transgenic APPswe/PS1ΔE9 mice. In the present study, 
transgenic APPswe/PS1ΔE9 mice were used, which express high 
levels of mutated APP in neurons and develop AD-like amyloid 
pathology by 4 months of age (Jankowsky et al., 2001; Jankowsky et 
al., 2003; Van Tijn et al., 2012).  Furthermore, hippocampal amyloid 
plaque loads were analyzed in these mice to verify Αβ deposition.  
 
Materials and Methods 
2.1. Animals 
The present study used 11 male WT C57bl6J and 9 male transgenic 
APPswe/PS1ΔE9 mice on a C57BL6 background. The double 
transgenic APPswe/PS1ΔE9 line 85, originally described by 
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(Jankowsky et al., 2004), carries a co-integrate of 1) chimeric 
mouse/human APP695 carrying the Swedish mutation 
(K594M/N595L) and 2) human PS1 with deletion of exon 9 
(Jankowsky et al., 2001), each under control of a mouse prion 
protein promoter. Line 85 was back-crossed to a C57Bl6 background 
for more than seven generations. PCR amplification of genomic DNA, 
isolated from the mouse tails, was performed in order to determine 
the presence of the APP and PS1 mutations and verify the genotype 
of the mice used in the present study as described previously (Van 
Tijn et al., 2012). All mice were housed in groups of 2, with ad 
libitum access to food and water, kept on a 12/12 hours light:dark 
circle and under standard temperature, humidity and specified 
pathogen free (SPF) conditions. All experiments were approved by 
the Animals Ethics Board of Maastricht University. 
 
2.2. Experimental Design 
Mice were sacrificed at ages of 3 and 9 months for 
immunohistochemical analysis. Thus, 4 experimental groups were 
generated based on age and genotype: 1) 3-month-old-WT mice (n = 
5), 2) 9-month-old WT mice (n = 6), 3) 3-month-old APPswe/PS1ΔE9 
mice (n = 4), and 4) 9-month-old APPswe/PS1ΔE9 mice (n = 5). 
 
2.3. Tissue processing 
The mice were anesthetized and transcardially perfused with tyrode 
solution and fixative solution (4% parafolmaldehyde, 0.9% NaCl, 1% 
acetic acid). Subsequently, the brains were removed and stored in a 
1% sodium azide TBS solution (at 4o C). They were then embedded 
in 10% gelatin and cut serially in 50 μm-thick free-floating sagittal 
sections using a vibratome (VT 1200S, Leica, Wetzlar, Germany), 
yielding 10 subseries of every 10th section and stored again in 1% 
sodium azide TBS solution at 4o C until further histological 
processing.  
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2.4. Immunohistochemical detection of 5-mC and 5-hmC 
For each immunohistochemical procedure, a series of sections was 
stained using standard immunohistochemical protocols as previously 
described (Chouliaras et al., 2011a). Briefly, the sections were rinsed 
in TBS and TBS-T, after which antigen retrieval was performed with 
10 mM citrate buffer (PH 6.0) at 95o C for 20 minutes. The sections 
were then rinsed again, and incubated with 1% H2O2 for 1 hour to 
quench endogenous peroxidase activity. Subsequently, the sections 
were rinsed and blocked with 3% normal donkey serum and 
incubated overnight at room temperature with the primary 
antibodies (see below). The sections were then rinsed again with 
TBS and TBS-T, followed by incubation with the secondary 
antibodies (see below), After rinsing with TBS and TBS-T the sections 
were incubated with avidin–biotine–peroxidase complex (diluted 
1:400; Vector laboratories, Burlingame, CA, USA) for another 2 
hours. To visualize the horseradish peroxidase reaction product, the 
sections were incubated in 3,3’-diaminobenzidine 
tetrahydrochloride (DAB) solution (1:1 DAB:Tris–HCl, 0.3% H2O2) 
(Sigma, Uithoorn, The Netherlands). The reaction was stopped after 
10 min by rinsing with TBS. Subsequently, the sections were 
mounted on gelatin-coated glasses, dehydrated, and coverslipped 
using Pertex (Histolab Products AB, Göteborg, Sweden). Mouse 
monoclonal anti-5-mC (dilution 1:500, Genway Biotech, San Diego, 
CA, USA) was used as a primary antibody for 5-mC, and a 
biotinylated donkey anti-mouse (dilution 1:200; Jackson Westgrove, 
PA, USA) as the secondary antibody. For the detection of 5-hmC, a 
rabbit polyclonal anti-5-hmC antiserum (dilution 1:25,000; Active 
Motif, Rixensart, Belgium) was used as a primary antibody and a 
biotinylated donkey anti-rabbit (dilution 1:200; Jackson Westgrove, 
PA, USA) as the secondary antibody. 
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2.5. Analysis of 5-mC and 5-hmC IR 
 Mean intensity and surface area of 5-mC and 5-hmC IR were 
analyzed. For each of the two markers, 2 images from the CA1-2 
region, 2 images from the CA3 pyramidal layer and 4 images from 
the granule cell layer of the DG were taken (Fig. 1) at 4 different 
lateral levels (2.525 mm, 1.95 mm, 1.35 mm and 0.675 mm 
according to the Allen Brain Atlas  ( www.mouse.brain-map.org ), 
using a 40x objective. Thus, a total of 32 images were taken for 
every animal for each marker, with a digital camera (F-view; 
Olympus, Tokyo, Japan) connected to an Olympus AX70 brightfield 
microscope (AnalySIS; Imaging System, Münster, Germany). Mean 
intensities and surface area measurements of each image were 
obtained using the ImageJ software program (version 1.42q, Wayne 
Rasband, National Institutes of Health, Bestheda, Maryland, USA), 
after delineating the regions of interest and correcting for 
background variation by setting minimum thresholds. Surface area 
measurements might be affected by volume changes and could be 
corrected for that (Chouliaras et al., 2011a). However, in the present 
study no significant hippocampal volume changes were detected 
(data not shown) and thus corrections for volumes were not 
performed.  
 
2.6. Hippocampal Aβ plaque load IR 
Hippocampal amyloid plaque loads were determined in a series of 
sections from the same mice used for 5-mC and 5-hmC IR analyses, 
with a triple fluorescence immunohistochemical analysis. An 
antibody against the N-terminal of Aβ (Amyloid β *Ν+ IBL 
international, Hamburg, Germany) was used to stain all Aβ, 
thioflavin S (Sigma Aldrich, Zwijndrecht, The Netherlands) to stain 
highly dense-core plaques and DAPI (4′,6-diamidino-2-phenylindole 
dihydrochloride; Sigma Aldrich, Zwijndrecht, The Netherlands) was 
used as a counterstain. Briefly, antigen retrieval was performed with 
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10 mM citric buffer pH 6.0 at 95oC. Then, the sections were with TBS 
and TBS-T, incubated with H2O2 to quench endogenous peroxidase, 
washed again with TBS and TBS-T and blocked with 3% normal 
donkey serum (NDS) in TBS-T before overnight incubation with the 
primary antibody (Amyloid β *Ν+; IBL international, Hamburg, 
Germany;  diluted 1:1000 in 0.3% NDS). The next day, the sections 
were rinsed again with TBS and TBS-T, incubated with the secondary 
antibody (donkey anti-mouse Alexa 594 Invitrogen, Grand Island, NY, 
USA), rinsed again with TBS and TBS-T, incubated with Thioflavin S 
(0.0075%) for 10 minutes and then rinsed for 5 minutes in 70% 
ethanol. Subsequently, the sections were washed again with TBS 
and TB-T and counterstained with DAPI. Accordingly, the sections 
were mounted on gelatin-coated microscope glasses, taken through 
sudan black (Sigma Aldrich, St Louis, MO, USA) to reduce 
autofluorescence and coverslipped using 80% glycerol in TBS.  
 
2.7. Analysis of Hippocampal Aβ plaque load densities 
All measurements were performed using a modified BX50 bright 
field microscope (Olympus, Tokyo, Japan), Olympus UPlanApo 
objectives (Olympus, Tokyo, Japan), a three-axis high-accuracy 
computer-controlled stepping motor specimen stage for automatic 
sampling (4x4 Grid Encoded Stage; Ludl Electronics, Hawthorne, NY, 
USA), a linear z-axis position encoder (Ludl), a MBF-CX9000 CCD 
color camera (1200x1800 pixels; CX9000; MBF Bioscience) and 
controlling software (Stereo Investigator, MBF Bioscience, Williston, 
VT, USA). Plaque density analysis was performed in all the 
hippocampal sections stained for Aβ. Delineations of the total 
hippocampus and the cell layers of the DG, the CA3 and the CA1-2 
were performed using the 20x objective. Within the delineated 
areas, the plaque area was measured with the Area Fraction 
Fractionator probe of the Stereo Investigator software using a 40x 
objective (oil, NA=1.00). Thioflavin S staining indicated the presence 
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of dense-core plaques, while antibody Aβ *N+ could demonstrate the 
less fibrillar plaque load. The plaque area was compared to the total 
hippocampal area of that respective section to obtain an estimate of 
the plaque load.  
 
2.8. Statistical Analysis 
All data are presented as mean and standard error of the mean 
(S.E.M.). The general linear model univariate analysis of variance 
(GLM) was used for comparisons between groups, accounting for 
the main and interactive effects of age, and genotype. Statistical 
significance was set at α = 0.05. Pair-wise comparisons were 
performed with a Bonferroni post-hoc test. In the absence of a 
significant interaction, main effects of age were analyzed by an 
additional stratified analysis per genotype, in order to assess 
whether overall effects of age were more pronounced in a particular 
genotype group. All statistical calculations were performed using the 
Statistical Package for the Social Sciences, (SPSS 17, SPSS Inc., 
Chicago, IL, USA). Graphs were built in GraphPad Prism (Version 4, 
GraphPad Software, San Diego, USA).  
 
Results 
 
3.1. Qualitative analysis of 5-mC and 5-hmC IR 
Nuclear IR of both 5-mC and 5-hmC was observed in the 
hippocampal subregions (Figs 2, 3). 5-mC IR consisted mainly of 
compact condensations, while 5-hmC IR was spread throughout the 
nucleus (Figs 2, 3). Qualitative microscopic inspection indicated 
marked increases of both 5-mC and 5-hmC IR in all 3 hippocampal 
subregions of 9-month-old as compared to 3-month-old WT mice 
(Figs 2A-F, 3A-F). In contrast, an age-related decrease of 5-mC IR 
(Fig. 2G-L) was observed in the 9-month-old as compared to 3-
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month-old APPswe/PS1ΔE9, while no apparent differences in 5-hmC 
IR (Fig. 3G-L) were observed in these same mice. 
  
3.2. 5-mC intensity 
GLM revealed a main effect of genotype in the DG (p < 0.001) and 
CA1-2 (p = 0.008) regions and a main effect of age in the DG (p = 
0.02) (Fig. 4A-C). Furthermore, significant age x genotype 
interactions were observed in all hippocampal subregions (p = 0.001 
for DG, p = 0.002 for CA3, and p = 0.004 for CA1-2; Fig. 5A-C). 
Pairwise Bonferroni post-hoc comparisons showed that age was 
associated with a significant increase in the intensity of 5-mC IR in 
the DG (+8,6%, p = 0.001) and the CA3 (+6,5 %, p = 0.044) regions of 
WT mice. Moreover, Bonferroni post-hoc comparisons revealed a 
decrease of 5-mC IR intensity in  the 9-month-old APPswe/PS1ΔE9 
mice compared to 9-month-old WT mice in all hippocampal 
subregions (-11,3%, p < 0.001 for DG; -9,1%, p = 0.004 for CA3; and -
10,8%, p = 0.001 for CA1-2). Thus, age was associated with 
significantly higher levels of 5-mC IR in WT mice, whereas the 
APPswe/PS1ΔE9 genotype with lower levels of 5-mC IR in 9-month-
old mice.  
 
3.3. 5-mC surface area 
GLM for surface area measurements of 5-mC IR showed a significant 
age x diet interaction in the DG (p = 0.031) (Fig. 4D), but not in CA3 
(p = 0.079) or CA1-2 (p = 0.104). Pair wise post-hoc comparisons 
using the Bonferroni correction showed that the observed changes 
were not specific for any individual experimental groups.  
  
3.4. 5-hmC intensity 
GLM revealed a tendency towards statistical significance for the 
main effect of age in the DG (p = 0.053) and the CA3 (p = 0.099) 
subregions (Fig. 5A-C), and no effect in the CA1-2 region (p = 0.149). 
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Stratified analyses per genotype showed an increase of mean 
intensity of 5-hmC IR associated with aging from 3- to 9-month-old 
mice in all hippocampal subregions (p = 0.022 for DG, p = 0.016 for 
CA3, and p = 0.044 for CA1-2) in the WT mice, but not in the 
APP/PS1 mice (p = 0.565 for DG, p = 0.688 for CA3, and p = 0.726 for 
CA1-2). 
 
3.5. 5-hmC surface area 
GLM revealed only non-significant trends for increased 5-hmC 
surface area IR by age in the DG (p = 0.074 ) and the CA3 (p = 0.054) 
subregions, and no effect in CA1-2 (p =0.249). 
  
3.6. Hippocampal Aβ plaque load densities and correlation with 5-
mC and 5-hmC IR 
Amyloid plaque analysis demonstrated an age-dependent deposition 
from 3-9 to month-old mice (Supplementary Fig.1).  
 
 
 
Discussion 
 
Qualitative and quantitative assessment of the various hippocampal 
subregions revealed that aging in WT mice was associated with 
increased levels of 5-mC and 5-hmC. APP/PS1 mice showed however 
lower levels of 5-mC IR at 9 months of age and no significant 
alterations in 5-hmC levels. Altogether, these findings indicate that 
mutations in APP and/or PS1 impact on the balance between DNA 
methylation and hydroxymethylation in the aging hippocampus 
 
4.1. Age-related increase of hippocampal 5-mC and 5-hmC IR in WT 
mice 
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 In the present study, 5-mC IR was increased in 9-month-old 
compared to 3-month-old WT mice. As the anti-5-mC antibody 
particularly detects CpG-rich loci with higher sensitivity, the 
observed increase of 5-mC IR likely reflects increased methylation of 
CpG islands (Chouliaras et al., 2011b). These findings are in 
agreement with recent studies reporting that aging is associated 
with aberrant DNA methylation patterns, such as hypermethylation 
of CpG islands and loss of methylation of loci outside CpG islands 
(Christensen et al., 2009; Hernandez et al., 2011; Siegmund et al., 
2007). Altered DNA methylation of the Arc gene has also been 
observed in the hippocampus of aging rats (Penner et al., 2010), 
while an age-related increase in global DNA methylation has been 
observed in brains of rodents (Rath and Kanungo, 1989; Ryu et al., 
2011). Our current findings of increased 5-mC IR from 3- to 9-month-
old WT mice are in accordance with our earlier findings of age-
associated increases in levels of 5-mC (Chouliaras et al., 2011b) and 
DNA methylation-associated markers like Dnmt3a (Chouliaras et al., 
2011a), as well as HDAC2 (Chouliaras et al, submitted), in 24-month-
old mice compared to 12-month-old C57Bl6 mice. Similar to the 
findings on 5-mC IR in WT mice, 5-hmC IR in hippocampal subregions 
showed an age-related increase from 3- to 9-month-old in WT mice. 
5-hmC has recently gained increased attention as it was described to 
be particularly abundant in the brain (Kriaucionis and Heintz, 2009; 
Munzel et al., 2010). A number of studies have shown that 5-hmC, 
which is a product of 5-mC, might have a different role in the 
regulation of gene expression when compared to 5-mC (Ito et al., 
2010; Jin et al., 2010; Jin et al., 2011; Valinluck and Sowers, 2007; 
Valinluck et al., 2004). In fact, 5-hmC has also been identified as an 
intermediate step in active DNA demethylation (Guo et al., 2011).  
Our finding of an age-associated increase of 5-hmC IR in WT mice 
parallels a recent report showing increases in 5-hmC in the aging 
mouse cerebellum (Song et al., 2011). Interestingly, the increases in 
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DNA hydroxymethylation in that study were particularly pronounced 
in genes related to neurodegeneration, including those encoding 
presenilins and secretases (Song et al., 2011). Our current findings 
are furthermore in agreement with our previous observations of 
increased 5-hmC IR in the hippocampus of 12- to 24-month-old mice 
(Chouliaras et al., 2012).  
  
4.2. Disturbed age-related alterations of 5-mC and 5-hmC in 
APP/PS1 mice  
Striking differences were observed in the temporal patterns of age-
related changes in 5-mC IR in WT as compared with APPswe/PS1ΔΕ9 
mice: 5-mC IR increased with aging from 3 to 9 months of age in WT 
mice, while aging from 3 to 9 months of age in APPswe/PS1ΔΕ9 mice 
was associated with lower levels of5-mC IR. A similar, but less 
pronounced, opposition of age-related patterns was found for 5-
hmC IR in the hippocampus: 5-hmC IR increased with aging from 3 to 
9 months of age in WT mice, but did not show significant age-related 
changes in APPswe/PS1ΔΕ9 mice. Thus, our findings indicate that 
mutant APP and/or PS1 induce alterations in the molecular cascade 
of DNA methylation and hydroxymethylation during aging in the 
mouse hippocampus, and suggest that aberrant amyloid processing 
may be associated with DNA (hydroxy)methylation changes also 
observed in the human AD brain (Chouliaras et al. submitted). The 
observed negative correlation between 5-mC IR and hippocampal 
amyloid plaque load in the CA1-2 subregion further supports this 
notion. 
The age-related disturbances in 5-mC and 5-hmC in the 
APPswe/PS1ΔΕ9 from 3 to 9 months of age coincide with the 
development of AD-like pathology and behavioral deficits in this 
model (Garcia-Alloza et al., 2006; Ruan et al., 2009; Savonenko et al., 
2005). Although our findings indicate that mutant APP and/or PS1 
impact on age-related changes of DNA methylation and 
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hydroxymethylation, it remains to be answered whether age-related 
changes of DNA methylation and hydroxymethylation are primarily 
causal or compensatory. In this context, other studies have 
documented that intervening in the DNA methylation processes has 
consequences on amyloid processing. For example, dietary 
disturbances of the one-carbon metabolism, which regulates the 
methylation potential, induced promoter hypomethylation of the 
PS1 gene and increased amyloid plaque deposition in mice (Fuso et 
al., 2008; Fuso et al., 2011; Scarpa et al., 2006). Clearly, the 
interrelations between aging, amyloid processing, and DNA 
methylation are complex and further work in this area is needed. 
The present findings can be linked to our previous observations of 
decreased 5-mC and 5-hmC in the hippocampus of AD patients and 
controls (Chouliaras et al. submitted), and suggest that the presence 
of amyloid pathology is closely related to robust changes in global 
DNA methylation. In line with our present findings, various reports 
have shown alterations in DNA methylation in certain brain regions 
as well as in lymphocytes of AD patients when compared to controls 
(for review see (Chouliaras et al., 2010a)). For example, Mastroeni 
and colleagues have shown a robust loss of 5-mC IR and DNA 
methylation-stabilizing factors, like Dnmt1, MeCP2 and HDAC2 in the 
entorhinal cortex of AD patients when compared to controls 
(Mastroeni et al., 2010), while these findings were also replicated in 
a monozygotic twin pair discordant for AD (Mastroeni et al., 2009). 
Studies focusing on methylation changes in specific genes, repetitive 
elements and ribosomal DNA have furthermore reported significant 
changes in AD cases as compared to controls (Balazs et al., 2011; 
Bihaqi et al., 2011; Bollati et al., 2011; Mastroeni et al., 2011; 
Pietrzak et al., 2011; Wang et al., 2008; Wu et al., 2008).  
It is important to mention that most of the current techniques used 
so far for the detection of DNA methylation, and thus applied in AD 
research, either cannot detect 5-hmC or cannot discriminate it 
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reliably from 5-mC (Huang et al., 2010; Jin et al., 2011; Nestor et al., 
2010). Thus, the importance of 5-hmC might be underrepresented in 
current epigenetics research on aging and AD (Van den Hove et al., 
2012). 
 
4.4. Future prospects and conclusions 
While the current immunohistochemical approach allows for the 
detection of subregion-specific changes and gives an estimate of 
total levels of 5-mC and 5-hmC, it would be interesting to investigate 
gene-specific changes of the two epigenetic markers and identify 
potential target pathways that are specifically affected by aging and 
by mutated APP and PS1. Evidently, the appropriate methods for the 
precise detection of each modification should be selected. 
Furthermore, the functional impact of epigenetic changes in DNA 
(hydroxy)methylation on gene expression, associated AD-like 
pathology, and behavioral correlates should be further examined. 
Moreover, whereas the present study focused solely on the 
hippocampus of male mice, investigation of potential sex effects and 
examination of other brain regions that are either heavily affected 
by aging and AD or are resilient are equally of high importance. The 
fact that 5-mC but not 5-hmC decrease in correspondence with Aβ 
plaque deposition in these mice suggests that mutant APP and/or 
PS1 disturb the balance between these 2 epigenetic processes 
during aging. Clearly, the exact implications of this disturbance and 
its possible role in the pathophysiology of AD remain to be 
elucidated. The current study design involved WT and double 
transgenic APP/PS1 mice. As such, it cannot be explained whether 
the findings of this study are due to genetic variation in the APP 
gene, the PS1 gene or the combination of both. While the observed 
epigenetic changes might be associated with the presence of AD 
pathology in the transgenic mice and the stochastic events that 
occur with aging, it should be noted that epigenetic mechanisms are 
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dynamic processes that are subject to environmental exposures and 
thus the effects of the environment and its impact on the 
epigenome should be more thoroughly investigated in the context of 
AD (Chouliaras et al., 2010a; Chouliaras et al., 2010b; Mill, 2011)  
In conclusion, the present findings reveal differential age-associated 
changes of DNA methylation and hydroxymethylation in the 
hippocampus of WT and transgenic APP/PS1 mice and suggest that 
an altered DNA methylation/hydroxymethylation balance is likely 
implicated in the pathophysiology of AD.  
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Figures 
 
 
Figure 1. Hippocampal 5-hydroxymethylcytidine (5-hmC) 
immunoreactivity (IR). Representative photomicrograph of a 
hippocampal section stained for 5-hmC (lateral level 1.35 mm). The 
black boxes indicate where the high-magnification photomicrograph 
were taken for both the 5-hmC and the 5-methylcytidine (5-mC) 
analysis. A total of 32 photomicrographs per animal (4 
photomicrographs in the dentate gyrus (DG), 2 in the CA3, and 2 in 
the CA1-2 regions, at 4 different lateral levels) were taken for each 
staining (see text for more details). Scale bar = 200 μm 
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Figure 2. Representative photomicrographs of 5-mC IR.  High-
magnification representative fields of the hippocampal DG, CA3, and 
CA1-2 regions. A-C represent a 3-month-old wild-type (WT) mouse, 
D- F represent a 9-month-old WT mouse. G-I, represent a 3-month-
old APPswe/PS1dE9 (APP/PS1) mouse, and J-L a 9-month-old 
APP/PS1 mouse. Note that an increase in 5-mC IR is observed from 3 
to 9 months, in WT mice while a loss of 5-mC IR is observed in from 
3- to 9-month-old APP/PS1 mice in all three hippocampal 
subregions. The photomicrographs were taken with a 40x objective. 
Scale bar = 50 μm. 
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Figure (3). Representative photomicrographs of 5-hmC IR. High 
magnification representative photomicrographs of the hippocampal 
DG, CA3, and CA1-2 regions. A-C represent a 3-month-old WT 
mouse, D- F represent a 9-month-old WT mouse. G-I, represent a 3-
month-old APP/PS1 mouse, and J-L a 9-month-old APP/PS1 mouse. 
Note that an increase in 5-hmC IR is observed from 3 to 9 months in 
WT mice while no apparent differences are observed in the APP/PS1 
mice in all three hippocampal subregions. The images were taken 
with a 40x objective. Scale bar = 50 μm. 
 
177 | P a g e  
 
 
 
 
 
 
 
 
 
Figure (4). 5-mC intensity and surface area. Mean and standard error 
of means of mean intensity value measurements of 5-mC IR (A-F). 
Pooled data from the 4 groups of 3-month-old (white bars) and 9-
month-old WT and APP/PS1 mice (black bars) are represented 
separately for the DG (A, D), CA3 (B, E), and CA1-2 (C, F). Significant 
effects (p < 0.05 in all cases) in each analysis are indicated with an 
asterisk in the top right corner of each graph. AU= arbitrary units.   
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Figure  (5). 5-hmC intensity and surface area. Mean and standard 
error of means of mean intensity value measurements of 5-hmC IR 
(A-F). Pooled data from the 4 groups of 3-month-old (white bars) 
and 9-month-old (black bars) WT and APP/PS1 mice are represented 
separately for the DG (A, D), CA3 (B, E), and CA1-2 (C, F). Significant 
effects (p < 0.05 in all cases) in each analysis are indicated with an 
asterisk in the top right corner of each graph. AU= arbitrary units.   
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Abstract 
 
Transcription of DNA is essential for cell maintenance and survival; 
inappropriate localization of proteins that are involved in 
transcription would be catastrophic.  In Alzheimer’s disease brains, 
and in vitro studies, we have found qualitative and quantitative 
deficits in transport into the nucleus of DNA methyltransferase 1 
(DNMT1) and RNA polymerase II (RNA pol II), accompanied by their 
abnormal sequestration in the cytoplasm.  RAN (RAs-related Nuclear 
protein) knockdown, by siRNA and oligomeric Aβ42 treatment in 
neurons, replicate human data which indicate that transport 
disruption in AD may be mechanistically linked to reduced 
expression of RAN, a pivotal molecule in nucleocytoplasmic 
transport.  In vitro studies also indicate a significant role for 
oligomeric Aβ42 in the observed phenomena.  We propose a model 
in which reduced transcription regulators in the nucleus and their 
increased presence in the cytoplasm may lead to many of the 
cellular manifestations of Alzheimer’s disease. 
  
 
 
Introduction 
 
Normal cell function requires constant exchange of molecules 
between the nucleus and the cytoplasm.  Classically, RNA from the 
nucleus is packaged and transported to the cytoplasm for 
translation, and the resulting, newly-synthesized molecules either 
remain in the cytoplasmic compartment or are transported back into 
the nucleus to participate in a variety of functions.  Virtually all 
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nuclear proteins begin their existence in the cytoplasm, and their 
failure to be translocated back to the nucleus could be as 
catastrophic as their failure to be synthesized.  Nucleocytoplasmic 
transport in both directions is mediated by transport proteins and 
macromolecules that carry molecules through the nuclear pore 
complex, a process that depends on the active participation of the 
pivotal molecule RAN[1].  
     Epigenetic and other highly-conserved transcription-related 
factors are among important proteins that depend on RAN-
mediated transport for appropriate nuclear localization[2,3].  DNA 
methylation by DNA methyltransferases (DNMT1 for example), can 
alter binding of transcription factors to their target genes, as well as 
recruit methyl-CpG-binding domain (MBD) proteins to the locus[4].  
This, in turn, may recruit other chromatin remodeling proteins such 
as histone deacetylase 1 (HDAC1), thereby modifying histone 
proteins and transcriptional access[5].  Likewise, RNA pol II, which is 
essential for transcribing RNA also requires RAN-mediated transport 
directly, or indirectly, in order to fulfill its functional roles[6,7]. 
Several previous studies have suggested deficits in Alzheimer 
disease (AD)  of molecules related to transport between the nucleus 
and the cytoplasm [8-10].  These reports led us to hypothesize 
disrupted transport of transcription-related molecules between the 
cytoplasm and the nucleus in AD.  In view of the emerging evidence 
of the importance of epigenetic molecules in regulating gene 
expression in AD[11-13], our tests of this hypothesis concentrated 
on a fundamental epigenetic molecule, DNMT1, as well as one other 
molecule representative of an additional aspect of  regulation of 
transcription, RNA pol II.                                                   Examination of 
human, and in vitro samples using immunohistochemistry, Western 
blots, in situ hybridization, gene expression microarrays and siRNA 
revealed a potentially catastrophic failure of transport into the 
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nucleus of DNMT1 and RNA pol II in pathologically-vulnerable AD 
neurons.  We show, for the first time, decreased appearance of 
these molecules in the nucleus and their cytoplasmic sequestering.  
Our data also indicate that this phenomenon may be causally linked 
to reduced protein and mRNA expression of RAN, a pivotal 
component in the transport of molecules between the cytoplasm 
and nucleus, and that oligomeric Aβ42 plays a significant role in the 
phenomena we describe. 
 
Materials and methods: 
 
*Ethics Statement:   
Written informed consent for autopsy was obtained for all cases in 
compliance with institutional guidelines of Banner Sun Health 
Research Institute.  Banner Sun Health Research Institute review 
board approved this study including recruitment, enrollment, and 
autopsy procedures. All donors and their respective next-of-kin 
consented to brain autopsy for the purpose of research analysis as 
participants in the Banner Sun Health Research Institute autopsy 
program. The human brain tissue used in this manuscript was from 
routine existing autopsies, which fully qualifies for 4C exemption by 
NIH guidelines.     
 
 
1.1. Subjects, brain samples and cells.   
Samples of human limbic cortex, and cerebellum were secured from 
AD and ND brains obtained at autopsy at the Banner Sun Health 
Research Institute Tissue Bank.  Cognitive status of all cases was 
evaluated antemortem by board-certified neurologists, and 
postmortem examination by a board-certified neuropathologist 
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resulting in a consensus diagnosis using standard NIH Alzheimer’s 
Center criteria for AD or neurologically normal, non-demented 
elderly control (ND).  The AD and ND groups were well matched for 
age (AD: 83 +/- 3.3 years; ND: 84 ± 2.4 years), gender (3 females and 
2 males in each group), and postmortem interval (PMI) (AD: 3 hours 
12 min +/- 9 min; ND: 3 hours 48 minutes +/- 8 min).   For in vitro 
studies, SK-N-BE(2) neuroblastoma cells (ATCC) were reconstituted 
and maintained following ATCC guidelines.  Cells were maintained in 
a humidified 37ºC incubator with 5% CO2, and were supplied with 
complete DMEM (500 ml DMEM  with high glucose, minus phenol 
red (Invitrogen-Gibco)50 ml FBS (Gemini Bio-Products; West 
Sacramento, CA), 10 ml HEPES (Irvine Scientific, Santa Ana, CA.), 5 ml 
sodium pyruvate (Mediatech Cellgro), 5 ml penicillin/streptomycin 
(Invitrogen-Gibco), and 0.5 ml gentamycin (Irvine Scientific) every 
three days until experiments were performed (approx. 1 week after 
initial platting  The general health of the neurons before and after 
treatment was tested using both calcein AM (Invitrogen) and LDH 
assays (Invitrogen)  (supplementary  fig 1), which showed excellent 
health. 
   
Affymetrix Array studies:   
RNA was isolated from laser captured pyramidal single neurons from 
postmortem human samples of CA1 of the hippocampus, superior 
frontal gyrus, and visual cortex.  Gene expression was analyzed using 
Affymetrix Human Genome U133 plus 2.0 microarrays. The AD 
(n=10) and ND (n=10) groups were well matched for age (AD: 77.8 
+/- 4 years; ND: 81.5 +/- 1.2 years), gender (AD: 3 females and 7 
males, ND: 4 females and 6 males). See section 1.4. for further 
details. 
 
1.2. Immunohistochemistry/Immunocytochemistry.   
Brain tissue or cells were fixed in PFA, washed in phosphate 
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buffer (PB).  Tissue samples were sectioned at 40µm on a 
cryostat, and stored in a cryoprotectant solution of 33% 
glycol/33% glycerol/33% PB at -20°C until required for 
experiments.  Sections were washed, incubated in 10mM citrate 
buffer (antigen retrieval) for 10 min at 95 C, washed, blocked in 
1% hydrogen peroxide followed by 1h incubation in 3% bovine 
serum albumin (BSA), and incubated at 4ºC overnight in primary 
antibody solutions containing 0.25% BSA.  Sources and dilutions 
for antibodies are given in Table 1.  After incubation, the 
sections were washed, incubated in biotinylated, species-
specific secondary antibodies (Vector), and incubated in avidin-
biotin complex (Pierce).  Following incubation with secondary 
antibodies, the sections were washed and immersed in DAB 
solution for no longer than 10 min, followed by two quick rinses 
in 50 mM Tris to stop the reaction.  AD and ND sections were 
immunoreacted simultaneously using netwells in well-less 
plates.  Sections were mounted with Permount (Pierce).  For 
fluorescence microscopy, the sections were washed 3X, blocked 
with either 3% normal goat serum or 3% BSA, and incubated for 
1h.   After further washing, sections were incubated in primary 
antibody, washed again, and incubated in species–specific, 
fluorophore-conjugated secondary antibodies (Molecular 
Probes).  After a final wash, the sections were mounted, taken 
through Sudan Black to reduce autofluorescence, and 
coverslipped with Vectashield (Vector).   Deletion of primary 
antibody or incubation with pre-immune serum resulted in 
abolition of specific immunoreactivity in all cases (data not 
shown).   Adjacent serial sections were stained with cresyl 
violet, or within sections with neutral red for structural 
visualization.  For some sections, nuclei were counterstained 
with 4',6'-diamidino-2-phenylindole (DAPI) (Invitrogen), a 
nuclear counterstain, before mounting.   
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Immunostained tissue sections were examined on Olympus IX51 and 
Olympus IX70 microscopes equipped with epifluorescence 
illumination or with confocal laser scanning using argon and krypton 
lasers (Olympus IX70).  The findings were documented 
photographically with an Olympus DP-71 color digital camera or, for 
confocal microscopy, by Fluoview software (Olympus).  Following 
photographical imaging, cellular localization was quantified using 
Image J software. 
 
1.3. Western blot analysis.  
 For Western blots, tissue was cut into 1cm cubed pieces and white 
matter was carefully removed under a dissecting microscope, 
reserving the grey matter only for processing.   After dissection, 
tissue was lysed in a solution containing 20mM Tris pH7.5, 0.5% 
Nonident (Sigma), 1mM EDTA (Sigma), 0.1M NaCl (Sigma), 1mM 
PMSF (Sigma), Sigma protease inhibitors 1, 2, and complete protease 
inhibitor cocktail (Roche).  Protein concentrations were determined 
by BCA assay (Pierce) using bovine serum albumin as the standard.  
A total of 20ug of sample protein was combined with Laemmli 
sample buffer for separation by SDS-PAGE, followed by transfer to 
PVDF membrane (Bio-Rad).  Membranes were blocked using 5% 
non-fat dry milk and probed with primary antibodies (Table 1).  After 
incubation with primary antibody, membranes were washed, 
incubated with secondary antibody, washed again,  reacted with 
chemiluminescence substrate (Pierce), imaged on an Alpha Ease 
detection system, and analyzed using AlphaEaseFC software (Alpha 
Innotech).   
 
1.4. RAN and RAN Binding Proteins in Gene Expression Microarray 
To extend the RAN data to selected RAN related transcripts, we 
mined a recent, collaborative, gene expression microarray study in 
which AD and ND cortical and hippocampal neurons were evaluated 
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after laser capture microdissection.  Detailed methods for the study, 
which employed autopsy specimens from our Institution’s brain 
bank and the brain bank at Washington University, have been 
previously published[14].  Briefly, RNA was isolated from 
approximately 500 laser-captured pyramidal neurons from the 
superior frontal gyrus (BA 10 and 11), visual cortex (BA 17), and CA1 
of the hippocampus.  Following amplification 10µg of fragmented 
cRNA was hybridized to an Affymetrix Human Genome U133 plus 2.0 
Array.  All genes that did not meet a 10% present call threshold were 
removed by Genespring GX 7.3 Expression Analysis software 
(Agilent, technologies: Palo Alto, CA).   
 
1.5. RAN mRNA probe construction and In situ Hybridization:  
Probe Construction:  
RAN DNA oligonucleotide template was designed using Primer 3 
software (http://frodo.wi.mit.edu/primer3/).  Palindromic 
sequences were omitted using palindromic sequence finder 
(http://biophp.org/minitools/find_ palindromes/demo.php), and 
sequence combinations stretching across exon-exon boundaries 
were omitted.  The resulting templates were 5’-
TGGTTGGTGATGGTGGTACTGGAAAAACGACCTTCGTGAAACGTCA 
TTTGACTGGTGAATTTGAGAAGAAGTATGTAGCCACCTTGGGTGTTGAG
GTTCAT-3’ and 5’-AAGAAGAATC TTCAGTACTACGACATT-3’ (Sigma).  
Both sequences required the addition of an eight nucleotide 
sequence to the 3’ end of the oligonucleotide (5’-CCTGTCTC-3”).  
Sense probes were constructed as negative controls.   The mRNA 
probes for sense and anti-sense were constructed following the 
manufacturer’s instructions, using the mirVana miRNA Probe 
Construction Kit (Applied Biosystems).   
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In situ Hybridization:  
20µm hippocampal AD (n=3) and ND (n=3) brain sections were 
mounted onto plus slides and allowed to dry overnight, immersed in 
a 0.007% pre-warmed 600 mAU/ml solution of proteinase K 
(Qiagen), and washed in DEPC ddh20 followed by the addition of 
125µl acetic anhydride in 0.1M TEA.  After incubating for 15min at 
RT, sections were washed in 2x SSC (saline sodium citrate), 
incubated in pre-hybridization solution, rinsed, and reacted with 
RAN-specific biotinylated mRNA probe in hybridization solution.  
Tissue was then incubated for 16h at 42°C in a humid chamber.  
After incubation, slides were washed, incubated with 50% 
formamide, rinsed in 2X SSC, incubated in 100µg/ml Rnase A 
solution, washed, and incubated in a series of SSC buffer.   For 
staining, samples were treated as stated in section 1.2., with the 
exception that Streptavidin-conjugated secondary antibodies were 
employed to detect the biotinylated probes.  
 
1.6. siRNA RAN knockdown: 
  SK-N-BE(2) neuroblastoma cells were seeded at a density of 15,000 
cells/well in 12-well plates using antibiotic-free medium.  The next 
day, cell culture medium was removed, replaced with Opti-MEM 
(Invitrogen), and cultures were placed in a 37ºC incubator with 5% 
CO2.  ON-TARGETplus Non-targeting Pool negative control siRNA 
(Dharmacon) and ON-TARGETplus SMARTpool siRNA to human RAN 
(Dharmacon) and cells were resuspended in nuclease free H2O and 
diluted in Opti-MEM to various concentrations.  The manufacture’s 
protocol for Lipofectamine 2000 (Invitrogen) RNAi transfection mix 
was employed throughout, except for the Lipofectamine 2000 
volume, which was increased to 2µL.  Opti-MEM was then removed 
from the SK-N-BE(2) cells and each siRNA transfection complex was 
added to a specific well of cells.  The cells were rocked every 10min 
for 0.5h in a 37ºC incubator with 5% CO2.  After 0.5h the cells were 
196 | P a g e  
 
overlaid with 900µL Opti-MEM for a final volume of 1mL.  Final 
concentrations of negative control siRNA and RAN siRNA are 
indicated in the Figure legend.  After 6h the Opti-MEM medium was 
removed and replaced with DMEM (Gibco) supplemented with 10% 
fetal bovine serum.  Post transfection of RAN and control siRNA took 
place for 48h in a 37ºC incubator with 5% CO2.   Following 
experimental manipulation, cells were immunoreacted against 
antibodies (Table 1), following the methods stated in section 1.2.  
Cells were examined using epi-fluorescences (IX-71) microscopy. 
Experiments were performed in triplicate. 
 
1.7. In vitro Amyloid beta 42 Treatment. 
SK-N-BE(2) neuroblastoma cells were treated as described in section 
1.1. prior to the addition of  higher oligomeric  or   lower oligomeric 
amyloid beta 42 (Bachem).  Amyloid beta 42 peptides were 
reconstituted in 0.5% ammonium hydroxide, and were immediately 
frozen down (lower molecular weight oligomeric Aβ42), or allowed 
to sit at room temperature for 96 hours (higher molecular weight 
oligomeric Aβ42).  Western blot analysis using oligomeric antibody 
A11 (Sigma), revealed the presence of oligomers in both 
preparations, with higher weight oligomers in lane 1 (96 hour 
aggregation), compared to lane 2 (immediately frozen down) (Figure 
3g).  Amyloid beta 42 peptides were diluted in serum free Opti-
Mem(Gibco) at an experimentally determined concentration of 
1uM.  Cells were incubated for 36 hours in triplicate and 
immunoreacted against antibodies (Table 1), following the methods 
stated in section 1.2.  Cells were examined using confocal and epi-
fluorescences microscopy and quantified using image J software. 
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1.8. Statistical analysis:  
 
Tissue and Cells: 
Fluorescence and bright field intensity analysis was performed using 
the Image J software.  The intensity measurements were corrected 
for background differences by dividing the measured intensities with 
the average intensity of a region that showed no reactivity. Per 
image, the fluorescence intensity of 20 individual neurons per 
sample per condition, totaling 100 neurons from AD and 100 
neurons from ND were analyzed.  Neurons were evaluated by 
delineating the nucleus (dashed circle) from cytoplasm (solid black 
line, see figure 1), of each cell and measuring the mean intensity 
value of each area (i.e. nuclear and cytoplasmic).  Analysis of 
fluorescence intensities were calculated in arbitrary units and do not 
represent the absolute quantity of these markers. Significance was 
determined using a two-tailed, paired student’s t-test and declared 
significant at a p-value < .05.  Correlation analysis was determined 
by using Pearson product-moment correlation coefficient analysis. 
Significance was set at the .05 level. 
 
Array     
A two-tailed unpaired t-test, assuming unequal variance (using 
multiple testing corrections by Benjamini and Hochberg False 
Discovery Rate), was applied to identify genes whose expression was 
significantly different in AD and ND.  Fold changes were calculated 
by taking the ratio of the average expression signal for a particular 
gene across all samples (ND and AD) divided by the average 
expression signal for the same gene in ND samples (see [14]for 
further details). 
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Results 
Reduced nuclear localization and cytoplasmic sequestration of 
DNMT1 and RNA pol II in CA1 neurons of human AD hippocampus. 
Both epigenetic and transcription-related nuclear proteins 
evaluated, DNMT1, and RNA pol II exhibited markedly reduced 
nuclear immunoreactivity in AD hippocampal CA1 neurons 
compared to matched, cognitively normal ND cases.  In AD, only very 
faint, punctate, nuclear immunoreactivity could be observed, 
whereas cytoplasmic staining was readily apparent.  The cytoplasmic 
accumulation of nuclear proteins was largely contained within the 
cell soma, with some extension to first order dendrites and less 
extension to distal dendrites (Figure 1, a2, b2).   ND neurons, by 
contrast, showed profuse immunoreactivity for both DNMT1 and 
RNA pol II within the nuclear compartment, with only modest 
cytoplasmic accumulation (Figure 1, a1, b1 respectively).  
Pathologically spared cerebellum was virtually identical in nuclear 
immunoreactivity in both ND and AD samples (Figure 1, c1-c2, d1-
d2).  Quantitation of AD neurons within CA1 (Figure 1e) showed 
significant decrease in DNMT1 nuclear immunoreactivity p= 8.5e-7 
(t-test), and for RNA pol II p= 1.2e-4 (t-test).  Cytoplasmic 
immunoreactivity for DNMT1 was significantly increased in AD, p= 
1.8e-10 (t-test), and for RNA pol II, p= .001 (t-test).  Moreover, 
correlation analysis between nuclear and cytoplasmic 
immunoreactivity revealed a significant negative correlation (r= -.45, 
p= .006 for DNMT1, and r= -.27, p=.012 for RNApol II) in AD neurons. 
Thus, as nuclear immunoreactivity decreases, cytoplasmic 
immunoreactivity increases.  Similar regression analysis of control 
samples showed no significant correlation for DNMT1 (r=.12, 
p=.234) or RNA pol II (r=.22, p=.19). Array analysis of transcript 
expression of ten Alzheimer’s cases and ten well matched controls 
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showed decreased expression of both DNMT1 and RNA pol II (Figure 
1f).  Although both mRNA probes show decreased expression in the 
CA1 of hippocampus, RNA pol II was the only probe to reach 
significance p=.0029 (t-test).    
 
Decreased neuronal RAN mRNA and protein in AD CA1 of human 
hippocampus. 
To investigate potential mechanisms that might underlie reduced 
nuclear and increased cytoplasmic localization in AD neurons, we 
assessed the expression of the key nucleocytoplasmic transport 
molecule, RAN.  In ND hippocampus, RAN immunoreactivity was 
abundant, and localized throughout the nuclear compartment and 
cell soma, extending into the apical dendrites (Figure 2a).  This is the 
appropriate distribution for RAN [15], a molecule whose function 
requires it to be transiently present in the cytoplasm or nucleus 
depending on the direction of transport.  In AD cases, however, RAN 
immunoreactivity was qualitatively decreased, with the limited 
amount of staining being primarily localized to the nucleus (Figure 
2b).  Western blots of AD and ND cortical grey matter from temporal 
neo cortex quantitatively confirmed reduced protein expression, 
showing significant RAN decreases (p =0.0001) in AD compared to 
ND samples (Figure 2e).  RAN deficits in AD were negligible in the 
pathologically-spared cerebellum, although an occasionally void in 
immunoreactivity could be seen in the larger Purkinje neurons in AD 
(see asterisk, Figure 2c, 2d).   
 At the transcript level, analysis of Affymetrix Human Genome 
U133 Plus 2.0 microarray data showed significant differences in RAN 
mRNA expression in AD compared to ND in laser captured neurons 
from CA1 of hippocampus, superior frontal gyrus, and primary visual 
cortex (Figure 2 h and i).  Fold changes were similar in the heavily-
impacted hippocampus and superior frontal gyrus (-4.6  and -5.0, 
respectively, for AD relative to ND case), and were substantially less 
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(-0.25) in the primary visual cortex, a cortical region with only 
modest AD pathology[16] (Figure 2 j and k).   In addition to RAN 
mRNA, transcript expression for several key RAN binding proteins 
was analyzed and found to exhibit significant AD deficits (Table 2). 
     Reduced RAN transcript in AD was also demonstrated by 
fluorescence-label in situ hybridization.  Signal for RAN mRNA was 
strongly localized to the nucleus, nucleolus, and cytoplasm of ND 
hippocampal CA1 neurons (Figure 2f), but was negligible in AD 
neurons (Figure 2g).  Although the reactivity was weak in AD, the 
most prominent labeling could be observed within the nuclear 
compartment, with limited cytoplasmic signal that was consistent 
with the findings from immunohistochemistry (c.f., Figure 2b).   Both 
AD and ND samples were incubated with sense probes and showed 
no obvious immunoreactivity (data not shown). 
 
Reduced nuclear localization of epigenetic and other transcription-
related molecules in oligomeric Aβ42 treated SK-N-BE(2) 
neuroblastoma cells. 
Since disrupted nuclear localization was observed in AD in which 
amyloid precursor protein is expressed in excess, we confirmed the 
relationship between Abeta and RAN expression experimentally by 
treating cells with Abeta in vitro. Experimental treatment of 
neuroblastoma cells with 1µm oligomeric Aβ42 corroborated our 
hypothesis that amyloid is involved in reduced expression of RAN 
and consequent aberrant cytoplasmic sequestering of DNMT1 and 
RNA pol II. Figure 3, a1  shows the normal distribution of RAN 
protein in untreated cells and the aberrant loss of nuclear and 
cytoplasmic RAN with higher MW oligomeric Aβ42 (Figure 3, a2) and 
lower MW oligomeric Aβ42 treatment (Figure 3, a3).  Although both 
species of Aβ42 were found to reduce RAN protein, higher MW 
oligomers was found to reduce RAN 19% more than lower MW 
oligomers (Figure 3d).  Both epigenetic and transcription-related 
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nuclear proteins evaluated, DNMT1, and RNA pol II, showed 
qualitative and quantitative decreases in nuclear immunoreactivity 
and increased cytoplasmic sequestering when treated with both 
lower and higher MW oligomeric Aβ42 (Figure 3e and 3f).  All 
experiments were performed in triplicate.       
 
Knock down of RAN message by SMARTpool siRNA in vitro induces 
cytoplasmic sequestering of nuclear proteins similar to that 
observed in situ in the AD brain.  
 To further validate a link between aberrant localization of nuclear 
proteins in AD neurons and RAN deficits, we conducted RAN 
knockdown experiments in SK-N-BE(2) neuroblastoma cells using an 
experimentally-determined optimum concentration of RAN siRNA of 
100nM.  After knock down, Western blots of RAN protein showed a 
mean RAN reduction of 71% (Figure 4a).  Prior to exposure, SK-N-
BE(2) exhibited normal nuclear localization of RNA pol II and DNMT1 
(Figure 4, c1 and d1 respectively), but this pattern was disrupted 
after 48 hours of RAN siRNA treatment (Figure 4, c2 and d2).  
Nuclear localization of RNA pol II, for example, was reduced, 
whereas abnormal accumulation in the cytoplasm was readily 
apparent, similar to the pattern observed in AD neurons (compare 
Figure 4 c2, with Figure 1, b2).   
 
 
Discussion 
     Our data demonstrate in Alzheimer’s disease greatly diminished 
nuclear localization and increased cytoplasmic localization of two 
molecules representative of two different classes of mechanisms in 
the regulation of expression:  DNMT1, an epigenetic molecule 
modulating DNA methylation, and RNA pol II, central to 
transcription.  The diminished nuclear localization is demonstrated 
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in brain regions conventionally affected in AD but not in regions 
traditionally less affected in AD.   We show this altered 
nuclear/cytoplasmic ratio associated with reduced expression of 
RAN.  We also demonstrate reduced expression of RAN and altered 
nuclear/cytoplasmic localization in a mouse model of AD.   Since 
both human AD and the mouse model of AD are associated with 
expression of Abeta, we demonstrate that in vitro treatment with 
Abeta results in both reduced expression of RAN and aberrant 
nuclear and cytoplasmic localization of DNMT1 and RNA pol II.  In 
order to separate the effect of reduced RAN expression from effects 
of Abeta we used siRNA to knock down of RAN expression in vitro 
and showed that this resulted in reduced nuclear and increased 
cytoplasmic localization of DNMT1 and RNA pol II. 
 
Miss-localization of transcriptional regulators 
Failure of nuclear proteins to reach the sites at which they act would 
have many pathogenic consequences.  For example, nuclear loss and 
cytoplasmic sequestering of DNMT1 has been linked to increased α-
synuclein in Parkinson’s disease, Lewy body disease, and α-synuclein 
transgenic mice[18], and has been suggested to underlie global DNA 
hypomethylation in affected neurons similar to that which we 
previously reported in AD[12,19].  More globally, inadequate 
transport of epigenetic and other nuclear proteins would be 
expected to disrupt chromatin structure, which could lead to large-
scale changes in gene expression such as have been described in 
microarray studies of AD brain where thousands of genes mediating 
dozens of essential cell functions are altered [14,18,20-22].  
 In addition to the pathogenic potential of reduced presence of 
transcriptional regulators in the nucleus, their aberrant presence in 
the cytoplasm may also have deleterious consequences on 
cytoskeletal elements, mitochondria, and other organelles.  For 
example, Husseman and colleagues observed that cytoplasmic 
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phosphorylated RNA polII co-localized with cdc2, a cell cycle enzyme 
that phosphorylates and inhibits RNA pol2, an event that was 
suggested to precede neurofibrillary tangle formation [23].  Other 
reports have shown that other epigenetic factors such as 
extracellular HDAC1 disrupts axonal transport by interacting with 
motor proteins, leading to axonal loss [24] 
 
The involvement of amyloid  
 The role of Aβ42 in disrupted nuclear transport suggested by the 
abundance of amyloid pathology in the vulnereable CA1 of the 
hippocampus, is further supported by our data showing that Aβ42 
treatment of neurons mimics aspects of our human data in spite of 
the time course differences in Aβ42  exposure.  We certainly do not 
suggest that APP is the only potential modulator of nuclear 
transport, as it is known, for example, that reactive oxygen species 
may also modulate nuclear transport [9]. The relative contributions 
of APP and/or its fragments, reactive oxygen species as well as other 
modulators of transport on the AD cellular phenotype remain to be 
tested in detail.   Our study however, demonstrates a relationship 
among Aβ42 treatment, loss of RAN, and cytoplasmic sequestering 
of nuclear proteins.  Although it remains to be determined what 
portion of APP may be responsible for the effects reported in vivo, 
our data implicate oligomeric Aβ42 in knocking down RAN protein 
and subsequently reducing nuclear localization.  
An additional aspect of reduced expression of RAN may be its 
effect on the synapse through activation of caspase 3.  In vitro 
analysis of RAN knockdown has shown been shown to activate 
caspase 3 [25], both a potent activator of apoptosis [26] and also a 
trigger of early synaptic dysfunction [27].  Activated caspase 3 has 
been implicated in multiple effects seen in AD, including GGA3 
cleavage, which is required for BACE lysosomal degradation[28], the 
PI3k-Akt/mTOR pathway which regulates Aβ oligomer induced 
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neuronal cell cycle events[29] and tau hyperphosphorylation, which 
cleaves tau and initiates/or accelerates tau pathology[30].  
Microarray data indicate a strong positive correlation of gene 
expression between RAN and synaptophysin, r = 0.85 (, p=0.000005) 
for AD and r= 0.82 p=0 .00001) for age matched controls.  
Collectively, these data suggest a cascade of events which includes 
the down-regulation of RAN by Aβ42 oligomers (shown here), the 
release of caspase 3 in response [25], and resulting degeneration of 
synapses [27]. Whether the many other nuclear proteins that rely on 
RAN-mediated nucleocytoplasmic transport follow similar pattern 
we observed in DNMT1 and RNA pol II remains to be determined.  If 
they do, however, deficits in RAN followed by ectopic intracellular 
localization of epigenetic and other transcription-related molecules 
could well be a central event in the pathophysiology of AD, and 
could provide an overarching, integrative mechanism for the myriad 
pathogenic processes that occur in the disorder. Moreover, it is 
important to note, that the current study focused solely on neuronal 
populations and non-neuronal cells (i.e. glia) could prove to be 
similarly affected.  
In closing, our data suggest a model in which ectopic intracellular 
localization of epigenetic molecules may be a central event in the 
pathophysiology of AD.  This model, driven by Aβ42 resulting in RAN 
depletion, has several components that suggest broader 
implications.  These components are:  1) Failure of epigenetic 
molecules to translocate to the nucleus in affected neurons in AD, 
with consequential effects on chromatin structure and, as a result, 
gene expression. 2) Increased epigenetic molecules in the cytoplasm 
which may lead to detrimental interactions with cytoskeletal 
elements, an insult in transport along neuronal processes, 
mitochondria and other organelle dysfunction, affecting structural 
and functional cellular properties.  
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Figures / Tables 
 
 
 
Figure 1.  Cellular localization of epigenetic and other transcription-
related molecules in CA1 of the hippocampus from AD and ND 
cases.  All tissue samples were counterstained with neutral red for 
cell layer and cell landmark verification.  (a1) high power micrograph 
of CA1 labeled with an antibody to DNMT1 in a typical ND case, 
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showing appropriate cellular distribution. Comparable field in a 
typical AD case shows cytoplasmic accumulation and nuclear loss of 
DNMT1 immunoreactivity (a2). Figures (c1) and (c2) show normal 
nuclear immunoreactivity for both ND and AD respectively in the 
pathologically spared cerebellum.  Similar patterns of 
immunoreactivity were observed for RNA pol2 in ND (b1) and AD 
(b2) in CA1 of hippocampus and ND (d1) and AD (d2) in cerebellum.  
(Scale bars = 15µM).  (e) Quantification of the cellular distribution of 
immunoreactivity in CA1 of the hippocampus in 5 AD and 5 ND 
samples.  100 neurons from CA1 of AD and ND cases were quantified 
and the mean signal/group/area (i.e. signal intensity/ AD or ND/ 
nuclear, cytoplasmic or both) was analyzed.  Neurons were 
evaluated by delineating the nucleus (dashed circle) from cytoplasm 
(solid black line). (f) DNMT1 and RNA pol II affymetrix array data 
from AD (n=10) and ND (n=10) hippocampal CA1 neurons (500 
neurons/case).  * Indicates significant difference compared to 
control, 2-tailed t-test p= <.05. 
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Figure 2.  Decreased Ran protein and message in CA1 of AD 
hippocampus.   Confocal micrographs (488 nm bandwidth, green 
fluorphore) reveals robust nuclear and cytoplasmic  RAN 
immunoreactivity in ND hippocampal CA1 neurons (a), compared to 
AD (b). Pathologically spared cerebellum show similar patterns of 
immunoreactivity in both ND (c) and AD (d) samples in all but the 
larger Purkinje neurons (asterisks). (e) Significant AD decrements in 
RAN protein were confirmed in Western blot analyses (p<0.0001).   
(f) 40X micrographs show normal cytoplasmic and nuclear 
distributions of RAN message by fluorescence in situ hybridization in 
ND.  By contrast, there was a significant decrease (p=0.00001) in 
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overall signal in comparable fields from AD, with limited reactivity in 
the cytoplasm and slightly greater reactivity in the nucleus (g).  .  (h) 
Mean RAN expression, and fold change (i) from Affymetrix array 
data looking at AD (n=10) and ND (n=10) hippocampal CA1 neurons 
(500neurons/case).  * Indicates significant difference between AD 
and control at p<0.05.    Scale bars = 15µm. 
 
 
 
Figure 3. In vitro Aβ42 treatment replicates human neuronal 
distributions of nuclear proteins.  Micrographs of DNMT1 and RNA 
pol II in neurons (SK-N-Be(2)) treated with higher molecular weight 
(MW) oligomers of Aβ42 (1uM) or lower MW oligomers of Aβ42 
(1uM) for 36 hours.  High power micrograph (40X) of cultures 
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labeled with an antibody to RAN before (a1) and after treatment 
with higher MW oligomeric Aβ42 (a2) or lower MW oligomeric Aβ42 
(a3); shows nuclear and cytoplasmic loss with nuclear envelope 
accumulation (arrows), similar to that seen in vitro.  Western blot 
analysis confirms these data of an overall reduction in basal RAN 
protein levels when treated with oligomeric abeta (d).  Normal 
distributions for nuclear molecules DNMT1 (b1), and RNA pol II (c1) 
was readily apparent in the nucleus of untreated neurons, but 
translocation to the cytoplasm is seen in both molecules when 
treated with high or lower MW oligomeric Aβ42; Dnmt1 (b2, b3), 
and RNA pol II (c2, c3).  e) Mean nuclear fluorescence intensity and 
mean cytoplasmic fluorescence intensity (f) of nerve cells treated 
with either low MW Aβ42 oligomers, or high MW Aβ42 oligomers.  
Asterisk (*) signifies a significant difference compared to control 
samples (p<0.05).  Data are presented as mean +/- S.E.M. (g) 
Western blot analysis using oligomeric antibody A11, revealed the 
presence of oligomers in both preparations, with higher MW 
oligomers in lane 1 (96 hour aggregation), compared to lane 2 
(immediately frozen).  (Scale bars = 15um).   
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Figure 4.  RAN knock down in vitro replicates neuronal distribution 
of nuclear proteins. Neuroblastoma cells were treated with 100nM 
RAN SNArpol siRNA, a concentration that reduced RAN levels by 71% 
(a), but did not materially affect cell viability (b). Untreated, 
tranfection reagent only (c1, d1) and treated, RAN siRNA (c2-d2) 
cells were immunoreacted for RNA polII (c1, c2), and DNMT1 (d1, 
d2).  After 48 hours, RAN knockdown induced cytoplasmic 
accumulation and nuclear losses in both target proteins, 
recapitulating in vivo observations in AD brain. DNMT1 IR after 
siRNA treatment was largely localized in axons (d2, arrows), RNA 
pol2 immunoreactivity was chiefly located in the cytosol (c1, 
arrows).  
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Supplementary Figure 1. LDH and Calcein AM assays to determine 
cytotoxicity levels in culture. The general health of neurons in 
culture was analyzed using two tests.  1) Cultures were treated with 
Calcein AM to determine relative cell viability.   2) LDH assay was 
performed to analyze cellular toxicity and membrane integrity.   
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Table 1:  The antibodies used, sources, dilutions and 
recognition motif. 
 
 
 
 
 
 
 
 
 
. 
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Table  2: mRNA expression from laser captured neurons in the 
CA1 of the hippocampus, superior frontal gyrus, and visual cortex 
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using Affymetrix Human Genome U133 plus 2.0 microarrays. 
mRNA data from all three brain regions show a significant 
decreases in RAN and RAN binding proteins, with lesser amounts 
in the visual cortex, an area with only modest AD pathology [16].  
With the exception of RANBP6 in the hippocampus, all other RAN 
binding proteins were significantly down in AD compared to 
controls. 
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“The Human Genome Project provided the blueprint for life, but the 
epigenome will tell us how these genes are excuted”-Alexander Olek 
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Discussion 
 
Conventional  insight  into  human  health  and  disease  is  
dominated  by  gene-based theories that often fail to consider the 
environment in which genes reside.  The milieu inside the cell, 
however, is dynamic, an ever-changing microenvironment capable 
of altering gene expression.  Genetics and the cellular environment 
are therefore intertwined, and the vehicle by which they are 
intertwined is epigenetics.  Epigenetics is, essentially, the interfacing 
software between the cell environment and the genome.  Without 
epigenetics, neither could function nor survive. Decades of research 
has revealed significant gene expression changes in AD, in dozens of 
major pathologic pathways, including tau phosphorylation1, Aβ 
deposition2, inflammation3, oxidative stress4, and mitochondrial 
metabolism5, as well as consistent changes in the expression of 
thousands of genes6, 7.  Moreover, these alterations are evident in 
some neurons but not adjacent neighboring neurons8, despite the 
fact that they all share the same genetic code, genetic risk factors, 
and local microenvironment.  This bewildering complexity and 
pathologic diversity strongly suggests that investigations into broad, 
integrative mechanisms such as epigenetics and nuclear transport at 
the level of the single cell could be a fruitful strategy compared to 
the studies of restricted molecular events that now characterize AD 
research. 
The present thesis therefore addresses an integrative, 
epigenetic mechanism for AD pathogenesis and provides a deeper 
look into how epigenetic changes might arise in AD neurons.   At the 
level of basic research, it well established that methylation and 
methylation stabilizing factors can orchestrate changes in expression 
of a wide range of genes 9-15. Accordingly, one of the central 
hypotheses tested in this thesis is that alterations in DNA 
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methylation and DNA methylation stability might provide an over-
arching mechanism that could explain expression differences in the 
thousands of genes that are reportedly altered in AD (chapter 3).    
From  a genome-wide perspective,  the  present  thesis  research  
demonstrates decreased nuclear immunoreactivity (IR) for seven 
different markers of DNA methylation in AD compared to matched, 
non-demented elderly control (ND) cortical neurons and glia, 
whereas no such changes were observed in cerebellum, a brain 
region that is relatively spared in AD.1 
Moreover, highly similar results were subsequently 
obtained in a set of monozygotic twins discordant for AD17 
(Chapter 4), which indicated for the first time that epigenetic 
mechanisms might provide a molecular basis for the effect of life 
events, including exposure to hazardous substances, on AD risk. 
Since epigenetic patterns can be passed on to subsequent 
generations, epigenetics may also constitute a mechanism by which 
AD in a first degree relative confers increased risk of ‘sporadic’’ 
disease. These findings are consistent with the hypothesis that 
epigenetic mechanisms may mediate, at the molecular level, the 
effects of life events on AD risk, and provide, for the first time, a 
potential explanation for AD discordance despite genetic 
similarities. 
Furthermore, these effects were recapitulated in a detailed 
study analyzing nuclear IR for both 5-methylcytosine and 5-
hydroxymethylcytosine in CA1 of the hippocampus (chapter’s 5-6).   
Similar to the highly impacted entorhinal cortex, the CA1 of the 
hippocampus showed significant decrements in methylation and 
hydroxymethylation in AD compared to normal aging individuals.  In 
this comprehensive study an encouraging association between 
plaque load and methylation status was made, indicating that 
amyloid accumulation may account for the aforementioned loss of 
global methylation/hydroxymethylation. 
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The compelling research in chapters 3-6 begs the question, 
why is this happening? Where are the enzymes that maintain and 
methylate DNA?   In going back and reviewing chapter 3 we 
realized the answer was in plain sight, the methylation 
maintenance molecule DNMT1 is not lost, but miss-localized, and 
sequestered in the cytoplasm in AD brains. Accordingly, a key 
hypothesis of the present thesis research is that a major 
disruption of transport between the cytoplasm and the nucleus 
occurs in AD, and that this may account for many of the alterations 
in DNA methylation and, perhaps histone modification that have 
been reported in the disorder (chapter 7).   Through the 
examination of human, mouse model (data not shown), and in vitro 
preparations, the research in chapter 7 reveals an important role for 
the failure of RAN- mediated transport which prevents key 
epigenetic regulators from reaching their nuclear sites resulting in 
altered chromatin structure and consequently altered transcription 
as observed in AD6, 8, 18, 19.  We show that cytoplasmic sequestering 
of epigenetic proteins also lead to their abnormal localization to 
axonal and dendritic compartments, which impairs transport and 
yields a beading pattern (chapter 6).  Similarly, beading patterns 
within axons/dendrites has been shown to increase Ca2+20, which 
activates calpain21  and impairs axonal transport20.  Collectively, 
these data suggest a cascade of events that includes the down-
regulation of RAN by Aβ oligomers (chapter 7), the release of 
caspase 3 in response22, and resulting degeneration of synapses23. 
Moreover, current  research in our lab links the deficiencies 
in energy metabolism that have been shown to be a central event 
in Alzheimer’s disease pathophysiology 7(Appendix).  Epigenomic 
modification of nuclear DNA (nDNA) requires a constant 
consumption of calories.  Mitochondrial oxidative phosphorylation is 
a key factor, which drives an organism’s energetic demands.  This 
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system converts environmental calories into ATP, acetyl-Coenzyme 
A (acetyl-CoA), S- adenosylmethionine (SAM) and reduced NAD+ 24. 
When calories are abundant the potential energy generated by ATP 
and acetyl-CoA drives epigenetic mechanisms to phosphorylate and 
acetylate chromatin, resulting in active nDNA transcription, as well 
as maintenance of the methylation status  on  those  genes  that  
require  suppression  (i.e.  imprinting genes).  When calories are less 
abundant, as seen in AD 25, phosphorylation and acetylation 
mechanisms are suppressed and methylation mechanisms altered, 
as we have shown in AD brains (chapter 2), and in monozygotic 
twins discordant for AD (chapter 3) 16, 17.  It is well established that 
amyloid is a major player in AD pathophysiology, but recent 
evidence implicates the more oligomeric forms of Aβ as the more 
toxic species 26. Furthermore, recent work has demonstrated in a 
mouse model of AD, that oligomeric Aβ is toxic to mitochondria 
both at the level of the synapse and in the cytosol, an insult that 
precedes synaptic degeneration 27.   Because bioenergetics provides 
the link between the environment and the epigenome these data 
will reveal the importance of bioenergetics in regulating the 
epigenome, and may provide the framework for future therapeutic 
intervention (Mastroeni 2013) 
 
Future Perspectives 
 DNA methylation/hydroxymethylation profiling of aging and AD 
subjects is eagerly awaited in order to develop a better portrait of 
the normal methylation status of all genes across the normal 
genome, how that status may change in AD, and whether or not 
such changes implicate AD-related proteins and pathogenetic 
processes. These studies would be especially significant if they were 
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conducted in tandem with genome-wide gene expression arrays, for 
the experiments would then provide validation of the functional 
effects of DNA methylation changes on gene expression.   Because 
both hyper- and hypomethylation can occur at different CpG sites 
in the same gene, with one but not the other causing functional 
changes in gene expression28, follow-up studies giving detailed 
methylation maps of AD-relevant genes and concomitant changes in 
their expression will be essential. These same considerations may 
also apply to other neurologic conditions such as schizophrenia and 
bipolar disorders, where epigenetic mechanisms are being 
pursued 29.    Of course, to hypothesize that epigenetic changes 
play a role in brain aging, AD, and other neurologic disorders still 
begs the question of what causes the epigenetic changes. The 
environment that cells and organisms are exposed to can have a 
profound influence on epigenetic mechanisms 30, 31 but simple 
stochastic processes may do so as well32. Whether as 
environmentally driven or randomly occurring events, however, the 
probability of epigenetic changes must logically increase with time, 
and increased time is precisely what the advanced ages reached by 
many human beings may afford. Some of these modifications may 
be inconsequential, depending on the CpG site, the gene, or the 
organ. For example, inadvertent up-regulation of an Aβ-synthesizing 
gene might have little to no impact on a fibroblast, whereas it could 
be highly significant in a pyramidal neuron. Thus, the origin and 
organ-specific consequences of epigenetic modifications are 
important considerations for AD epigenetic studies, and will 
continue to be critical targets for AD basic research into epigenetic 
mechanisms. 
Although it is well established that DNA methylation and histone 
modification/chromatin remodeling are at the forefront of 
epigenetic research, these modifications are the result of a series of 
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biochemical processes.  In fact, molecules like DNMT’s, HDAC’s, and 
complexes like MeCP’s are ultimately the true regulators of 
methylation and histone patterns.   Future directions in epigenetic 
research will always include specific site methylation analysis, as AD 
will always include plaque burden, but methylation and 
hydroxymethylation profiling across the entire genome will be 
fundamental in future studies.  Although the technology to analyze 
the entire genome is still illusive, resent collaborations with 
University of Southern California, looking at 450,000 methylation 
sites per sample at single-nucleotide resolution of 200 controls and 
200 AD samples in mid temporal gyrus (MTG) and cerebellum has 
begun a new era of epigenetic research, one which holds much 
promise.  Although only covering a small percentage of the total 
methylation sites/gene, very interesting global data has already 
emerged. For example, using a principle component analysis, 
comparing all organs outside of the brain (i.e. heart, kidney, liver 
etc.) show a strong clustering pattern with much overlap, where the 
brain shows a much different story.  Both MTG and cerebellum are 
separate from the other organs outside the brain and furthermore 
are separated from each other, revealing a very different pattern of 
methylation within the same organ (Coleman 2013).  These data 
indicate that organs other than the brain are more stable, and 
perhaps may have remained the same for thousands of years, where 
the brain is constantly evolving, or is a multi-organ in itself; just 
another dimension we must consider when analyzing methylation 
patterns in aging and AD brains.  
Although our recent analysis of genome-wide DNA 
methylation has revealed a large number of significant changes in 
Alzheimer's disease, the magnitude of these statistically significant 
changes is uniformly extremely small.  In view of the fact that many 
changes in gene expression in AD are fairly large; the finding of very 
small changes in DNA methylation in AD raises a number of issues 
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regarding the relationship between DNA methylation and gene 
expression.  One hypothesis regarding the relationship between 
DNA methylation and gene expression is that small changes in DNA 
methylation are able to cause fairly large changes in gene 
expression, either directly, or through recruitment of intermediate 
molecules.   Ultimately, single gene analyses of every cpg site are 
mandatory in determining the specific patterns of methylation, and 
ultimately the functional relevance of these specific marks. We may 
find that methylation sites upstream/downstream from the 
regulatory region may have more influence on expression than 
methylation in the regulatory region itself.    Currently, we are in the 
process of analyzing AD disease specific genes, which will be of great 
interest and may indicate new future directions in AD research. 
The field of epigenetics is now poised to be at the forefront 
of AD research. The rise of epigenetics marks a new field of 
discovery.  Epigenetics is now a dynamic discipline, challenging and 
revising conventional paradigms of inheritance laid out by Darwin, 
Lamarck and Mendel.    The future of epigenetics will reveal the 
complexities of genetic regulation and one day answer many of the 
bewildering questions presented by Alois Alzheimer a hundred years 
ago, which still elude us today. 
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Abstract 
 
Alzheimer’s disease (AD) is associated with regional reductions in 
fluorodeoxyglucose positron emission tomography (FDG PET) 
mea¬surements of the cerebral metabolic rate for glucose, which 
may begin long before the onset of histopathological or clinical 
fea¬tures, especially in carriers of a common AD susceptibility gene. 
Molecular evaluation of cells from metabolically affected brain 
regions could provide new information about the pathogenesis of 
AD and new targets at which to aim disease-slowing and 
preven¬tion therapies. Data from a genome-wide transcriptomic 
study were used to compare the expression of 80 metabolically 
relevant nuclear genes from laser-capture microdissected non-
tangle-bear-ing neurons from autopsy brains of AD cases and normal 
controls in posterior cingulate cortex, which is metabolically affected 
in the earliest stages; other brain regions metabolically affected in 
PET studies of AD or normal aging; and visual cortex, which is 
relatively spared. Compared with controls, AD cases had significantly 
lower expression of 70% of the nuclear genes encoding subunits of 
the mitochondrial electron transport chain in posterior cingulate 
cor¬tex, 65% of those in the middle temporal gyrus, 61% of those in 
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hippocampal CA1, 23% of those in entorhinal cortex, 16% of those in 
visual cortex, and 5% of those in the superior frontal gyrus. Western 
blots confirmed underexpression of those complex I–V subunits 
assessed at the protein level. Cerebral metabolic rate for glucose 
abnormalities in FDG PET studies of AD may be associated with 
reduced neuronal expression of nuclear genes encoding subunits of 
the mitochondrial electron transport chain.  
 
Key Words 
Gene expression I Affymetrix microarrays I laser capture micro-
dissection 
 
 
 
Introduction 
 
Alzheimer’s disease (AD) is associated with characteristic and 
progressive reductions in regional positron emission tomography 
(PET) measurements of the cerebral metabolic rate for glucose 
(CMRgl). These CMRgl reductions have been reported in the 
posterior cingulate, parietal, and temporal cortex, and in the frontal 
cortex and whole brain in more severely affected patients (1–5). 
Other studies have reported CMRgl reductions in anatomically well 
characterized hippocampal and entorhinal cortical regions of 
interest (6–10). The posterior cingulate cortex (PCC) and the 
neighboring precuneus are metabolically affected in the earliest 
clinical and preclinical stages of AD (4, 11), and the primary visual 
cortex is relatively spared (4, 11). In an ongoing series of studies, we 
have detected CMRgl reductions in cognitively normal carriers of the 
apoli¬poprotein E (APOE) 64 allele (11–15), a common late-onset AD 
susceptibility gene (16–18). CMRgl reductions in AD-affected areas 
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were correlated with APOE 64 gene dose (i.e., three levels of genetic 
risk for AD) and were progressive in late-middle-aged persons (19). 
These reductions were also apparent in young adult APOE 64 
heterozygotes (13), more than four decades before the anticipated 
median onset of dementia, years before the expected onset of the 
major histopathological features of AD (neurofi¬brillary tangles and 
amyloid plaques), and, indeed, in anticipat¬ing the initial regional 
appearance of fibrillar amyloid deposi¬tion. (20, 21). 
AD-related CMRgl reductions could reflect reductions in the 
density or activity of terminal neuronal fields or peri-synaptic glial 
cells (22, 23), a metabolic dysfunction in neurons or glial cells not 
related to neuronal activity (24, 25), or a combination of these 
factors. These changes do not appear to be solely attributable to the 
combined effects of atrophy and partial-volume averaging (26). In a 
postmortem histochemistry study, we previously found that AD 
cases had lower cytochrome c oxidase activity than controls in the 
PCC, and that this reduction was significantly greater than that in 
primary motor cortex (27), another region that is relatively spared. 
Based on this observa¬tion, we proposed that AD might be related 
to an impairment in neuronal metabolism. 
Molecular evaluation of the cells from metabolically affected 
brain regions could provide new information about the pathogenesis 
of AD and new targets at which to aim disease slowing and 
prevention therapies. Data from a genome-wide transcriptomic 
study were used to compare, in each of our sampled brain regions, 
the expression of metabolically relevant nuclear genes from laser-
capture microdissected non-tangle bearing neurons of expired cases 
with clinically characterized and histopathologically verified AD and 
expired controls who did meet clinical criteria for dementia and 
histopathological criteria for AD. 
In particular, the data were used to compare cases and controls in 
the expression of 80 nuclear genes encoding mitochondrial electron 
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transport chain (ETC) subunits along with translocases of the inner 
and outer mitochondrial membranes(TIMMs and TOMMs, 
respectively), in six brain regions. These nuclear genes included 39 
complex I genes coding for NADH dehydrogenase, all 4 nuclear-
encoded complex II genes coding for succinate dehydrogenase, 9 
complex III genes coding for ubiquinolcytochrome c reductase, 13 
complex IV genes coding for cytochrome c oxidase, and 15 complex 
V genes coding for ATP synthase, as well as 11 TIMMs and 6 TOMMs, 
which regulate the transport of nuclear-encoded electron transport 
subunits into the mitochondria. These ETC complexes and 
translocases are illustrated in Fig. 1. The six brain regions included 
the PCC, which is associated with unusually early CMRgl reductions 
in AD (4, 28); the middle temporal gyrus (MTG); the hippocampal 
field CA1 (HIP) and entorhinal cortex (EC), which are also 
metabolically affected in AD (1, 20); the superior frontal gyrus (SFG), 
which is associated with preferential CMRgl reductions in normal 
aging (29–33); and the primary visual cortex (VC), which is relatively 
spared from CMRgl reductions in both aging and AD (4, 11). 
We initially tested the hypothesis that AD would be 
associated with reduced neuronal expression of metabolically 
relevant nuclear genes in the PCC and that these AD-related 
reductions would be significantly greater than those in VC. (Findings 
from our survey of 55,000 neuronal transcripts have been published 
in ref. 54.) AD-related reductions in the posterior cingulate 
neu¬ronal expression of several of the implicated complexes I–IV 
and ATP synthase (complex V) subunits were subsequently validated 
at the protein level, suggesting that the reductions in the neuronal 
expression of metabolically relevant nuclear genes might be 
associated with the CMRgl reductions found in fluorodeoxyglucose 
positron emission tomography (FDG PET) studies of AD. 
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Results 
 
Fold change values and P values for the 80 ETC and translocase 
genes in each of the sampled regions are posted at www.tgen.org/ 
neurogenomics/pcc, and additional expression results have been 
reported in ref. 54. The proportion of significantly underex¬pressed 
ETC and translocase genes in each of the sampled brain regions (P < 
0.01 after correction for multiple comparisons) is shown in Table 1. 
In comparison with controls, AD cases had significantly lower 
expression of 70% of the nuclear genes encoding mitochondrial ETC 
subunits in PCC pyramidal neu¬rons, 65% of those in MTG neurons, 
61% in HIP neurons, 23% in EC layer II stellate neurons, 16% in VC 
neurons, and 5% in SFG neurons. By comparison, AD cases had 
significantly higher expression of only 4% of the nuclear genes 
encoding mitochon¬drial ETC subunits in PCC pyramidal neurons, 
13% of those in MTG neurons, 8% of HIP neurons, 1% of EC neurons, 
4% of VC neurons, and 0% of SFG neurons (data for these genes are 
listed on the supplementary data site). Additional factors that 
displayed statistically significant underexpression in the PCC, and 
which may influence mitochondrial energy metabolism, include the 
TIMMs and TOMMs (Table 1; individual P values and fold changes 
are located on the supplementary data site), which are required for 
the transportation of proteins, including ETC components, from the 
cytoplasm to the inner mitochon¬drial membrane and different 
compartments in the mitochon¬dria (34–37). Overall, 35% of these 
translocases demonstrated underexpression in the PCC neurons, 
47% in the MTG neurons, 41% in the HIP neurons, 35% in the EC 
neurons, 6% in the VC neurons, and 24% in the SFG neurons. By 
comparison, only 6% of the translocases showed overexpression in 
the PCC and HIP; 12% in the VC; and 0% in the MTG, EC, and SFG. 
237 | P a g e  
 
In a post hoc analysis, we compared the proportion of all genes 
underexpressed in the neurons of AD cases and controls. AD was 
associated with underexpression of 61% of statistically signifi¬cant 
(P < 0.01, corrected for multiple comparisons) genes in the PCC, 43% 
of those in the MTG, 56% of those in the HIP, 69% of those in the EC, 
81% of those in the SFG, and 58% of those in the VC. These findings 
suggest that although metabolism genes may not be 
disproportionately affected in AD, the regional pattern of 
underexpressed metabolic genes (PCC > SFG and VC) more closely 
reflects the pattern of metabolic reductions observed in PET studies. 
To validate our findings of underexpression of energy meta¬bolic 
factors, we performed Western blots on the posterior cingulate in 
controls and AD cases. Concurrent with expression findings, 
statistically significant decreases were found in the protein levels of 
each enzyme complex subunit assessed using two-tailed t tests, P < 
0.01): complex I (mitochondrially encoded subunit ND6), 41.9 ± 7.0% 
(mean ± 95% CI) of control, P < 0.006; complex II, 70.6 ± 9.5% of 
control, P < 0.000005; complex III, 45.3 ± 7.8% of control, P < 0.008; 
complex IV (mitochon¬drially encoded subunit COXII), 59.1 ± 9.3% of 
control, P < 0.002; and complex V, 72.4 ± 11.1% of controls, P < 
0.000008 (Fig. 2; human heart was used as positive control)  
 
Discussion 
This study provides transcriptomic and protein evidence of neuronal 
metabolic impairments in AD brains, complementing previously 
established PET evidence of metabolic impairments in per¬sons 
afflicted by or at risk for this disorder. In our analysis of the nuclear 
genes influencing mitochondrial energy metabolism (i.e., 80 nuclear 
genes encoding ETC subunits and 17 nuclear genes encoding 
mitochondrial translocases responsible for the entry of ETC subunits 
into the mitochondria), the largest proportion of underexpressed 
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genes was in the PCC, a region which PET studies find to be 
metabolically affected in the earliest stages of AD. The proportion of 
underexpressed genes was significantly greater than those in the VC, 
which is relatively spared in PET studies of AD. The MTG, EC, and 
HIP, which are also affected in PET studies of AD, had proportions of 
underexpressed genes in between those in the PCC and VC. 
Because our analysis was confined to laser-capture 
microdissected neurons, our findings suggest that the CMRgI 
reductions observed in PET studies of AD are at least partly related 
to molecular processes in neurons themselves, and are thus not 
solely attributable to a reduction in the activity of perisynaptic glial 
cells known to influence CMRgI (23). They also suggest that the 
CMRgI reductions could be at least partly related to molecular 
processes in neuronal cell bodies (i.e., changes in nuclear gene 
expression), even though alterations in PET CM¬RgI measurements 
have been suggested to be more strongly influenced by the activity 
of terminal neuronal fields (22). Furthermore, this differential 
pattern of ETC and metabolic involvement across the cortex 
highlights the differential vulner¬ability of various regions to the 
pathophysiology of AD. Our current transcriptomic findings and 
previous PET studies raise the possibility that the molecular 
processes involved in neuronal energy metabolism may be involved 
in the earliest pathogenesis of AD, possibly preceding the onset of 
neuritic plaques. 
Earlier gene expression and functional activity studies 
provide confirmatory evidence of this regional pattern of ETC 
changes. Underexpression was found for mitochondrially-encoded 
and nuclear encoded ETC subunits in the middle temporal cortex, 
but not in motor cortex, of AD patients (38, 39). In a laminar 
analysis, the PCC also showed the most prominent and signifi¬cant 
functional declines across each cortical layer in complex IV activity, 
whereas the motor cortex was relatively spared (27). Middle 
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temporal, superior temporal, and inferior parietal cortices showed 
significant layer III activity declines, in agreement with our gene 
expression data, with the midfrontal cortex showing the smallest 
decline (40). Further, as the layer III cell bodies from which the 
expression data were taken project apical dendrites (containing the 
highest metabolic demand) into the superficial layers of the cortex, 
these layers (I and II) showed globally, albeit not always significantly, 
reduced ETC activity that could result from decreased subunit 
expression in the layer III soma (40). 
The regional pattern of underexpression in the genes 
encoding ETC subunits, which have been validated here with 
Western blots, corresponds to the regional pattern of CMRgI 
reductions observed in PET studies of patients with AD (28, 41–45) 
such that the PCC and precuneus are preferentially affected in AD 
(11, 16, 17, 19). Because PET studies have also identified the PCC as 
showing the earliest metabolic changes in cognitively normal 
carriers of the APOE 64 allele (19), these changes may precede 
downstream development of AD pathologies including amyloid 
plaque and neurofibrillary tangle formation. Metabolic alterations in 
the PCC have also been implicated in maintaining the brain’s 
“default”state when it is not engaged in the performance of specific 
tasks (46) or episodic memory tasks (20), as well as in the 
predisposition to initial hypometabolic (11–13) and subsequent 
fibrillar amyloid changes (20, 47, 48) associated with AD. The current 
study provides new information about the neuronal processes 
involved in these normal and pathological human behaviors. 
This study capitalized on the genome-wide evaluation of gene 
transcripts from laser-capture microdissected neurons from 
ex¬tremely high-quality brain tissue [mean postmortem interval 
(PMI) = 2.5 h] in clinically and neuropathologically well-characterized 
AD cases and age-matched controls, and on theanalysis of neurons 
from brain regions preferentially affected or spared in PET studies of 
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AD. Although this study provides clues about the molecular 
processes related to the CMRgI reductions observed in persons 
afflicted by and at genetic risk for AD, it has several limitations. First, 
given the descriptive nature of our findings, it remains to be clarified 
whether the changes in the nuclear expression of mitochondrial 
metabolism genes cause reductions in the density or activity of 
terminal neuronal fields or instead are a consequence of the 
reduced metabolic demands associated with terminal neuronal 
changes in AD. Second, it also remains to be clarified whether or not 
AD is also associated with underexpression of mitochondrially 
encoded genes from the same neurons (a technically challenging 
question to address in laser-capture microdissected cells) or in the 
nuclear or mitochondrial genes of perisynaptic glial cells. Third, 
although we controlled for mean age at death and gender, there is a 
small possibility that other group differences in the agonal state 
preceding death contributed to some of the AD related reductions in 
neuronal gene expression observed in this study. Finally, findings 
from our study suggest that a high proportion of genes are 
underexpressed in AD, whether or not they are known to directly 
influence neuronal metabolism. However, the regional pattern of 
underexpressed genes regulating mitochondrial metabolism appear 
to correspond to the pattern of CMRgI changes in AD. 
Noting the pattern of metabolic changes in our PET studies of 
AD, Roses et al. have suggested that insulin sensitizers may be 
helpful in the treatment and prevention of AD (49, 50). Findings 
from our neurotranscriptomic study could provide clues about the 
molecular mechanisms that may be involved in the earliest 
pathogenesis of this disorder and potential targets at which to aim 
new disease-slowing and prevention therapies  
Conclusion 
This study provides transcriptomic and protein evidence that 
the neuronal nuclear genes influencing mitochondrial energy 
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metabolism are underexpressed in AD, particularly in brain regions 
like the PCC, which are found to be preferentially affected in PET 
studies of AD patients and cognitively normal persons at genetic risk 
for this disorder. In doing so, this study provides information about 
the molecular processes involved in the pathogenesis of AD and 
potential therapeutic targets at which to aim disease-slowing and 
prevention therapies. 
  
Materials and Methods 
 
Tissue Collection.  
Brain samples were collected at three Alzheimer’s Disease Centers 
(Washington University, Duke University, and Sun Health Research 
Institute) from clinically and neuropathologically classified late-onset 
AD-afflicted individuals (15 males and 18 females) with a mean age 
of 79.9 ± 6.9 years. Tissue collection of healthy elderly controls was 
published in a previous report (51); Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) neuritic plaque densitywas 
infrequent and Braak stages ranged from Ito II. All individuals were 
Caucasian and were matched as closely as possible for gender and 
mean age at death. Subjects in the AD group had a Braak stage of V 
or VI (47) with a CERAD score of moderate or frequent (52). Samples 
were collected (mean PMI of 2.5 h) from six brain regionsthat are 
either histopatho¬logically or metabolically relevant to AD. These 
include the EC (BA 28 and 34), SFG (BA 10 and 11), HIP, VC (BA 17), 
MTG (BA 21 and 37), and PCC (BA 23 and 31). The EC and HIP are 
preferentially affected by intracellular neurofibrillary tangles, the 
MTG and PCC are preferentially affected by metabolism and 
extracellular p-amyloid plaques, the SFG is preferentially affected by 
aging, and the VC is relatively spared from both aging and AD 
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pathologies. After dissection, samples were frozen, sectioned (10 
m), and mounted on glass slides. 
As previously described (53), brain sections were stained with a 
combination of thioflavin S (Sigma) and 1% neutral red (Fisher 
Scientific), pyramidal neuronswere identified bytheir characteristic 
size, shape, and location within the region of interest, and tangles 
were identified by the bright green fluorescence of thioflavin-S 
staining. In the EC, the large stellate neurons lacking thioflavin S 
staining were collected from layer II, and pyramidal cells lacking 
thioflavin-S staining were collected from CA1 of the HIP. The CA1 
region was selected for study because this area is the most, and 
earliest, affected region in terms of tangle formation, and it has 
already been expres¬sion profiled in neurologically healthy elderly 
individuals. In all other regions, cortical layer III pyramidal neurons 
lacking thioflavin-S staining were collected (for all collected neurons, 
cell bodies were extracted). For each individual, 500 
histopathologically normal pyramidal neurons were collected from 
the six brain regions by using laser-capture microdissection (Veritas 
automated laser-capture microdissection system; Arcturus). Cells 
were collected onto Arcturus CapSure Macro LCM caps and 
extracted according to the manufacturer’s instructions. Total RNA 
was isolated from the cell lysate by using the Arcturus PicoPure RNA 
isolation kit with DNase I treatment using the Qiagen RNase-free 
DNase set. 
 
Expression Profiling. 
 Expression profiling was performed as previously de¬scribed (51). 
Isolated total RNA was double-round amplified, cleaned, and biotin 
labeled with the AffymetrixGeneChip two-cycle target labeling 
kitwith a T7 promoter and the Ambion MEGAscript T7 high-yield 
transcription kit according to the manufacturer’s instructions. 
Amplified and labeled cRNAwas quantitated on a 
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spectrophotometer and run on a 1% TAE gel to check for an evenly 
distributed range of transcript sizes. Twenty micrograms of cRNA 
was fragmented to 35–200 bp by alkaline treatment (200 mM Tris-
acetate, pH 8.2; 500 mM KOAc; 150 mM MgOAc) and run on a 1% 
TAE gel to verify fragmentation. Separate hybridization cocktails 
were made by using 15 g of fragmented cRNA from each sample 
according to Affymetrix’s instructions. 
 
Microarray Analysis.  
Two hundred microliters of each mixture was separately hybridized 
to an Affymetrix Human Genome U133 Plus 2.0 array for 16 hat 45°C 
in the Hybridization Oven 640. The Affymetrix human genome arrays 
measure the expression of over 47,000 transcripts and variants, 
including 38,500 characterized human genes. Hybridization cocktails 
for nine EC samples (normal neurons from AD brains) previously 
collected following the same profiling methodology used in this 
project (53) were reanalyzed on the U133 Plus 2.0 array to be 
evaluated in this study; a 10th EC sample was also separately 
processed for this sample group. Arrays are washed on the 
Af¬fymetrix upgraded GeneChip Fluidics Station 450 by using a 
primary strepta¬vidin phycoerythrin (SAPE) stain, subsequent 
biotinylated antibody stain, and secondarySAPE stain. Arrays are 
scanned on the Affymetrix GeneChip Scanner 3000 7G with 
AutoLoader. Scanned images obtained by the Affymetrix Ge¬neChip 
Operating Software (GCOS) v1.2 were used to extract raw signal 
intensity values per probe set on the array and calculate detection 
calls (absent, marginal, or present). Assignment of detection calls is 
based on probe-pair intensities for which one probe is a perfect 
match of the reference sequence and the other is a mismatch probe 
for which the 13th base (of the 25-oligonucleotide reference 
sequence) is changed. All raw chip data were scaled to 150 in GCOS 
to normalize signal intensities for interarray compari¬sons. Reports 
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generated by GCOS were reviewed for quality control; we looked for 
at least 20% present calls, a maximum 3'/5' GAPDH ratio of 30, and a 
scaling factor <10. Twenty arrays that failed to pass these standards 
were not included in further analyses. 
 
Pyramidal Cell Quality Control.  
To ensure neuronal cell purity in the samples, we evaluated 
expression of GFAP, an astrocyte cell marker. Fourteen samples that 
had GFAP expression greater than one standard deviation from the 
mean were removed from statistical analyses. 
 
Statistical Analysis.  
Data for samplesfrom neurologically healthy elderly controls were 
generated in a previous study (51). Microarray data files of the 
normal samples are available on the Gene Expression Omnibus site 
at www.ncbi.nlm. nih.gov/geo/query/acc.cgi?acc = GSE5281 (project 
accession no. GSE5281), and regional analyses are posted at 
www.tgen.org/neurogenomics/data/private3. 
We compared AD cases and controls in the neuronal expression of 
80 nuclear genes encoding subunits of the mitochondrial ETC in each 
of our sampled brain regions. The nuclear genes included 39 
complex I genes coding for NADH dehy¬drogenase (NDUFA1–A13, 
NDUFAF1, NDUFAB1, NDUFB1–B11, NDUFC1 and -C2, NDUFS1–S8, 
and NDUFV1–V3), all 4 complex II genes coding for succinate dehy-
drogenase (SDHA, SDHB, SDHC, and SDHD), 9 complex III genes 
coding for ubiquinol-cytochrome c reductase (UCRC, UQCR, UQCRB, 
UQCRC1, UQCRC2, UQCRFS1, UQCRH, CYC1, and CYCS), 13 complex 
IV genes coding for cytochrome c oxidase (COX4I1, COX5A, COX5B, 
COX6A1, COX6A2, COX6B1, COX6C, COX7A2L, COX7B, COX7B2, 
COX7C, COX8A, and COX8C), and 15 complex V genes coding for ATP 
synthase (ATP5A1, ATP5B, ATP5C1, ATP5D, ATP5E, ATP5F1, ATP5G1–
G3, ATP5H, ATP5I, ATP5J, ATP5J2, ATP5L, and ATP5O). TIMM and 
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TOMM expression was also evaluated (TIMM8A, TIMM8B, TIMM9, 
TIMM10, TIMM13, TIMM17A, TIMM17B, TIMM22, TIMM23, 
TIMM44, TIMM50, TOMM7, TOMM20, TOMM22, TOMM34, 
TOMM40, and TOMM70A). Mitochondrial DNA-encoded subunits 
were not assessed in this study. 
Direct comparisons between neurologically healthy and AD-afflicted 
brains were performed in all six regions to analyze expression 
differences in the above listed ETC subunits. For each analysis, genes 
that did not demonstrate at least 10% present calls across all 
transcripts profiled for each region-specific com-parison were 
removed by using Genespring GX 7.3 Expression Analysis software 
(AgilentTechnologies). A two-tailed unpaired ttest, assuming 
unequal variances (with a multiple testing correction using the 
Benjamini and Hochberg false discovery rate), wasapplied to each 
comparison forall genesthat passedthe 10% present-call criterion to 
locate genes that were statistically significant in differ¬entiating 
expression between healthy brains and AD brains. (After the 
present-call filter, 32,153 genes in the PCC were used for P value 
correction, 30,897 genes in the EC, 32,265 genes in the MTG, 31,496 
genes in the HIP, 32,482 genes in the VC, and 32,118 genes in the 
SFG.) For each analysis comparing AD expression levels with control 
levels, genes that had a corrected P value ~ 0.01 were collected, and 
those genes whose average AD signal and average control signal 
were both below a threshold of 150 were removed. Fold-change 
valuesweredetermined by calculating the ratio between the 
averages called expression signal (for all affected samples) for a gene 
from the AD sample region and the average scaled expression signal 
for the same gene from the normal samples across all regional 
comparisons. 
Using this approach, we evaluated ETC and translocase genes that 
were differentially expressed in the AD cases versus controls for 
each of the six brain regions of study. Proportions of ETC and 
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translocase genes demonstrating under-and overexpression were 
determined by calculating the number of subunits (at least 10% 
present calls with corrected P < 0.01) showing such changes over the 
total number of nuclear-encoded subunits (at least 10% present calls 
with corrected P < 0.01) on the Affymetrix human genome array. 
Evaluation of all human genes demonstrating underexpression in 
each region focused on only those genes with statistical significance 
(P < 0.01 with multiple testing correc¬tions, after present-call filters) 
for each regional AD versus controls comparison; underexpression 
percentages were calculated based on a ratio of underex¬pressed 
statistically significant genes over all genes. 
 
Data Posting. 
 Minimum information about a microarray experiment (MIAME)- 
compliant microarray data files for control samples are located on 
the Gene Expression Omnibus (GEO) site at 
www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc=GSE5281 (project 
accession no. GSE5281). Fold changes and cor¬rected and 
uncorrected P values for all ETC and translocase genes on the 
Af¬fymetrix Human Genome Array for each of the six regional 
comparisons are available online at 
www.tgen.org/neurogenomics/pcc. Posted lists show respective 
genes that have at least 10% present calls across regional samples 
(no fold change thresholds have been applied on these lists). 
Additional expression results will be published in a separate report. 
 
Western Blotting Validation.  
Based on availability, 10 profiled AD PCC cases and 5 profiled healthy 
control cases were collected for Western blot validation. Blotswere 
run by researchers blind to subject condition. Sectionswerewashed 
from slides by using PBS, and 35 g of protein per lane was loaded 
into 10–20% 1.5 mm Tris-glycine 15-well minigels (Invitrogen) with 
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Novex Tris¬glycine SDS 2x sample buffer. Gels were run in Novex 
minicell (Invitrogen) for 90 min at constant 150 V with Novex Tris-
glycine SDS running buffer. Proteins were transferred to Immobilon 
P (Millipore) PVDF membrane, fully sub¬merged in CAPS transfer 
buffer (10 mM 3-[cyclohexylamino]-1-propane sul¬fonic acid, pH 11 
with NaOH, 10% methanol) by using constant 150 mA for 2 h. 
Membranes were blocked overnight in 5% Carnation dry milk in PBS 
at 4°C and then probed with the total OXPHOS detection kit (MS601; 
1:1,000 in 1% dry milk; Mitosciences) for 2 h at room temperature 
with gentle rocking. This five-antibody mixture marks the 20-kDa 
subunit of complex I (ND6; mitochon¬drially encoded), the 30-kDa 
iron–sulfur subunit of complex II, the core 2 subunit of complex III, 
COX II of complex IV(mitochondriallyencoded), and the F1a subunit 
of ATP synthase.  
Goat anti-mouse alkaline phosphatase (AP)- conjugated secondary 
antibody (1:10,000 in 1% dry milk; Santa Cruz Biotech¬nology) was 
used (2 h at room temperature with rocking), followed by 
application of an AP substrate detection kit (Bio-Rad), according to 
the manufacturer’s instructions. Membranes were dried overnight, 
then simulta¬neously scanned on a Mustek A3 EP flatbed scanner. 
All blots were performed in duplicate. The image was imported into 
Optimas image analysis software (Media Cybernetics), and average 
OD measures of each band were taken by using a sampling window 
of constant size. Groups were compared by using Student’s two-
tailed t tests, uncorrected for multiple comparisons, and 95% 
confidence intervals for each complex were calculated in Excel. 
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Tables / Figures 
 
 
 
 
Table 1. The proportion of underexpressed metabolism-related 
genes in each of the sample brain regions 
 
 
 
 
 
 
 
 
 
 
Complex I Complex II Complex III Complex IV Complex V TIMMs TOMMs 
Brain 
region 
No. of 
subunits Fold 
 
No. of  subunitsFold 
 
No. of  subunitsFold 
 
No. of  subunitsFold 
 No. of 
subunits Fold 
 No. of  
subuni ts  Fo ld  
 
No. of  
su b u n i t s  F o l d  
PCC 28/39(72) -3.0 2/4(50) -2.8 8/9(89) - 3 . 6  7 / 1 3 ( 5 4 )  - 2 . 8  11/15(73) - 3 . 8  3 / 1 1 ( 2 7 )  - 3 . 2  3/6(50) -2.6 
MTG 27/39(69) -2.5 2/4(50) -2.5 6/9(67) - 2 . 3  8 / 1 3 ( 6 2 )  - 2 . 4  9/15(60) - 3 . 3  3 / 1 1 ( 2 7 )  - 2 . 2  5/6(83) -2.3 
HIP 25/39(64) -2.5 2/4(50) -2.7 5/9(56) - 2 . 8  7 / 1 3 ( 5 4 )  - 2 . 2 10/15(67) -2.7 3 / 1 1 (2 7 )  - 2 . 6  4/6(67) -2.7 
EC 9/39(23) -4.5 0/4 (0) 1/9(11) -3.7 3/13(23)-4.5 5/15(33) -4.3 5 / 1 1 (4 5 )  - 3 . 7
 1/6(17) -2.8 
VC 7/39(18) -1.8 0/4 (0) 1/9(11) -2.0 1/13 (8)-1.5 4/15(27) -2.1 0/11 (0) 1/6(17) -2.2 
SFG 4/39(10) -3.9 0/4 (0) 0/9 (0) 0/13 (0) 0/15 (0) 2 / 1 1 (1 8 )  - 3 . 6
 2/6(33) -2.4 
The numerator indicates the number of subunits showing statistically significant ( P < 0.01 with multiple testing corrections) underexpression and 
the denominator indicates the total number of nuclear-encoded subunits for the complex/translocase. This ratio is expressed as a percentage in 
parentheses. PCC 
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Fig. 1. Altered expression of mitochondrial energy metabolism 
elements. Energy metabolism-relevant elements showing 
statistically significant underex¬pression in the PCC are shown. 
These elements include the five complexes of the ETC and TIMMs 
and TOMMs. OM, outer mitochondrial membrane; IMS, 
intermembrane space; IM, inner mitochondrial membrane. 
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Fig. 2. Western blot validation. (A) Western blots using a five-
antibody mixture labeling a subunit of each mitochondrial enzyme 
complex from PCC whole-brain extract. H, human heart for positive 
control; AD, Alzheimer’s patient; NC, normal control. Apparent 
molecular mass scale is indicated on the right. From highest to 
lowest are complex V alpha subunit, complex III core 2 subunit, 
complex II 30-kDa subunit, complex IV subunit II, and complex I 20-
kDA subunit. Results are representative of duplicate blots. (B) 
Western blot-band optical density, expressed as percentage of 
normal-aged control. Subunit protein expression was significantly 
lower (two-tailed t test, P < 0.01) for each subunit tested. n = 10 AD; 
n = 5 NC. 
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